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ABSTRACT 
The regulation of tryptophan-2,3-dioxygenase (TDO) (EC 1.13 .1.12) and, to a lesser extent, pineal 
indoleamines, both in vitro and in vivo, is examined in this study. 
Rat liver TDO is a cytosolic enzyme which plays a crucial role in the regulation of circulating tryptophan 
(TRP) levels. Stimulation of this enzyme by heme enhances the catabolism of TRP, making less TRP 
available for uptake into the brain and other tissues, and for protein synthesis. At pH 7, the enzyme has 
an approximate Km of lOOILM, is subject to substrate inhibition immediately beyond Sopt ([S] at V maJ, and 
response of the enzyme is cooperative in both uninhibited and inhibited regions. Hill analysis of the 
uninhibited region reveals a biphasic plot and two classes of binding sites. Negative cooperativity is 
brought about through deprotonation of the enzyme. Substrate iphibition also occurs at both acidic and 
basic pH values with concomitant shifts in Sopt. The results obtained indicate that substrate inhibition could 
be an additional mechanism whereby the flux through the TRP-kynurenine pathway is regulated. 
TDO is subject to a diurnal rhythm, with peak activity during the pre-dark period and the loweSt activity 
towards the end of the dark period. It is possible that the enzyme controls the synthesis of the 
neurotransmitter serotonin (5-HT), and that the circadian rhythm in TDO activity is due to the endogenous 
rhythm of melatonin (aMT) production by the pineal gland. In the present study, aMT displaces TRP from 
bovine serum albumin (BSA) in vitro, and it is therefore possible for the indole amine to regul'!:t~ the 
availability of TRP for uptake into the brain for conversion to its derivatives. 
Chronic intraperitoneal administration of aMT affects physiological hepatic parameters in rats, such as 
TDO activity and stromal fatty acid composition, whilst no observable effect is demonstrable with respect 
to protein synthesis, nucleic acid metabolism, membrane fatty acid composition and pineal indole 
biosynthesis. On the other hand, chronic treatment of rats with antidepressants, the tricyclic 
des methyl imipramine (DMI) and the selective serotonin reuptake inhibitor (SSRI), fluoxetine, reveals 
significant negative alterations in TDO concentrations and pineal indole amine synthesis. Combining aMT 
with any of these two drugs normalises the activity of the hepatic enzyme. 
DMI is found to be an effective inhibitor of TDO in the micromolar range in vitro, and also affects total 
enzyme concentrations in vivo. Fluoxetine has no effect on TDO in vitro, but in vivo also reduces total 
enzyme levels in the liver. However, the SSRI does not affect conjugation between apo- and holoenzyme. 
Instead, it decreases extant holoenzyme levels. Indoleamine synthesis by the pineal gland, in organ culture, 
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is altered by both antidepressants, although in different ways. DMI increases N-acetylserotonin levels and 
- reduces the output of meth_oxyindole acetic acid and meth6xytryptophol. Fluoxetine treatment markedly 
reduces aMT concentrations and also brings about high levels of the 5-HT catabolites, 5-hydroxytryptophol 
and 5-hydroxyindole acetic acid. 
Insulin also lowers aMT synthesis significantly in pineal organ cultures, via a mechamsm that involves 
inhibition of the enzyme, N-acetyl transferase, that regulates aMT synthesis. The effects of insulin on 
pineal indole metabolism are due to the observation that a carbohydrate rich diet which induces insulin 
release elevates plasma TRP and brain 5-HT, but has no effect on pineal TRP and indole amine synthesis. 
It could thus be possible for insulin to have an effect on the pineal,since the latter is outside the blood brain 
barrier. 
The finilings of this study support the biogenic amine deficiency hypothesis, implicating some of the major 
biogenic amines such as noradrenaline (NA), 5-HT and aMT in depression. There is believed to be a 
deficiency of NA and 5-HT at their respective synapses in the depressed state. The drug DMI could act, 
firstly, by inhibiting TDO and thus increasing plasma TRP levels, and could, secondly, stimulate NA 
- "<._" 
release and inhibit NA reuptake at the pineal membrane. The combined effect would be to enhance aMT 
synthesis, with eventual remission. Fluoxetine, on the other hand, appears to utilize a slightly different 
mode of action to DMI, which seems to focus on the preservation of 5-HT. The fact that aMT counteracts 
the effects of both antidepressants, and restores the activity of TDO to that of the controls, is also 
consistent with the observation that the therapeutic action of drugs such as these coincides willi the 
restoration of normal plasma levels of the neurohormone in depressives. 
In view of the biogenic amine deficiency hypothesis of depression and the contentious claim that TDO is 
the major peripheral determinant of brain TRP, brain 5-HT and ultimately aMT, the regulation of TDO 
is investigated and discussed. The study concludes that TDO activity is regulated by a number of 
endogenous compounds which are mainly derivatives of TRP, such as aMT and oxidized nicotinamide 
adenine dinucleotide and exogenous substances, of which DMI and fluoxetine are but two. In addition, 
modulation of IDO activity in depression appears to be an important aspect of antidepressant action. aMT, 
the product of the pineal gland, also has the potential to increase plasma TRP and hence forebrain TRP 
levels, and ultimately 5-HT concentrations, firstly by displacing TRP from serum albumin and secondly 
by inhibiting TDO. 
1 INTRODUCTION 
1 
CHAPTERl 
LITERA TURE REVIEW 
Hepatic enzyme tryptophan-2,3-dioxygenase (TDO) is a branch point in the metabolic pathway of L-
r - , 
tryptophan (TRP) metabolism. The activity of this enzyme determines fIrstly how much of the essential 
amino- acid is converted to nicotinamide adenine dinucleotide (phosphate) (NAD(P)H) and ultimately to 
nucleic acids, and secondly the amount of TRP available for uptake into the brain to be converted to 
serotonin (5-HT). Intermediates and end products of both pathways are crucial in the proper functioning 
of any organism. It is therefore conceivable that the relative concentrations of these catabolites of TRP 
need to be finely regulated to achieve that objective. Excesses and defIciencies of TRP and its metabolites, 
such as the neurotransmitter 5-HT, the neurohormone melatonin (aMT), the vitamin niacin etc, could 
result in affective disorders and diseases such as pellagra. 
One such affective disorder is depression, for which various theories have been proposed in an attempt to 
define the underlying neurobiological aberrations that precipitate this potentially debilitating illness. The 
disease is a major source of loss of productive individuals in a rapidly expanding and competitive society 
with its myriad of challenges and needs. Some of the negative aspects of the depressive episode are, 
amongst others, destruction of the family, alienation from society, loss of a sense of responsibility, drug 
abuse and in extreme instances suicide. 
Thus there is a crucial need to gain insight into some of the sociological and biochemical events that 
precipitate depression if there is to be a rational strategy to deal with the problem both on the psychological 
and neurobiological levels. Any attempt at effectively treating this disorder requires knowledge of the 
pathophysiology of the disease, ie the biochemical changes that accompany the appearance of the 
symptoms of depression. One of the hypotheses which have been proposed to account for depression 
symptomatology asserts that IDO is the major peripheral determinant of brain TRP, and ultimately 5-HT 
concentrations, the latter being implicated in depression. Dysregulation of this hepatic enzyme's activity 
consequently results in imbalances in the serotonergic neurobiological system, and eventually in aMT 
levels. aMT, the major indolealkyleamine product of the endocrine gland, the pineal, is generally accepted 
as the endogenous circadian rhythm generator, besides having other purported roles which include that of 
an antioxidant and a neuroprotectant. 
The biological rhythm of this neurohormone is known to be disturbed in depression, as is that of a number 
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of other important biological substances such as 5-HT and glucocorticoids. Efficacious antidepressants such 
as tht:_ tricyclic desipramine (DMI) and the selt:ctive serotonin reuptake inhibitors (SSRIs) (such as 
fluoxetine) used to treat major depression have as part~{ their mechanism of action the ability to inhibit 
TDO, and thus increase plasma TRP concentrations, in addition to influencing aMT and 5-HT synthesis 
by the pineal gland. Thus, knowledge about the precise regulation of TDO in vivo is of fundamental 
importance. 
It is apparent after surveying the vast literature available on depression and its therapy that the unifying 
factor in almost all subtypes of depression is TRP. Curtailed serum and cerebral TRP levels and brain 5-
HT turnover, as a consequence of an enhanced TDO rate of catalysis, are causally linked to the 
pathogenesis of the clinically characterised depressive episode in humans. TDO thus has the potential to 
be a key regulatory site in the modulation of certain aspects of central nervous system activity, and 
alterations in the functioning of TDO could influence the individual's behaviour. In this study an effort is 
made to examine some of the supposed biochemical parameters involved. The questions to be addressed 
are as follows: 
i) How is the activity of TDO regulated in vitro? 
ii) To what extent is brain 5-HT altered when TDO is activated? 
iii) 00 some antidepressant drugs such as OMI and fluoxetine, whose mode of action is not 
completely known, exert their therapeutic effects by altering hepatic TOO activity? 
iv) Does the pineal gland hormone aMT, a structural analogue of TRP, regulate TDO activiry- and 
have an influence on plasma TRP levels and how does this inhibition differ from that effected by 
5-HT? 
v) What effects do OMI, fluoxetine (in vitro and in vivo) and the pancreatic hormone insulin (in 
vitro) have on pineal indole metabolism? 
Both male and female Wistar rats are used as models to evaluate the effects of various TRP derivatives 
and antidepressants in vitro and in vivo, and as a source of TDO. In Chapter 1, the literature survey 
overviews the relevant written material relating to some of the pertinent aspects of TRP metabolism, the 
biological determinants of depression, primarily TDO and, to a minor extent, TRP-hydroxylase. The 
various hypotheses regarding depression are also reviewed, however the indoleamine hypothesis and the 
roles of 5-HT and various antidepressants are covered in greater detail. Finally some of the biological 
functions of aMT in metabolism and its role in depression and neuroprotection are briefly overviewed. 
In Chapter 2 the phenomenon of substrate inhibition of TDO by TRP is examined in vitro. The in vitro 
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effects of selected TRP derivatives and the in vivo consequences of the heme precursor 5-aminolevulinic 
acid (l-ALA) on IDO acti,:,ity are examined, as well as the iirtluences of 5-ALA on forebrain 5-HT levels. 
Chapter 3 outlines the experimental work performed with the tricyclic antidepressant (TAD) DMI and the 
SSRI fluoxetine, either individually or in combination with aMT, to observe their effects on TDO and on 
indoleamine metabolism in pineal organ cultures in vivo. The effect of insulin on pineal indole metabolism 
r -
in pineal organ culture is investigated in Chapter 4. Finally, Chapter 5 examines the in vivo effects of aMT 
on TOO, pineal indole metabolism and various other physiological parameters such as hepatic nucleic acid 
synthesis, protein metabolism and fatty acid status. The effects of melatonin and selected antidepressants 
on bovine serum albumin (BSA)-bound TRP are also experimentally ascertained in vitro. The concluding 
chapter (6) presents a summary of the research fmdings, and suggests possible future areas of research. 
1.0 TRyPTOPHAN: ESSENTIAL AMINO ACID 
L-TRP: one of the eight essential amino acids encoded by ribonucleic acid (RNA), has to be obtained from 
the diet in human beings. This molecule is the only indole of all the amino acids and has the greatest 
molecular weight of the twenty known amino acids incorporated into protein. TRP derivatives constitute 
a number of physiologically important molecules such as the neurotransmitter 5-HT, the neuf()hormone 
aMT, the vitamin niacin, proteins, and pyridine nucleotides (Maurizi, 1990) such as nicotinamide adenine 
dinucleotide (NAD+) (Feigelson et al., 1951; Williams et al., 1950; Nishizuka and Hayaishi, 1963) (figs. 
1 & 2). 
PROT8N 3-0H f FORMYL· 3-OH . ANTHRANILIC TRYPTOPHAN~ KYNURENINE - KYNURENINE - KYNURENINE - ACID 
! 
NADH -NAD+--DEAMINO-NICOTINIC ACID - QUINa...INIC-2-ACROLEYL 
J 
NADPH-NADPoI-
NAD+ MONONUClEOTDE ACID 3-NAINO f FUMARATE 
NICOTINIC AOD 
FIG. I: The TRP - kynurenine pathway [Cho-Chung and Pitot, 1967]. 
The D-isomer is poorly absorbed and metabolised in both humans and animals (Langer and Berg, 1955; 
Price and Brown, 1956). In mice, exogenous TRP increases, in vitro, hepatic protein synthesis (Sidransky 
etal., 1967; Sidransky etal., 1968). Deficiencies of this essential indole result in a reduced rate of liver 
enzyme protein synthesis in the rat (Nishizuka and Hayaishi, 1963). 
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There are essentially two sources of plasma TRP in the body: increased hepatic portal output after a 
- protein rich meal, and secretion by the tissues as- a consequence of alterations in the concentrations of 
-~ # 
bound and free TRP pools in the body. The manner in which TRP exits from the blood potentially involves 
three mechanisms: fIrstly, by uptake into the tissues, secondly, due to hepatic TDO catabolism and, 
thirdly, a small proportion is eliminated in the urine (Fernstrom and Wurtman, 1971). TRP is transported 
in the blood either free or ionically bound (70-90%) to serum albumin (SA) (Mcmenamy and Oncley, 
1958;~ Smith, 1991). This binding is highly stereospecifIc, saturable and reversible (Mcmenamy and 
Oncley, 1958). The ionic nature of the association is demonstrated by the fact that a reduction in pH of 
the environment causes a release of TRP into the surrounding medium (Mcmenamy et aI., 1958). Human 
serum albumin has two specifIc binding sites (known as site one and site two (Muller et al., 1994)) one 
for warfarin and another for indoles (Sjoholm and Ljungsteadt, 1973; Noctor et al., 1992 ) and 
benzodiazepines, as well as a number of non-specifIc binding sites (Geisow, 1992). Receptor binding sites 
- -
also exist for the amino acid on hepatic nuclear envelopes in rats, where stimulation of these receptors by 
TRP could enhance protein synthesis (Sidransky et al., 1994). The binding to these receptor sites is also 
saturable, stereospecifIc and highly specifIc. Other indolic compounds, such as 3-methylindole, apparently 
compete with the parent indole for binding to these receptors (Sidransky et al., 1992). 
On the other hand, non-essential fatty acids (Curzon et al., 1973; Badawy et al., 1984) and certain drugs 
(Badawy et al., 1984) increase free TRP levels through displacement of TRP from serum albumin both 
in vitro and in vivo (Badawy et al., 1984; Smith and Poison, 1980). Generally, compounds with large 
hydrophobic groups could readily displace TRP from serum albumin due to the presence of expansIve 
nonpolar regions on the albumin molecule that straddle the specifIc binding site of TRP (Mcmenamy and 
Oncley, 1958). However, for any compound to have an effect on increasing the free serum TRP levels 
by displacement from SA, the rate of displacement would have to be more rapid as opposed to the rate of 
TRP passage through the liver. In addition there would have to be a large hepatic fractional extraction. 
The latter is necessary so as to assist in maintaining the equilibrium between bound and free TRP (Salter 
et al., 1989). TRP levels in plasma can be measured in the picogram range using high performance liquid 
chromatography (HPLC) coupled to an electrochemical detector (ECD) on a reverse phase column 
(Mefford and Barchas, 1980) or using HPLC coupled to a fluorometric detection system (Anderson and 
Purdy, 1979). Hallucinogenic derivatives of TRP such as lysergic acid, bufotenine, methoxybufotenine, 
psilocybin, dimethyltryptamine and harmaline have their biosynthetic origin in plants. These indoles can 
act as inhibitors of monoamine oxidase (MAO) (Maurizi, 1990). The major factor generally accepted to 
be important in determining brain TRP concentrations is the plasma free TRP level (Bloxam and Curzon, 
1978; Curzon et al., 1975). In the brain, conversion to indoleamine derivatives such as the 
6 
neurotransmitter 5-HT occur (Wurtman, 1982). Uptake of TRP into the brain occurs to a limited extent, 
- passively, via diffusion, and albumin inhibits TRP uptake (Etienne et al., 1976; Curzon et al., 1973). 
-q; # 
However an active uptake system is present that transports the amino acid into the brain in competition 
with other large neutral amino acids (LNAAs) (Wurtman, 1982; Goldstein and Betz, 1983). In rats, high 
levels of the dietary amino acid TRP, increases brain concentrations of the indole (Block and Harper, 
1991). 
For any dietary precursor molecule to have an influence on increased neurotransmitter synthesis in the 
brain five sequential biochemical phenomena are required: 
i) A pronounced rise in the plasma levels of the precursor after the ingestion of a meal rich in the 
starter molecule is necessary. 
ii) A positive correlation must exist between plasma and brain levels of the precursor nutrient. 
iii) The transport mechanism at the blood/brain barrier should be acutely sensitive to alterations in 
plasma levels of the relevant substrate. 
iv) In addition, the neuronal enzyme catalysing the transformation of the substrate shoulqbe'of the 
low affinity type. 
v) The neuronal enzyme should not be subject to feedback inhibition. 
These conditions have to be met in order to demonstrate the reliance of brain neurotransmitters such as 
5-HT, acetylcholine and the catecholamines on their plasma precursors. This points to a real precursor-
neurotransmitter relationship which implieS an adaptive value. However, it should be emphasised that 
although there is both an increase in substrate levels and an enhanced rate of neurotransmitter synthesis, 
there is not a concomitant rise in neuronal firing rate (Wurtman, 1982). 
Increasing consumption of protein would appear to be a logical way of ensuring an adequate supply of 
TRP. However, the TRP content of good quality protein is relatively small when compared with other 
LNAAs. These LNAAs are also necessary for synthesis of certain neurotransmitters and protein (Etienne 
etal., 1976; Yokogoshi etal., 1987). The LNAA's compete with TRP for cellular uptake and are present 
in much higher levels in protein. On the other hand TRP has a greater molecular weight than any of its 
uptake competitors and, in addition, its numerical disadvantage on a stoichiometric basis is even more than 
the listed gram weight ratios. In the light of these factors it is not surprising that the intake of good quality 
protein paradoxically lowers brain TRP (Goldstein and Betz, 1983; Yokogoshi et al., 1987). However, 
another dietary paradox is that consumption of a protein-poor carbohydrate-rich meal increases brain levels 
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ofTRP (Goldstein and Betz, 1983; Brindley et al., 1984). This is because carbohydrate induced secretion 
of insulin decreases the serum levels of the amino acids that compete with TRP for brain uptake, due to 
- the fact that TRP is the only amino acid that is transported in the blood bound to serum albumin; while the 
LNAAs are free and therefore readily taken up into the tissues (Goldstein and Betz, 1983). The continued 
uptake of carbohydrate alone will obviously also precipitate a TRP deficiency (Bloxam and Curzon, 1978), 
and large carbohydrate meals do not increase 5-HT or 5-hydroxyindole acetic acid (5-ijlAA) levels in the 
rat brain (Brindley et al., 1984). 
Brain TRP levels, however, appear to be influenced to a greater extent by changes in free plasma TRP 
levels than by changes in the serum concentrations of competing amino acids (Bloxam and Curzon, 1978) 
or total plasma TRP. More specifically it is the ratio of TRP to LNAA that ultimately determines the 
translocation of TRP into the brain (Wurtman, 1982). It is this ratio that depicts more accurately the 
concentrations of brain TRP and 5-HT and not the total basal TRPvalue (Green et al., 1962, Delgado et 
al., 1990). In the blood, however, the diet seems to have a greater influence on TRP levels (Delgado et 
al., 1990) than on the concentrations of other amino acids. The magnitude of this elevation depends on the 
time of day that the protein is ingested, given that the plasma TRP is subject to a circadian rhythmt!tat is 
possibly due to the intrinsic diurnal rhythm of the hepatic enzyme TDO which catabolises TRP to N'-
formylkynurenine (Fernstrom and Wurtman, 1971). Plasma TRP levels peak at midday and the troughs 
occur at night (Sugden, 1983) (fig. 3). 
Diets free from or low in TRP cause a lowering of plasma levels of TRP in healthy humans. How~yer, 
this is not accompanied by any adverse or serious medical or psychological manifestations if the period 
involved is kept to a minimum (Delgado et al., 1990). TRP is also metabolised by the non-specific, 
ubiquitous indoleamine-2,3~oxygenase found in both animals and bacteria (Shimizu et al., 1978; Taylor 
and Feng, 1991). Research data supports the notion that the availability of the amino acid constitutes a 
major factor controlling the rate of conversion to brain 5-HT (Fernstrom and Wurtman, 1971; Green et 
al., 1962, Delgado etal., 1990) and also enhances the production of aMT. Thus physiological changes in 
plasma TRP appear to cause parallel alterations in brain 5-HT synthesis. Plasma TRP has a negligible 
effect on the pineal TRP and thus there appears to be differential metabolism of 5-HT and TRP (Sugden, 
1983). Concentrations of central 5-HT display a diurnal rhythm that is possibly due to the rhythm in 
plasma and brain TRP levels (fig. 3), which in turn is dependent on the activity of TDO (Fernstrom and 
Wurtman, 1971). A recent report, however, indicates that administration of fatty acids to rats results in 
an accumulation of brain TRP, but no concomitant enhanced brain 5-HT synthesis until ± 5 hours later 
(Yokogoshi etal., 1993). There appears to be no relationship between the circadian rhythm of pineal TRP 
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(fig. 3) and the bio-rhythm of serum TRP. These two events seem to be independent of one another. Pineal 
TRP levels rise prior to any increase in serum fr~e or total TRP. It is possible that this event could take 
place in order to prime the pineal for the night-time ele~aiion in aMT concentrations when high levels of 
TRP are required for neurohormone synthesis. This phenomenon seems to indicate that an active TRP 
uptake mechanism exists within the pineal, in addition to passive diffusion, that transports the amino acid 
into the endocrine gland against a concentration gradient. The independence of pinearTR1> concentration 
from serum TRP levels is further demonstrated by the fact that the end of the light period is accompanied 
by a rapid reduction in pineal TRP (which could probably be ascribed to enhanced transformation to 5-HT 
(Sugden, 1983», and this decrease in TRP is not parallelled in blood. 
FIG. 3: 
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Circadian changes in serum free, serum total, brain and pineal TRP levels of the rat. (The 
mean (± SEM) value for five rats is shown at each time point) [Sugden, 1979]. 
FUNCTIONS OF TRP DERIVATIVES 
Due to stress and the dietary limitations of TRP, lack of this essential amino acid with concomitant 
secondary deficiencies of its derivatives 5-HT and aMT could be common. Brain function, with respect 
to second messengers, receptor synthesis, peptides and a variety of interrelated metabolic phenomena, can 
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be adversely altered by acute TRP depletion. Interactions between the serotonergic and other neuronal 
_ systems can be similarly disrupted. The finding that !"emitted depressed patients relapse within a very short 
time interval after acute TRP withdrawal implicate~ ·TRP and its derivatives specifically in the 
pathophysiology of depression (Delgado et al., 1990). However, it does not exclude the involvement of 
factors unrelated to TRP metabolism in the depressive episode. Thus the process of becoming depressed 
possibly encompasses a whole range of interrelated phenomena including genetic factors:- It suffices to state 
that attempts to understand the underlying neurobiological and biochemical events that occur in the 
depressed state depend almost entirely on studying the mechanism of action of the range of antidepressant 
drugs in use at present. 
Proposed roles of 5-HT include, inter alia, neural development, sleep, feeding, temperature regulation, 
pain, maternal behaviour and adrenocorticotrophic hormone (ACTH) secretion (Soubrie, 1986; Lopez-
Ibor, 1988). aMT on the other hand is implicated in circadian rhythmicity(Axelrod, 1974) and seasonal 
reproduction (Reiter, 1982) in certain animal species, but the role of this neurohormone has not been 
adequately clarified in humans. Possible roles with regard to humans have, however, been postulated. aMT 
is implicated in a number of diseases particularly with respect to its role as the natural antidepressant, 
neuroprotectant (Blickenstaff et al., 1994) and free radical scavenger (Hardeland et al., 1993a), and its 
involvement in human behaviour (Maurizi, 1990). 
1.2 DYSFUNCTION OF TRP DERIVATIVES 
1.2.0 Mental depression 
Evidence indicates that TRP deficiencies and excesses are common and have a role to play in human 
disease (Vaughan, 1984). TRP depletion appears to have a negative effect on learning ability in individuals 
(Park et al., 1994). Excess TRP has been implicated in hepatocyte lipid accumulation in rats by certain 
researchers. However, large doses of TRP administered to rats could not demonstrate such an effect on 
fatty livers or any morphological alterations. The lipid accumulation in this instance is believed to be 
related to the imposed food deprivation (Mathies and Jacobs, 1993). In another report, TRP loading 
promoted lipid peroxidation in rats. However, this effect is thought to be due to the anticipated concomitant 
increase in 5-HT plasma levels (Aviram et al., 1991). Pellagra, a disease caused by a shortage of TRP and 
niacin, is linked to severe depression and dementia. However, it was recently discovered that the disease 
is also due to a lack of iron in the diet which reduces TRP utilization. This is understood to be a result of 
the fact that two enzymes in the pathway of TRP metabolism, one of which is TDO, require iron (Fe) for 
activity. Thus a lack of iron in the diet would restrict conversion of TRP to niacin (Oduho et al., 1994). 
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A negative correlation exists between free plasma TRP levels and depression during acute TRP depletion 
(Mcdougle et al., 1993), .where a lack of the amino acid has a pronounced effect on the depressive 
-:; p 
symptoms (Curwn and Bridges, 1970). There is considerable evidence that TRP metabolism is disturbed 
during depression, namely: 
a) The therapeutic activity of MAO inhibitors (MAO!) is enhanced by TRP (this urtplies a lack of 
- 5-HT). TRP treatment has also been found to be efficacious in some depressives. 
b) Low levels of 5-HIAA, the excretory product of 5-HT metabolism, implies a decreased level of 
5-HT, and is also indicative of dysregulated TRP metabolism. 
c) There is increased secretion of cortisol with a consequent rise in TDO, 3-0H-kynurenine and 3-
OH-anthranilate concentrations. 
. . 
Abnormal5-HT levels in the brain and cerebrospinal fluid (CSF) could be due to a number of biochemical 
variables of which high TDO activity is one. Although animal studies indicate a negative correlation 
between 5-HT levels and TDO activity (Curzon and Bridges, 1970; Litman and Correia, 1985), resultS 
obtained from clinical studies reveal elevated TDO activity even after recovery from the ~epfessive 
episode in some patients. Thus, in human subjects, there appears to be no consistent temporal relationship 
between excreted metabolites or the severity of the depressive illness and enzyme activity (Curzon and 
Bridges, 1970). 
Most antidepressant drugs involve either noradrenaline (NA) or 5-HT, or both neurotransmitters.-It is 
believed that the therapeutic effect of certain antidepressant drugs could be dependent on the availability 
of 5-HT (Delgado et al., 1990). 5-HT is implicated in a variety of functions by virtue of the anatomy of 
the serotonergic system. 
The 5-HT system originates in the raphe nuclei of the brain stem from where it branches into diverse 
cerebral areas such as the cortex, hypothalamus, basal ganglia and the limbic system (specifically the 
septohippocampalsystem and the amygdala). The limbic system is associated with mood and emotions, and 
harbours 5-HT receptors. Thus, specific antidepressants targeted at these receptors are likely to 
profoundly affect the patient's mood (Eison, 1989). In addition, the regions of the locus ceruleus and the 
dorsal raphe nucleus lack a blood brain barrier (Felten and Crutcher, 1979) and are therefore likely to be 
extremely sensitive to fluctuations in the serum levels of the amino acid (Maurizi, 1990). Dysfunction of 
these neurons is implicated in depression because they are important elements of the sleep/wake 
mechanism, and disruptions of this cycle are characteristic of depression of the bipolar variety (Jouvet, 
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1972). Cellular losses in the locus ceruleus (Zwieg etal., 1988; Zubenko and Moossy, 1988), dorsal raphe 
- nucleus, and serotonergic ~entral superior nucleus-(Zubenko and Moossy, 1988) are linked to symptoms 
-~ # 
of depression in Alzheimer's disease. 
In addition to its dietary disadvantage, TRP levels are also subject to depletion by stress. Cortisol 
~ - . 
stimulates RNA and protein metabolism in rat liver (Feigel son et al., 1962) through direct interaction with 
deoxyribonucleic acid (DNA). Increased cortisol sequestration by the adrenal glands is stimulated by stress 
resulting in an enhanced catalytic rate of hepatic TDO (Young, 1981) with consequent elevated TRP 
catabolism and kynurenine production. Cortisol release is normally regulated by vasotocin, a hormone 
whose excretion is in turn curtailed by aMT input (Pavel and Goldstein, 1979; Pavel et al., 1977). The 
resultant effect of elevated cortisol concentrations is inhibition of aMT synthesis, thereby effectively 
removing the modulatory influence of the indolealkyleamine. It is thus reasonable to assume that prolonged 
stress w~uld institute an undesirable cyclical chain of events in the following sequence: raised cortisol -+ 
reduced TRP -lowered 5-HT -+ decreased aMT -+ elevated cortisol (Maurizi, 1990). 
Identifying the determinants which control brain TRP thus becomes an important issue, given ~afbrain 
TRP has a major influence on 5-HT synthesis and ultimately on the activity of a population of central 
nervous system neurons. Acute or chronic diseases of the liver are normally characterised by changes in 
the levels of the monoamines, 5-HT and dopamine (DA), and also in the activities of hepatic enzymes such 
as TDO (Litman and Correia, 1985). There are accompanying increases in the levels of certain metabolites 
such as 5-HIAA, homovanillic acid (HV A), neurotransmitters, and also TRP and tyrosine in the bram and 
CSF. These changes are important for two reasons: fIrstly, they cause neurological disturbances (Bloxam 
and Curwn, 1978; Litman and Correia, 1985) and secondly, the mechanism of hepatic TRP elevation in 
the diseased state is unclear. Thus a means is provided whereby the regulatory mechanisms involved in 
the control of TRP levels can be studied. In acute liver failure in animals and man these changes can be 
explained by an increase in plasma free TRP. However in chronic liver failure in man and portocaval 
anastomosis this is not the case (Bloxam and Curzon, 1978; Hirayama, 1971). 
Nonetheless, given that TRP levels in plasma and brain are important, the question arises as to what 
ultimately determines these circulating levels. Are they determined by the enzyme TDO, which is believed 
to be the major peripheral determinant of circulating TRP, or is the regulatory decision made in the brain 
via the rate limiting TRP-hydroxylase? It is speculated that it is specifIcally the ratios and absolute levels 
of the aromatic amino acids, TRP, tyrosine and phenylalanine, which are crucial for uptake into the brain 
for biogenic amine generation. Thus, alterations in the activities of the so-called 'rate limiting hepatic 
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enzymes' - TDO, tyrosine amino transferase and phenylalanine hydroxylase - could secondarily manipulate 
neurotransmitter synthesis via amino acid extraction from plasma. It is inconceivable that anyone 
particular enzyme could have absolute control over a speC"ific pathway, because the metabolic regulatory 
motif invariably involves a 'sharing' between various components of any particular pathway. Although the 
fact that the activity of one enzyme can play a major role is not discounted, it is highly likely that in 
addition to competition for transport into the brain, there is also a scramble for uptake into The hepatocytes 
(Salter etat., 1986). It is thus possible that imbalances in certain amino acid concentrations could give rise 
to alterations in biocatalyst activity - for example, in the TRP-nicotinamide pathway (Shibata et al., 1993). 
1.2.0.1 Biochemical theories of depression 
1.2.0.1.1 Biogenic amine deficiency hypothesis 
The biogenic amine deficiency hypothesis (Schildkraut, 1965; Bunney and Davis, 1965; Lapin and 
Oxenkrug, 1969) states that there is an absolute or relative deficiency of monoamines (Schildkraut, 1965). 
According to this theory, two subtypes of depression prevail. Firstly, there could be a lack of NA at 
noradrenergic receptor sites (or DA at DA receptor sites) or secondly, there could be a deficiency of 5-HT 
at serotonergic receptors in the brain (Bunney and Davis, 1965; Schildkraut, 1965; Coppen, 19~7;Lapin 
and Oxenkrug, 1969). In the case of mania or elation there is a surplus of the neurotransmitter at the 
synapse. Support for this hypothesis stems from clinical observations that efficacious antidepressants act 
by supplementing the available neurotransmitter levels at the post-synaptic receptors via either a blockade 
of monoamine reuptake (as is the case with most T ADs) or, alternatively, through inhibition of monoamine 
catabolism by the enzyme MAO. Results obtained from studies thus far have failed to demonstraie-the 
hypothesised randomness of biogenic metabolism in the depressed state. In addition, these empirical 
observations have neglected to illustrate a clearcut relationship between alterations in monoamine levels 
and antidepressant therapy (Charney et al., 1981). Further criticisms against the simplistic nature of this 
hypothesis are the following: 
a) The efficacious atypical antidepressants, mianserin and iprindole, have a different mode of action 
(Fan etal., 1972 cited in Skene, 1979). 
b) The therapeutic action of antidepressant drugs involves a lag period of approximately 2 to 3 
weeks, but inhibition of reuptake and MAO occurs within minutes (Blier and de Montigny, 1994). 
c) Compounds ineffective as antidepressants, such as cocaine and amphetamines (Hanson, 1967), 
raise the concentrations of catecholamines at their respective synapses. 
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1.2.0.1.2 Dopamine hypothesis 
A major paradox of the indoleamine hypothesis. of depression is the fact that the levels of the DA 
metabolite HV A are lower than those of the NA metabolite 4-methoxy-3-hydroxyphenyl glycol (MHPG) 
as opposed to normal controls in the central nervous system (CNS) (Syvalahti, 1994). This observation 
could imply that DA has a major role to play in depression (Syvalahti, 1994; Blier and de Montigny, 
1994). Support for the involvement ofDA in depressive illness comes from the observation"that TADs and 
some_of the recently developed antidepressants are potent inhibitors of DA uptake in rat brain 
synaptosomes (Randrup and Braestrup, 1977). On the other hand, a reversal of the symptoms of depression 
occurs in some patients treated with a DA agonist, piribedil (Post et aI., 1978) . Nomifensine, which is 
also an inhibitor of NA reuptake, has a similar action (Costall et al., 1975; Schacht et al., 1977). 
1.2.0.1.3 Histamine hypothesis 
This theOry claims that a blockade of central histamine (H) receptors by antidepressants such as the T ADs 
mianserin, iprindole and viloxazine both in vitro and in vivo (fran et al., 1978, 1981; Hall and Ogren, 
1981) are responsible for remission in depressives. ~ receptors are acutely blocked by a range of 
antidepressant drugs (Figge et al., 1979). However the degree of blockade is unrelated to the concentration 
of the blockers. Instead, the potencies correlate well with their ability to induce sedation (Peroutka and 
Snyder, 1980a). 
1.2.0.1.4 Permissive amine deficiency hypothesis 
Here the hypothesis states that a central 5-HT deficiency increases the risk of depression but is not ill Itself 
sufficient to precipitate a depressive episode (Kety, 1971; Prange et al., 1974). What is also required is 
alteration in catecholamine levels, and this would produce the clinical syndrome, depression being 
associated with reduced levels of catecholamines and mania with high levels. The model claims that mania 
and depression are extremes of the same biological dysfunction, with mania being characterised by a more 
pronounced deviation from the normal mood (Court, 1968). This model is supported by the fact that both 
ailments respond to the same antidepressant treatment, for example with imipramine (IMI) (Akimoto et 
at., 1960 cited in Skene, 1979) or lithium (Goodwin et al., 1969). Furthermore, drugs such as cortisone 
can precipitate depression of the bipolar variety (Bunney, 1967). 
1.2.0.1.5 Kynurenine hypothesis 
This hypothesis claims that a link exists between abnormal 5-HT and adrenocortical metabolism (Lapin 
and Oxenkrug, 1969; Curzon, 1969). Hepatic IDO concentrations are increased by hydroxycorticosteroids 
(Knox, 1951; Knox and Auerbach, 1955). This observation provides a basis for the theory, which 
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maintains that in depression there is an increase in plasma cortisol which stimulates TOO synthesis at the 
level Qf the gene, thereby increasing TRP catabQIism and diverting free plasma TRP away from 5-HT 
formation in the brain (Curzon, 1969; Curzon and Bridg~s, 1970). It is thus possible that kynurenine and 
other tryptophan metabolites such as 3-hydroxykynurenine are responsible for the symptoms of depression. 
Experimentally, hydrocortisone has been shown to reduce brain 5-HT and CNS 5-HIAA levels indirectly 
(Curzon and Green, 1968). In addition, increased levels of 3-hydroxykynurenine Ii<ive been noted in 
individuals suffering from endogenous depression (Curzon and Bridges, 1970). Added support for this 
hypothesis comes from the fact that efficacious TADs IMI and DMI inhibit TOO in mice (Parachi, 1970). 
1.2.0.1.6 Tryptamine hypothesis 
This hypothesis (Dewhurst, 1968) has been proposed as an alternative to the monoamine theory of 
depression. It attempts to explain the functions of 5-HT and NA in terms of central receptors. Dewhurst 
asserts- that two types of monoamine receptors prevail: an excitatory type, of which the 5-HT receptor 
(Type A) is an example, and a depressive type, such as the NA adrenergic receptor (Type C). 
Experimental findings obtained from studies on immature chicks after stimulation of the respective 
receptors produced behavioural and physiological excitation (Type A) on the one hand and sedation (Type 
C) on the other (Dewhurst, 1968). The theory supposes that depression is a result of the lack of a 
monoamine or hyposensitivity at a particular receptor, with mania due to excess neurotransmitter or 
supersensitivity of the relevant receptor (Dewhurst, 1968). The hypothesis has two major drawbacks: 
a) The first is the claim that NA and 5-HT have opposite effects. In humans NA is excitatory and 
not inhibitory. 
b) The theory does not account for other neurotransmitters which are known to be implicated in the 
pathophysiology of depression such as DA (Skene, 1979). 
1.2.0.1.7 False transmitter theory 
Examples of false transmitters are ~-methyl-dopa and octopamine (which has 1I100th of the efficacy of 
NA), as these compounds produce very little or no excitation when released. This theory (Murphy, 1972) 
proposes a role for such molecules in depression and states that the reduced central noradrenergic activity 
in depression could be a result of these false neurotransmitters. The overall result is a depletion of central 
biogenic monoamines similar to that effected by reserpine, as proposed by Schildkraut (1965). In patients 
with a history of depression, administration of the precursor of ~-methyl-dopa gave rise to depressive 
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symptoms and suicidal behaviour (Smirk, 1963 cited in Skene, 1979), while in other depressed patients 
with reduced MAO activity:, an accumulation of octopamine occurred in blood platelets (Murphy, 1972). 
-~ . 
Thus far, a limited amount of evidence has been accumulated in support of this hypothesis, and the exact 
role of these substances in depression requires further clarification (Skene, 1979). 
1.2.0.1.8 Cholinergic - adrenergic hypothesis 
This theory (Janowsky et al., 1972a, 1972b) not only implicates the monoamines in affective disorders but 
also other biological amines such as acetylcholine. There is believed to exist a balance between cholinergic 
and monoaminergic transmissions. Disruption of this equilibrium precipitates a major affective disorder. 
Mania results from hyperactivity of the central monoaminergic system and depression is due to central 
cholinergic predominance. In other words, high monoamine and low acetylcholine levels give rise to mania 
while low monoamine and high acetylcholine concentrations result in depression. 
This hypothesis has a strong empirical basis, and major support comes from studies with cholinomimetic 
agents in humans such as physostigmine. Administration of physostigmine to already depressed patients 
promoted depression symptomatology (Janowsky et al., 1972b; Modestin et al., 1973). Furth~nn6re an 
acute dose of physostigmine had a sedative-like effect in a person suffering from mania, which eventually 
resulted in a state of psychomotor retarded depression (Janowsky et al., 1972a; Carroll et al., 1973). The 
indirectly acting cholinomimetic compound, reserpine, produces depression when administered to 
hypertensive patients (Goodman and Gilman, 1975). More evidence in support of this theory stems from 
the fact that the efficacious T ADs· block central cholinergic activity with a concomitant increase in 
adrenergic transmission (Janowsky et al., 1972b; Sulser et al., 1964). However, a-methylparatyrosine, 
a specific blocker of catecholamine synthesis, does not affect acetylcholine levels when given to 
hypertensive patients, nor does it precipitate a depressive episode (Charalampous and Brown, 1967 cited 
in Skene, 1979). 
1.2.1 THE BIOLOGICAL DETERMINANTS OF DEPRESSION 
Research into the biological determinants of depression focuses mainly on two areas: the 
psychopathological and the biochemical (Van Praag, (1982). In most instances depression involves the 
interaction of both biological and psychosocial factors (Blier and de Montigny, 1994; SyvaIahti, 1994). 
Depression is not just due to a shortage of some vital brain neurotransmitter, but rather to a disrupted 
equilibrium between different regulatory systems with resultant neuronal hyperactivity in certain cerebral 
areas. Thus far, a definite causal relationship between the various determinants has not been established. 
There could however be a variety of different types of biological depressions which would require widely 
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differing biological treatment regimens to effect remission (Blier and de Montigny, 1994). There exists 
a relalionship between monoamines and depressi.on that is characterised by disturbances in the normal 
-;t ~ 
levels of certain neurotransmitters. Disruptions in monoaminergic systems are believed to be more a result 
of depression than the cause, and the therapeutic effects of antidepressants apparently involve these 
systems. Principal monoamines are the indoleamine, 5-HT, and the catecholamines, NA and DA. It is 
possible that chronic treatment with antidepressants causes alterations in other neurobiological systems 
which. require monoaminergic input for effective operation. Withdrawal of monoamines in the interim 
would cause a collapse of those systems and result in a relapse with consequent reappearance of the 
symptoms of the depressed state (Delgado et al., 1993; Sulser, 1978). 
The pathophysiology of depression is also believed to include, inter alia, alterations in the effects of second 
and third messenger systems, protein kinases, phosphoproteins and phospholipids. Therapeutic action of 
antidepressants could depend on restoration of functional aberrations which· pertain to all of the above (Lui 
et al., 1985). 
1.2.1.0 5-HT and depression: Indoleamine hypothesis 
The indolealkyleamine, 5-HT, was fIrst discovered in the intestine (Vialli and Erpsamer, 1933), in serum 
(Rapport et al., 1947) and eventually also in peripheral tissues such as the gastrointestinal tract and heart 
(Twarog and Page, 1953). Ten years after its initial discovery, the neurotransmitter 5-HT's distribution 
profIle was histochemically characterised in the brain and this observation prompted intense investigation 
with respect to its localised physiological roles (Frazer et al., 1990). 
Interest in the possible role of 5-HT receptor operation in depression was stimulated by a number of 
observations : 
a) The requirement of an intact 5-HT system for antidepressant-induced changes to occur in 
adrenergic receptors (Sulser, 1984). 
b) The effects of antidepressants were either sensitisation of post-synaptic 5-HT3 receptors (De 
Montigny, 1981) or alterations in receptor number (Cowen et al., 1986). 
c) Animal models revealed post-synaptic 5-HT receptor sensitisation, as well as certain pre-synaptic 
effects on the 5-HT system using lithium (Price, 1989). 
Several lines of clinical and preclinical evidence implicate the 5-HT system in the therapeutic mechanism 
of action of antidepressants (Delgado etal., 1990; Blier and de Montigny, 1994). Firstly, all selective 5-
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HT reuptake inhibitors are effective in major depression. These drugs belong to different families, and the 
only Pioperty that they have in common is the ability to inhibit 5-HT uptake. Secondly, inhibition of 5-HT 
- -
synthesis in remitted patients results in an immediate~eiapse, with symptoms identical to those of the 
earlier depressed state. It is also possible that a component of plasma plays a role in depression via 
inhibition of 5-HT binding to its receptors. A peptide from bovine forebrain is known to inhibit 5-HT 
receptor binding by the selective antidepressants mianserin and ketanserin (Roth et aI., f985). 
However the notion that a number of different neurobiological systems are involved in the pathophysiology 
of depression is supported by the following observations: 
i) Not all patients suffering from major depression depict a reduced nor adrenergic and serotonergic 
output (Blier and de Montigny, 1994). 
ii) - It has not been possible to bring about a clinically certifiable depressed state in healthy individuals 
by inducing a lack of 5-HT or NA either through TRP depletion (in case of 5-HT) (Park et ai., 
1974) or with the use of a catecholamine inhibitor ("-methyl-para-tyrosine) for NA. 
Nevertheless, a substantial body of evidence has thus far been collected in support of the 30 year old 
indoleamine hypothesis, which asserts that modifications in 5-HT neuronal function are a core feature of 
depression. The traditional monoamine hypothesis asserts that there is a metabolic and functional 
aberration in depression, and drugs which curtail the availability of 5-HT and NA precipitate depression 
while those which enhance their abundance are therapeutic (Coppen, 1967). This, however, was modified 
once it was realised that some monoaminergic receptors could be downregulated (Sulser, 1979). It is now 
hypothesised that there is monoaminergic hyperfunction in depression, and antidepressants operate so as 
to downregulate post-synaptic monoamine receptors (Van Praag, 1982). 
Several research strategies have been employed to acquire empirical evidence to validate this theory. These 
include: 
a) measuring peripheral indices of monoamine metabolism, 
b) post-mortem determinations of the biogenic amine levels and identification in brain tissue of 
suicide and/or depressed individuals whose death was not due to unnatural causes, 
c) analysis of CSF monoamine metabolites, 
d) evaluation of the efficacy of drugs on central monoamine metabolism in depressives, and 
e) endocrine research stimulated by the knowledge that the release of hypophyseal hormones is to 
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a certain extent affected by biogenic amines and brought about through hypothalamic inhibiting 
_ and releasing f~rs, and thus disturbances in hormone release could be related to dysregulation 
of monoamine metabolism (Van Praag, 1982). 
Some of the major findings are, inter alia: 
a) The prime metabolite of 5-HT, 5-mAA, depicts reduced levels in the CSF of drug free depressed 
- patients (Davis et al., 1981). 
b) Post-mortem studies on brains of depressed or suicidal patients also display reduced concentrations 
of 5-HT and 5-HIAA (Gibbons and Davis, 1986). 
c) Chronic clinically efficacious antidepressant treatment enhances 5-HT neuronal transmission in 
the laboratory rat (De Montigny and Aghajanian, 1984). 
d) Depressed patients have a reduced level of plasma TRP, and serotonergic antidepressant-
dependent remittance depicts a clear dependence on an adequate supply of TRP, given that a lack 
of this precursor results in an immediate relapse (Delga,do et al., 1990). 
e) Post-mortem brain tissue of depressed suicide victims (Stanley and Mann 1983; Mann et al., 
1986), drug free depressed patients (Yates et ai., 1990) and platelets of drug free depres~cases, 
display definite increases in the levels of 5-HT2A receptor binding sites (Arora and Meltzer, 1989; 
Pandey et al., 1990). 
o There are lowered levels of the 5-HT transporter binding sites in the frontal cortex and 
hypothalamus of depressed suicide victims (Stanley et al., 1982), depressed patients (Leake et ai., 
. -
1991) and in the platelets of drug free depressed individuals (Nemeroff et al., 1988). This 
reduction in transporter binding sites in platelets is not due to prior drug treatment or 
hypercortisolemia and is also not present in mania, Alzheimer's disease, schizophrenia, panic 
disorder, atypical depression or fibromyalgia. This implies a depression peculiarity (Mann et al. , 
1989). 
g) Reserpine, which is a depleter of monoamines from synaptic vesicles and also prevents vesicular 
amine transport, produces depression-like symptoms in rats (Curzon, 1969). 
1.2.1.0.1 The significance of 5-HT disturbances 
The question now arises as to whether these abnormalities in 5-HT levels are necessary events for 
depression to occur, or whether these are disturbances that could make a particular individual susceptible 
to depression. Thus far, research fmdings point to the likelihood of aberrant 5-HT metabolism increasing 
the risk of depression. There are a number of factors in support of this hypothesis which are, inter alia, 
decreased levels of both 5-HIAA and MAO plus high TDO activity persisting after remission in certain 
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subtypes of depressives. By implication, increasing 5-HT concentrations should be prophylactic, because 
_ if 5~HI plays an important role in the pathogenesis of depression then factors that could potentially affect 
-~ # 
5-HT synthesis should be effective in treating depression. The molecular substances generally used 
normally increase 5-HT availability at the 5-HT receptors. Of the endogenous compounds, 5-
hydroxytryptophan (5-HTP) has been more successful than TRP in increasing 5-HT levels (Van Praag, 
1981; Jimerson et aI, 1990). The most efficacious antidepressants clinically are -fluoxetine and 
fluvox.amine. How effective a particular antidepressant therapy is ultimately appears to depend, to a certain 
extent, on dietary factors involved in 5-HT synthesis, as well as other changes in the implicated 
monoaminergic neurobiological system (Jimerson et aI, 1990). 
1.2.1.0.2 Biochemical studies 
The accumulation of the 5-HT metabolite 5-HIAA provides a crude yardstick of CSF 5-HT metabolism 
in clinicaI depression. Low levels of 5-HIAA in CSP are a comnion denominator in approximately 50% 
of all cases of vital depression (Ashberg et al., 1976). It is unclear whether there is a correlation between 
these two variables. However post-mortem studies on certain raphe nuclei revealed diminished 5-HT and 
5-HIAA concentrations. Thus far no consistent link can be shown to exist between low CNS 5-HIAA-levels 
and major depression, but in suicidal and aggressive depressives there appears to be a causal relationship 
(Twarog and Page, 1953). Concentrations of 5-HT and 5-HIAA have reportedly been reduced in certain 
rat cerebral areas following chronic treatment with the TAD, 1M!. In addition, the levels of DA were 
changed while those of N A displayed only minor alterations (Fernstrom et al., 1971). There could also 
be a link between low cholesterol and low 5-HIAA levels (Gross et aI., 1991). Another index of CSP-5:'HT 
turnover in clinical depression is the reduced plasma ratio of TRP to LNAA in depressives. The clinical 
efficacy of a SSRI such as tluvoxamine has been evaluated using this specific amino acid profIle in 
individuals suffering from major depression. This plasma TRP/LNAA ratio was found to serve as a good 
indicator of cerebral concentrations of TRP and 5-HT, and could function as a predictive biological index 
response to treatment with efficacious SSRIs (Carlson et al., 1972). 
1.2.1.0.3 Peripheral studies 
Peripheral serotonergic markers of a depressed patient' s clinical state are platelets and the neuroendocrine 
system. The function of 5-HT in platelets is believed to be in blood coagulation where it plays a role in 
platelet activation, alterations in shape and aggregation (Worral and Williams, 1994). Both peripheral 
indices, platelets and the neuroendocrine system studies indicate that there is serotonergic receptor 
dysfunctioning in depression. The availability of specific markers for the variety of 5-HT receptor subtypes 
should facilitate further clarification of the extent and nature of these proposed irregularities (Stahl, 1992). 
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1.2.1.0.4 5-HT receptors 
Several different subtypes of the 5-HT receptor are-believed to exist, namely 5-HTw 5-HT1B' 5-HT2B' 5-
- -(; # 
HTm , 5-HT1P' 5-HT2 and 5-HT3 (Zemlan et al., 1988). These subtypes are classified pharmacologically 
according to the drug that blocks the normal expression of the signal transducers and second messengers. 
As is the case with other biogenic receptors (cholinergic, dopaminergic and adrenergic), the various 5-HT 
~ - ~ 
receptor subtypes are linked to a number of different second messengers (Frazer et al., 1990). Three 
clearly defmed 5-HT receptor subtypes have been found to be linked to adenyl cyclase in the vertebrate 
brain - namely, 5-HT1A' 5-HTlB and 5-H1n . Even though these receptors are known to activate or 
stimulate AC via G-protein couplings, it is not as yet possible to discern whether the individual receptor 
subtypes are linked to Gs or Gj • Thus far, in the rat hippocampus, the 5-HT receptor has been found to be 
linked to both inhibitory and stimulatory G-protein. Two receptor subtypes 5-HT1C and 5-HT2 are believed 
to be linked to phosphoinositide hydrolysis via phospholipase C activity (Hanson et al., 1987). 
1.2.1.0.5 The 5-HT Transporter 
Four classes of neurotransmitter transport vesicles are recognised - namely, Ach, glutamate, 
GABNglycine and the monoamine transporters. These transporters are highly specific for their ~espective 
substrates (Mann et al., 1989). 
The mode of action of both the T ADs and certain 5-HT reuptake inhibitors involves binding to a 5-HT 
transporter protein. The T ADs bind specifically to this transporter with the most potent being 1M1 and 
citalopram (Worral and Williams, 1994). Biochemical and pharmacological studies reveal distinc( areas 
of specific functions (Giros et al., 1994), and SSR1s such as fluoxetine, paroxetine and citalopram bind 
almost to exactly the same site as 5-HT (Owens and Nemeroff, 1984). TAD binds to transmembrane 
domains 6 to 8, while 9 to 12 through the COOH terminus are responsible for stereoselectivity and high 
affinity for substrate (Helmeste and Tang, 1994). The 5-HT transporter is known to have two binding sites 
for 5-HT in addition to two sites for TADs (Worral and Williams, 1994). 
Molecular characterisation reveals that all known neurotransmitter transporters (5-HT, NA, DA, GABA 
etc.) display significant sequence homology within their 12 membrane spanning domains. They also exhibit 
- between the transmembrane domains 3 and 4 - glycosylation sites on the extracellular loop with tentative 
phosphorylation sites on the intracellular side (Owens and Nemeroff, 1984) (fig. 4). The 5-HT transporter 
has been isolated in three forms of 45-, 56- and 68kda (Tamir et al., 1994). Little is known about 
physiological transporter regulation with respect to activity, stability or lipid requirement. 
FIG. 4: 
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Determinants for 
substrate affinity 
and stereoselectivity. 
Working model of the various putative functional domains of Na+ ICI-- dependent 
transporters [Giros et aZ., 1994]. 
Certain transporters such as the GABA and glutamate require cholesterol with a high specificity and 
potency. The 5-HT binding protein and related members have, as previously stated, potential 
phosphorylation sites for cAMP dependent protein kinase A and protein kinase C. Protein kinase C is also 
possibly involved in regulation of transport (Worral and Williams, 1994; Helmeste and Tang, 1994). It 
has been reported that 5-HT transport in human blood platelets is reduced by protein kinase activatOrs 
(Worral and Williams, 1994). Marked reductions in transporter mRNA occurred after chronic 
antidepressant treatment with the non-specific 5-HT/NA reuptake inhibitor IMI and the selective 5-HT 
reuptake inhibitor fluoxetine. This effect, however, could not be duplicated with the MAO inhibitor 
clorgyline or a 5-HT agonist such as 8-hydroxydipropylaminotetralin (Lesch et aZ., 1993). However, 
experimental evidence does appear to support the notion of 5-HT transporter synthesis regulation at the 
level of mRNA transcription (Owens and Nemeroff, 1984). 
1.2.1.0.6 Pharmacological studies 
Pharmacologically, the biogenic amine deficiency hypothesis appears to be the most pertinent with respect 
to defining the underlying neurobiochemical phenomena responsible for depression symptomatology. This 
view is supported by the fact that remission in clinically depressed individuals is accompanied by a 
restoration of normal biogenic amine levels. Antidepressants such as the T ADs, MAOIs and SSRls, whose 
mode of action forms the basis of this theory, are at present the most effective in clinical treatment of 
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depression. These antidepressant drugs raise the synapse concentrations of 5-HT and catecholamines such 
as NA (Daya, 1994). Overall, however, the conventiona1.therapeutic strategy in the investigation of the 
events occurring during depression involves use of 5-HT precursors TRP, 5-HTP, the TADs,SSRls and 
post-synaptic 5-HT agonists. Thus far the results obtained implicate 5-HT in mood regulation (Van Praag, 
1982), and most antidepressants enhance serotonergic function (Lui et al., 1985). Drugs which selectively 
facilitate 5-HT mediated neurotransmission are d-fenfluramine, citalopram, fem9xetine, fluoxetine, 
zimel~dine and fluvoxamine (fig. 5). 
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Effective recovery due to antidepressant therapy depends on an intact and functional 5-HT neuronal system 
(Lui et al., 1985). Antidepressants that interact with neurotransmitters other than 5-HT induce 
carbohydrate (CHO) craving and weight gain (Wurtman and Wurtman, 1988). Not all antidepressants are 
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amine uptake inhibitors and these are called atypical antidepressants which are effective in treating atypical 
depression. Atypical depression does not express the conventional symptomatology of depression (such as 
insomnia, appetite loss and psychomotor agitation) and is Cbaracterised by hyperphagia, excessive sleeping, 
persistant fatigue, mood alterations and chronic sensitivity to rejection (Horwath et al., 1992). Examples 
of atypical antidepressants are iprindole and mianserin which block pre-synaptic ltz-receptors thereby 
raising NA synaptic junction levels (Pinder et al., 1982) in addition to inhibiting TDG. Three major 
groupings characterise antidepressant drugs pharmacologically: T ADs and MAOIs (both of which are 
termed first generation antidepressants), and the newer second generation antidepressants which differ both 
structurally and pharmacologically with respect to the TADs and MAOIs (see fig. 5). These so-called 
second generation antidepressants are further separated according to whether they prevent NA or 5-HT 
reuptake. Within this particular group are the previously mentioned atypical antidepressants and the SSRIs 
(such as fluoxetine) (Banoo, 1991). 
Most antidepressant drugs are thought to mediate their specific action through the 5-HT lA receptor sites 
located in the raphe of the hippocampus (Blier et at., 1987). First generation antidepressant drugs increase 
the availability of 5-HT and NA at their central receptors (Kopin, 1981). The mechanisms involvedjn this 
process are: 
a) reuptake inhibition by TADs mainly of NA and in certain instances 5-HT, and 
b) inhibition of degradation by MAOI. The T ADs such as DMI, nortryptaline, IMI, doxepin and 
amitryptaline are relatively selective NA reuptake inhibitors in vitro. 
The first clinically effective antidepressants were the MAOIs (eg tranylcypromine), but they were 
superceded by the T ADs for a number of reasons which mainly revolve around the undesirable side effect 
profile. The primary mechanism of action involves inhibition of MAO by binding to the active site on the 
enzyme (ie competitive inhibition) in brain and peripheral tissue (Kline, 1958). These antidepressants are 
effective in treating atypical depression, specifically the older type of non-selective MAOIs (Liebowitz et 
al., 1988). 
Antidepressants exert part of their therapeutic effect through enhancing serotonergic and noradrenergic 
activity at their respective synapses. The efficacy of the SSRls such as fluoxetine is believed to depend on 
5-HT while that of T ADs is more dependent on the availability of N A. This inference is based on the fact 
that remitted patients on fluoxetine experienced an immediate relapse during acute TRP withdrawal, while 
remitted patients on D MI hardly responded when subjected to similar treatment (Delgado et al., 1993). 
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Research data indicate that most antidepressants do not have a common mode of action: some such as the 
_ TADsp1ay affect the 5-HT neuronal system and the_ noradrenergic system (Lemberger et al., 1985) while 
others affect the serotonergic system only (eg SSRIs) (Delgado et al., 1993a; Lemberger et al., 1985), 
The second generation antidepressants have a similar mode of action and are selective reuptake inhibitors 
of catecholamines (maprotilene and nomifensine for N A, and nomifensine for DA):- T ms also inhibit 
hepati!: TDO in order to increase plasma TRP levels and ultimately brain TRP and 5-HT (Badaway and 
Evans, 1981). 
The atypical antidepressants, mianserin and iprindole, are drugs which are structurally and 
pharmacologically very diverse, have a limited ability to prevent reuptake of NA and 5-HT, but are 
known to inhibit TDO (Van Praag, 1982). The tricyclic DMI is also effective as an analgesic in diabetic 
neuropathy, acting via a noradrenergic dependent mechanism (Courteix et al., 1994). However, even 
though the T ADs have widespread use and are efficacious in clinical psychiatry, their use has a number 
of drawbacks. Due to their nonspecificity, these drugs have a broad pharmacological spectrum and affect 
a number of other physiological systems. 
Clinical data obtained from depressives indicate that chronic treatment with tricyclics, such as DMI, 
elevates plasma N A (Veith et al., 1 994). This effect could be primarily due to two reasons: firstly, there 
could possibly be desensitisation of CNS pre-synaptic ~-adrenergic receptors and, secondly, there might 
be enhanced sympathetic nervous system (SNS) activity. It was also experimentally determined that the 
increase in serum NA is not due to a redU(;ed plasma clearance rate. On the other hand, contradictory 
findings have been reported which claim that T ADs blunt SNS neurotransmission in both healthy and 
depressed subjects. Nevertheless, this latter effect can be ascribed to an initial brief transitory ~­
adrenergic receptor downregulation, and thus this manifestation could probably be an important aspect of 
the mode of action of the T ADs (Veith et al., 1994). 
However, chronic DMI therapy has been found to result in a reduction in the number of post synaptic p-
adrenergic receptors (Goodnough and Baker, 1994). In rats, chronic D MI causes p-adrenoreceptor 
downregulation in a dose dependent manner, an effect which is potentiated by fluoxetine. The SSRI 
fluoxetine on its own, however, does not induce a similar effect on either p-adreno- or 5-HT receptors 
(Banerjee and Kung, 1977; Goodnough and Baker, 1994). 
5-HT plays a role in controlling food intake and macronutrient selection. Stimulation of paraventricular 
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and ventromedial nuclei of the medial hypothalamus by 5-HT leads to satiety and termination of eating (Pijl 
et al., 1991). Fluoxetine has proven to be effective in treating obesity in humans, which provides evidence 
- -
for its action on serotonergic pathways (Wurtman<and Wurtman, 1989). In rats and mice, the 
antidepressant also causes a dose dependent reduction in food intake (Goodnough and Baker, 1994). 
The high specificity of the two SSRIs, fluoxetine and norzimelidine, has been aptdy demonstrated in 
humaQS. In depressed individuals the ratio of zimelidine to its N-methylated derivative norzimelidine is 
1:7 in the CSF, but with no accompanying reduction in CSF MHPG concentrations. DMI levels, however, 
correlated well with a reduced count of MHPG, and this highlights the specificity of newer SSRIs such as 
zimelidine/norzimelidine and fluoxetine, and the noradrenergic orientation in the mechanism of action of 
a tricyclic such as DMI (Potter et al., 1981). Further evidence, in support of the assertion that 
norzimelidine and fluoxetine selectively inhibit 5-HT uptake, is based on the fact that they both 
significantly lower the concentrations of the 5-HT metabolite 5-HIAA in the CSF (Meltzer et al., 1979). 
Chronic and acute treatment of depressed patients with SSRIs had almost no effect on the neuroendocrine 
system, and these results contrast with those obtained from using the rat as a model where significant 
changes are brought about when they are subjected to similar treatment regimes as humans (Syvalahti, 
1979). 
All SSRIs share the same pharmacological profIle but have different physicochemical properties, and thus 
have a varied physiologic disposition with respect to absorption, distribution, metabolism and excretion. 
However they are generally well absorbed, requiring from 4 to 8 hours to reach a plasma peak. -The 
treatment regime of the SSRIs depends to a large extent on their half life in the body (Lemberger et al. , 
1985). The half life of fluoxetine is 24-60h (Lemberger et al., 1978) and of citalopram is 33h (Overo, 
1982). These compounds require a once daily dose, whereas zimelidine (8h) and fluvoxamine (15h) have 
to be administered in multiple daily doses (Lemberger et al., 1985 ). 
A major criticism against the marketing of these SSRIs is that the clinical drug trials have been conducted 
over too short a time period - namely, less than 6 weeks - and have only involved out-patients with 
moderate degrees of depression (Ferrier, 1993). Recent chronic studies with fluoxetine, over a period of 
six months, indicated a loss of efficacy with prolonged use. Fluoxetine metabolism is not affected by age, 
obesity or renal impairment. However the dosage administered is important, given that high doses of 
+500jLg/l result in loss of efficacy (Altamura, 1994). This is ascribed to the fact that SSRIs such as 
fluoxetine depend on the presence of endogenous 5-HT to exert their therapeutic effect. Proof of this 
dependence comes from the observation that combined therapy with a partial agonist of the 5-HT lA 
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receptor subtype, buspirone, whose efficacy is independent of 5-HT, restored antidepressant activity 
(Fabr~ et al., 1990). 
In conclusion it can be stated that the SSRIs, because of their neurochemical specificity, have contributed 
significantly towards an understanding of some of the underlying mechanisms of depression (Ferrier, 
1993). However, as is the case with all other antidepressant therapies, short term treatment'is not effective 
in preyenting a relapse, and maintenance dosing regimens are required. There is now general consensus 
that depression necessitates prolonged therapy, since discontinuation of interim treatment results in re-
emergence of the earlier depressive symptoms in 50% of all clinical cases (Delgado et al., 1993). 
1.2.1.0.7 The 5-HT syndrome 
This disease arises due to elevated toxic concentrations of 5-HT which call occur in both animals and 
humans-. However most of the available literature on the 5-HT syildrome has been acquired from studies 
done on animals (Brennan et al., 1988) where the symptomatology includes, inter alia, tremor, rigidity, 
hypertonicity, hind-limb abduction, rigidly arched tail, lateral head shaking and generalised seizures 
(Gerson and Baldessarini, 1980). In humans the disease is not recognised and is generally known as 
neuroleptic malignant syndrome (Brennan et al., 1988). The most common manifestations of the syndrome 
in clinical subjects are psychological disturbances, agitation, myoclonus, hyperflexia, diaphoresis, 
shivering and tremor (Oates and Sjoerdsma, 1960). 
1.2.1.0.8 Why the three week delay in antidepressant action? 
A major criticism against the monoaminergic hypothesis of depression is its inability to explain the one to 
three week lag period before the therapeutic effects of antidepressants are manifested. Possible reasons 
for the delay which have been proposed are, firstly, adrenoreceptor downregulation (Reisine, 1981), 
secondly, tyramine accumulation which would result in desensitisation of adrenergic receptors (Edwards, 
1982) and, thirdly, the initial disorienting caused by the antidepressant drugs to dysregulated 
monoaminergic systems (Waldmeier, 1982). An alternative explanation proffered to account for the delay 
suggests that this period is necessary to allow for re-entrainment of the endogenous biological clock (Wehr 
and Wirz-Justice, 1982). However, this lag period could also indicate that receptor modification is a 
prerequisite that is necessary or sufficient for antidepressant activity (Stahl, 1992; Charney et al., 1981). 
A paradox in the treatment of depressives with SSRIs is the fact that they inhibit the reuptake system within 
minutes but require the usual lag period of up to three weeks to exert their therapeutic effect. This 
phenomenon clearly implies that inhibition of reuptake is only part of the mechanism of action of the SSRI 
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and that additional adaptive biological changes in serotonergic· receptor system operation underlie their 
action (Blier and de Montigny, 1994). 
1.3 MELATONIN 
The neurohormone melatonin is a ubiquitously acting biological substance within the mammalian body 
(Reiter, 1991a), and can be found in both pineal and extra-pineal tissue. At first, aMI was believed to 
origin_ate in the pineal only, but now the hormone is known to be synthesised in other tissues as well, 
particularly in the gut where its concentration can be several-fold (as much as 100 times) greater than in the 
pineal (Raikh1in et al., 1975). Rats appear to have extra-pineal aMT synthesising machinery due to the fact 
that large TRP doses increase serum aMT levels, but not pineal N-acetyl transferase (NAT) or hydroxyindole-
O-methyltransferase (HIOMT) activity (Yaga et al., 1993). In human beings no such effects are observed 
and no extra-pineal plasma aMT producing centres have been demonstrated as yet (Lewy, 1983). However, 
human- pineals have thus far been shown to contain the highest concentration of 5-HT for any neural 
structure (Gairman and Day, 1958). Nocturnal aMT levels in humans appear to be subject to large variations 
with no correlation between the concentrations and age, anxiety, depression or sleep ratings (Smith et al.; 
1991). 
There appears to be differential aMT metabolism in different organisms. Organ culture experiments indicate 
that in certain species, such as the Syrian hamster, a long lag period of ±7 hours after noradrenergic 
stimulation is required for mRNA transcription prior to aMT synthesis, unlike in the rat where pineal aMT 
synthesis can occur within 1 to 2 hours of enhanced nocturnal NA release (Santana et al., 1990). The pineal 
gland is the interface between the photoperiodic environment and the internal milieu, where it functions as 
a transducer of the photic signal into a chemical response via neural input in the form ofNA (Reiter, 1991 a). 
It is speculated that most body organs are subject to the influences of the pineal gland through the release 
of the neuroendocrine modulator, aMT. The aMT molecule is released from the pineal irrespective of whether 
the individual is diurnal or nocturnal and, in humans, aMT has a well developed circadian rhythm, peaking 
at subjective night while remaining basal during the subjective day (Lynch et al., 1975) (fig. 6). 
aMT secretion by the rat pineal gland provides a realistic assessment of noradrenergic neurotranmission 
within this species (Thompson et al., 1985). Denervation of the pineal gland prevents the nocturnal elevation 
in both brain and plasma aMT levels, which clearly demonstrates that the nightly rise in the neurohormone 
is a consequence of pineal secretion. Nocturnal increases in pineal aMT display species differences, and 
there is a proportional relationship between the photoperiod and nightly aMT levels. A relatively minor 
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there is a proportional relationship between the photoperiod and nightly aMT levels. A relatively minor 
number of animals do not display the nocturnal increas~ in pineal aMT even though the integrity of 
biochemical components,-believed to be instrumental' in aMT circadian rhythmicity and synthesis, is 
retained (Reiter et al., 1987). Blood and pineal aMT concentrations are very similar which seems to imply 
that there is a rapid output from the pineal into the bloodstream, apparently utilising an active secretory 
mechanism and short term retention that could be characteristic of both diurnal and-noeturnal animals. 
Circadian rhythms in body fluids also appear to be directly dependent on plasma aMT derived from the 
pineal gland (Reiter, 1988), and the aMT rhythm is constant and reproducible for any particular individual 
(Arendt, 1988). The levels of pineal aMT and 5-HT appear to be regulated independently of blood TRP, 
given the finding that a pronounced reduction in serum TRP had a negligible effect on pineal aMT and 5-
HT (Daya, 1989). 
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aMT is transported in the blood mainly bound to SA and the neurohormone has a half life of between 10 
and 40 minutes. Liver aMT metabolism clears approximately 90 % in a single passage through the hepatic 
portal system (Pardridge and Mietus, 1980). Of this 90 %, microsomal enzymes convert 75 % to 6-
hydroxy-aMT with subsequent conjugation of about 70 % to 6-sulphatoxy-aMT and the rest to glucuronide 
(Kopin et al., 1961) (see fig. 7). Urinary 6-sulphatoxy-aMT is a reliable indicator of pineal aMT output 
(Brown et al., 1991) (fig. 7). Of the total aMT released by the pineal, only approximately 1 % escapes 
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catabolism in the liver. Metabolism of the indoleamine in the brain follows a different route. Here the 
molecllle is transformed into N-acetyl-5-methoxykynurenamine and small amounts of other minor 
metabolites. All catabolic products are ultimately excreted in the urine with an obvious higher nocturnal 
than diurnal rate of urinary elimination. During TRP depletion there is a marked reduction (± 80 %) in 6-
hydroxy-aMT sulphate, which is coupled to a much reduced serotonergic tone in the presence of low levels 
of 5-HT (Zimmermann et al., 1993b). 
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aMI receptors 
aMT receptors have been identified and characterised in a large number of species such as the rat, Syrian 
hamster, bat, ostrich etc. These receptor sites are ubiquitous in lower vertebrate brain where they are 
predominantly found in retinal, auditory and limbic systems (Rivkees et al., 1989). In the mammalian 
brain they are to be found at a much lower density and are mainly limited to individual brain nuclei. No 
sex differences with respect to receptor density have as yet been demonstrated (Morgan et al., 1994). The 
most generously endowed area has been found to be the pars tuberalis (PT) (Morgan and Williams, 1989) 
of the pituitary followed by the supra chiasmatic nucleus (SeN) (Reppert et al., 1988) and the pars distalis 
(PD) (Williams et al., 1981). Receptors are also found in the gonads and gut. At present the physiological 
and functional significance of the distribution of aMT receptors is not clear. These receptors were 
identified using 2-[125I]iodomelatonin in both brain and peripheral tissues such as the gut and retina. The 
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strucrural analogues. Specific binding sites have only been demonstrated for those receptors of the PT and 
PD (Morgan et al., 1994). So far, research fmdings indicate that only high affinity receptors yield a 
consistent response when ·stimulated, and these are either linked to the second messengers cAMP or 
phosphoinositide, as has been shown in ovine PT (Morgan et al., 1990). It is possible that the entry of aMT 
into the cell does not necessarily require a receptor protein in all instances. The indoleamine could move 
freely into the cell due to its hydrophobic nature. Recent studies, however, demol'istrate that the 
neuro~ormone is soluble up to 5mM in aqueous media (Shida etal., 1994). 
1.3.0.1 Structure-activity relationships 
The elucidation of the strucrure-activity relationship of the aMT receptor involves not only pharmacological 
binding studies, but also functional bioassays. Little attention has, however, been paid to the relationship 
between binding activity and pharmacological efficacy, except in the retina where excellent correlation 
exists between these two parameters (Morgan et al., 1994). The high affmity of indolic compounds such 
as aMT and its derivatives depicts a large degree of consistency between different tissues and species. 
Amongst the indoleamine derivatives of aMT, N-acetyl-5~methoxytryptamine with a halogen substitution 
at the C2-atom displays the highest activity, surpassing even that of aMT when tested in functional 
bioassays (Sugden and Chong, 1991). 
1.3.0.2 Agonists of the aMT receptor 
The biological activity of aMT is not dependent on the 5-methoxy group, and aMT derivatives lacking the 
5-methoxy group have proven to be potent agonists of the aMT receptor (Sugden, 1991a). In the hamster 
brain the compound which lacks the 5-methoxy group, N-acetylserotonin, has also been shown to be as 
potent an agonist as aMT (Duncan et al., 1986). However the 5-methoxy group is generally important for 
binding (Sugden, 1994a). Synthetic aMT analogues can be created with modifications to the N-acetyl side 
chain or the C5-atom on the indole ring of the parent molecule aMT. Side chain modifications beyond five 
carbons and homologation resulted in a significant loss of activity (Sugden, 1991a). The indole nucleus was 
found not to be essential for activity or initiation of receptor mediated events. Substitution of the indole 
nucleus with naphthalene had no significant adverse effects, and cyclisation of the side chains of both 
naphthalene and aMT profoundly enhanced binding to the receptor protein (Sugden, 1994b) (fig.8). 
In hamster brains, prazosin, a non-indole and "cadrenergic selective blocker, has been reported to bind 
with high affmity to aMT receptors (Niles, 1989). Other agonists include the amidotetralines that cause 
Ca2+ -dependent dopamine release in humans (Dubocovich et al., 1992). 
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FIG. 8: Structures of the chroman analogues (1) and aMT (2) [Sugden, 1994b]. 
1.3.0.3 Antagonists of the aMT receptor 
The most potent naturally occurring antagonist of the aMT receptor in vivo has been found to be 6-
methoxybenzoxazolinone (Sanders, et al., 1981). However this effect could not be reproduced in-vitro 
(Sander et al., 1981). Luzindole, a competitive antagonist, inhibits Ca2+ -dependent release in rabbit retina 
and melanophores, but there is a lack of consistency in the molecule's affmity for the aMT receptor, given 
the observation that binding by the antagonist to aMT receptors is negligible in ovine PT (Niles, 1987). 
Generally, side-chain additions of more than five carbons function as antagonists (Sugden, 1991 a). At 
present, studies pertaining to the development of effective agonists and antagonists of the aMT receptor 
are still in their infancy, and thus preclude a definitive classification system based on the properties of these 
synthetic ligands (Morgan et al., 1994). 
1.3.0.4 Regulation of the aMT receptor 
Numerous experimental findings indicate that aMT operates via a cAMP dependent mechanism, 
particularly in melanocytes (White, et al., 1987; Sugden, 1989; Sammak, et al., 1992). However other 
observations indicate that the indoleamine could act through alternative second messenger signalling 
systems (Morgan et al., 1994; Sugden, 1991b). This inference is based on the fact that phorbol esters, 
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which activate PKC, reverse or inhibit the aMT initiated pigment aggregation in melanocytes. In the PD 
of the pituitary gland, aMT appears to act exclusively by i~ibiting Ca2 + by means of a voltage dependent 
L-type channel. The neurohormone could thus -influence membrane potential via hyperpcilarisation, 
repolarising the depolarising effects of lutenizing hormone releasing hormone (LHRH) (Sugden, 1994a; 
Vanacek and Klein, 1992a, 1992b) which involves the induction of calcium flux into the cell (Vanacek 
and Klein, 1992b). 
1.3.1 Regulation of aMI synthesis 
The rate limiting enzyme in aMT biosynthesis is accepted to be N-acetyltransferase, as has been shown 
empirically in the rat and the majority of other animals (Klein, 1985). However, a few exceptions exist 
where no correlation is noticeable between NAT activity and pineal aMT output (Reiter, 1991a). The 
activity of this enzyme changes positively during aMT synthesis (fig. 6). 
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- ---' Stimulation of NAT is initiated by NA interacting with adrenergic receptors of the pinealocyte membrane 
(Klein et al., 1981) which activate AC via Gs , with consequential increases in cAMP levels (Smith et al., 
1979) (fig. 10). 
A variety of factors influence the levels of circulating plasma aMT, and the major effector is believed to 
be the photoperiod. This regulatory influence holds for both humans and animals, and alterations in aMT 
blood patterns have parallel physiological modifications. The specific component of the aMT rhythm which 
imparts the message relating to the identity of the photoperiod to the organism, in order to effect the 
appropriate physiological changes, is stilI a matter of controversy. 
Three major hypotheses (fig. 68) have been proposed in an attempt to explain this phenomenon which 
pertains to that aspect of the neurohormone biological rhythm involved in conveying the neuroendocrine 
message to a particular organ. These are: 
i) the duration hypothesis (Carter and Goldman, 1983), 
ii) internal and external coincidence theory (Reiter, 1987), and 
iii) the amplitude hypothesis (Berga et al., 1988). 
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[Reiter, 1991b]. 
In the duration model, the aMT peak is set by annual oscillations in the daily photoperiod which exact 
appropriate physiological adaptations in the organism, as is the case with seasonal reproduction in animals 
such as sheep. On the other hand, the internal and external coincidence hypothesis asserts that there exists 
a window of sensitivity, equivalent to a time period at night within which the organism is sensitised to 
respond to the aMT peak. This time slot of susceptibility can either be determined by the environmental 
lighting conditions or by aMT itself. It is only when the peak of the indoleamine coincides with this time 
frame that a physiological change will be effected. Autoregulation of its receptor by aMT is possible. 
However, it would have to be dependent on the internal milieu of the organism, as a particular set of 
environmental conditions is a prerequisite for such a phenomenon to occur (Reiter, 1991 a). The amplitude 
theory is widely accepted as being appropriate for describing the events that occur in human beings. Here, 
the amplitude of the nocturnal rise in aMT is the parameter which imparts the message that will induce a 
physiological change (Berga et al., 1988). 
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In humans the physiological aMT dose is 20tJ-g for three hours when administered intravenously (Zaidan et 
aI., 1994), and the time of aMT administration affects the. onset, acrophase and offset of the circadian 
. rhythnilbese observations support the contention that the Beurohormone is the endogenous diurnal rhythm 
synchroniser. Exogenous aMT is also able to synchronise its own rhythm, and this harmonisation is subject 
to entrainment (Zaidan et ai., 1994). aMT can cause either a phase delay or phase advance in humans and 
rats, depending on the time and dosage of administration, in both central and peripheral nt;Ufal systems. The 
neurohormone has been effective in the treatment of jet lag, insomnia and synchronising the sleep/wake cycle 
in blind subjects (Lars et ai., 1991; Arendt, 1994). 
The indolealkyleamine may also be useful as an immunostimulant, regulator of blood pressure, and in 
potentiation of cancer therapy (Arendt, 1994). 
1.3.1.0 Assays for aMT 
Clinically, aMT levels can be assayed in blood and urine using two methods: by gas chromatography-mass 
spectroscopy for the 6-hydroxy-aMT or by radioimmunoassay to detect 6-sulphatoxy-aMT. These two 
methods are straightforward, reliable and non-intrusive markers of pineal aMT output (Tetsuo et ai., 1981; 
Bojkowski et ai., 1987). However, determining total aMT concentration is difficult due to the facfthat the 
indices of aMT turnover used, such as the urinary 6-hydroxy-aMT and 6-sulphatoxy-aMT levels, only yield 
a fractional value of approximately 80010. In addition, aMT can be reconverted to 5-methoxytryptamine 
(Hardeland et ai., 1993a) which points to a constantly fluctuating pool of the indoleamine that further 
complicates the determination. 
1.3.2 The noradrenergic system: regulation of pineal indole metabolism 
Studies pertaining to the neural route regulating the functions of the neuroendocrine gland, the pineal, have 
mainly been performed using the rat as a model. The rat has been an invaluable tool in the development of 
our understanding of the role that the SCN plays as mediator of the activity of the pineal gland (Klein, 1978). 
Ultimately pineal indole metabolism is regulated by the effects of catecholamines such as NA on p-
adrenergic receptors (Klein et ai., 1983) (fig. 12). However other neurotransmitters also have affinity for 
these receptor binding sites, but with little or no effect. Stimulation of pineal GABA receptors has been 
shown to inhibit aMT synthesis. The pineal gland contains the highest concentration of 5-HT in the body, 
and stimulation of aI-receptors promotes release of5-HT from the pineal. 
FIG. 12: 
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There is a distinct possibility that other neurobiological systems could influence pineal aMT synthesis aI).d 
release, due to the presence of other binding sites (glutamate, DA2, Ach, and substance P) on the 
neuroendocrine gland. Functional muscarinic l Ach receptors, independent ofthe noradrenergic system, and 
linked to the phosphoinisitide signalling system, are also present on the neuroendocrine gland (Laitinen et 
a!., 1989). The precise roles of these receptor sites are as yet undefined. Neuropeptides such as the vasoactive 
intestinal polypeptide, neuropeptide Y and vasotocin are involved in pineal aMT biosynthesis (Ebedi et aI., 
1989). Binding studies indicate that the adrenergic receptors have the greatest affinity for the catecholarnines, 
NA and adrenaline, plus the pcagonist, isoproterenol. 
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It is apparent that regulation of aMT synthesis is a complex process, but the most important controlling factor 
is the noradrenergic system without which the rhythmic secretion of the neurohormone would be lost (Klein, 
1978)(figs. 12 & IS). A deficiency in NAhas been showrfto be linked to aMT, and a reduction in the levels 
of the neurohormone in major depression is associated with a noradrenergic deficiency (Checkley et aI., 
1986). Other researchers, however, failed to demonstrate such a link (Waldhauser et aI., 1993). The initiation 
of aMT synthesis in all probability depends on the level of activity of the noradrenergic system, while the 
availability ofS-HT and/or aMT turnover could in tum determine the peak of the aMT rhythm (Skene et aI., 
1994). 
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The transfer of photic signals, received from the environment, involves a multi synaptic pathway, originating 
in the retina, through the CNS via the superior cervical ganglion (SCG) and the SCN, and ceasing as 
postganglionic sympathetic neurons within the pineal (Reiter, 1981) (fig. 13 & 14). This system imparts 
information concerning to the environmental lighting conditions to various regions of the brain and related 
tissues (petterborg et aI., 1991). The activity of the retinohypothalarnic tract, which originates in the retina 
and ends in the suprachiasmatic nucleus, determines the extent of the changes effected by lighting with 
respect to the circadian rhythm and pineal indolearnine metabolism (Reiter, 1991a). Normal activity is 
characterised by low aMT, high S-HT, and low NAT during the subjective day, and high aMT, low S-HT 
coupled with high NAT at night (Klein, 1978). The function of aMT appears to be in the transduction of the 
light signal and the conveyance of this data to inner areas of the brain and periphery (Short, 1993). 
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BlOMT is the enzyme involved in the conversion ofN-acetyl serotonin (NAS) to aMT, and is present in the 
pineal. This enzyme has a high degree of specificity for NAS and does not display wide variations in 
concentration due to its circadian rhythmicity. The magnitude and duration of the NA signal, via cAMP, is 
apparently finely modulated, and the initial burst in cAMP probably coincides with the aMT peak and 
window of sensitivity (Moore and Klein, 1974). 
The enzymes involved in the synthesis of aMT and its intermediates are subject to a circadian rhythm which 
is under the control of the SCN. Destruction of the SCN results in a loss of the NAT rhythm, and thereby 
implicates the SCN as harbouring the elements of the endogenous biological timing mechanism which 
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regulate the secretion of pineal aMT. The activity of the SCN appears to be entrained, a supposition which 
is based on the fact that this circadian rhythm ge~erator can operate, to a limited extent, in the absence of 
environmental lighting (LYnch et a!., 1973). Severing 6tthe neural tract between the retina and SCN fails 
to abolish the endogenous circadian rhythm in NAT activity. It is speculated that this entrainment of the SCN 
is possibly brought about by aMT (or 5-HT) because the SCN is rich in aMT receptors. 
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1.3.2.0 The NA transporter 
This neurotransmitter binding protein is ubiquitous with respect to the mammalian brain, albeit in low levels. 
The fact that the mammalian CNS is sparsely populated with these transporters makes isolation and 
purification difficult. The transporter is sodium ion dependent and inhibited by T ADs, the most potent being 
DMI, nortriptyline (NT), cocaine and amphetamines. The NA binding protein shares certain drug binding 
specificity with the 5-HT transporter (Worral and Williams, 1994). 
1.3.3 aMT in depression 
The neurohormone aMT is rhythmically secreted by the pineal gland. Circadian rhythmicity and 
noradrenergic neuronal activity are believed to be the mechanisms involved in regulation and control of aMT 
metabolism (Reiter, 1991a). Depression is characterised by diurnal variation in mood associated with 
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alterations in other circadian rhythms such as those of: 
a) 
b) 
salivary secretions, 
urinary electrolytes, 
c) plasma cortisol, and 
d) TRP metabolism (Curzon and Bridges, 1970). 
-< 
The dysregulation hypothesis of depression claims that in the depressed state there is chronobiological 
instability, and that disruption in circadian rhythmicity could take the shape of either a phase advance or a 
phase delay (Maurizi, 1984; Piletz, 1994). Thus, malfunctioning of the biological clock is symptomatic of 
the depressed state, and would arise due to the irregular firing rate of the neurons at the locus coeruleus as 
a result ofloss of specificity (Piletz, 1994; Faravelli et ai., 1985). Well- documented clinical observations 
allude to circadian alterations in the classical symptoms of depression such as mood and overall performance 
(Wirz-Justice and Arendt, 1980). 
Biochemical indices of the depressed state manifesting dysregulated bie-rhythms include, inter alia, earlier 
appearance of the reduced night-time temperature, lessened rapid eye movement (REM) sleep latency, phase 
advances in prolactin, ACTH-cortisol, thyroid stimulating hormone, NA, and aMI. In these instances there 
is a disruption in circadian rhythmicity by way of a phase advance (Maurizi, 1984). aMI has the ability to 
re-entrain the biological clock in a number of species including humans. This biological clock, universally 
accepted to reside in the SCN, is richly populated by aMI receptors, and clinical data indicates that regular 
physiological doses of the hormone result in re-entrainment of circadian rhythmicity in depressives. However, 
in healthy individuals similar regular doses cause a fall in basal body temperature (Short, 1993; Maurizi, 
1984). Chronic DMI treatment in depressives results in an increase in the intensity of the acrophase, but not 
the duration of aMI concentrations. In unaffected individuals, chronic DMI therapy causes an initial rise 
followed by aretum to normal baseline levels (Waldhauser et aI., 1993). Thus there appears to be differential 
regulation of aMI metabolism in healthy and depressed indi viduals (Daya, 1994). 
In rats and humans, aMI synthesis is contingent on noradrenergic output, so factors that influence NA 
release will invariably affect the release or synthesis of aMI. Antidepressants are believed to have an effect 
on monoaminergic systems, and should therefore have a bearing on aMI levels in blood. Clinical research 
indicates that depressed patients exhibit a reduced secretion of aMI, which can be corrected by chronic 
antidepressant therapy (Banoo, 1991). However it has been reported that chronic treatment with 
clomipramine (Cl) reduced aMI levels in depressed patients. The reduced aMI output in depression can thus 
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be maintained by chronic antidepressant treatment. This apparent phenomenon is possible if the question 
of the time of dosage has not been taken into consideration, given the finding that antidepressants retard the 
biological clock and therefore the normal aMT peak would appear later in the circadian cycle. Sampling for 
analysis at the usual time could yield a false result of reduced aMT concentrations. Thus, according to 
proponents of the dysregulation hypothesis of depression, an important parameter in depression therapy is 
the timing of dosage as opposed to the quantity of drug (Nyback et a/., 1975). 
Initially (as outlined in Chapter 3), the therapeutic efficacy of antidepressants was believed to be exclusively 
due to stimulation of the monoaminergic system. However, the fact that neither 5-HT nor NA is essential for 
maintenance of normal mood implies that additional disturbances in other neurobiological systems underlie 
depressive symptomatology (Sulser et al., 1978). This is further supported by the finding that the TAD 
iprindole, even though it has been proven to be effective clinically, did not affect monoaminergic 
neurotransmission in the conventional manner via a blockade ofNA -uptake, modification ofNA metabolism 
or the turnover ofNA and 5-HT. In addition, it prevented spontaneous noradrenergic neural transmission 
in the locus coeruleus, and thus did not elevate NA concentrations at post-synaptic receptor sites (Coppen 
et aI., 1976). Thus, there is a growing belief that the biogenic amine hypothesis only focuses on a particular 
aspect of the phenomenon of depression and does not adequately cater for all the associated symptoms 
(Sulser et ai., 1978). 
The efficacious antidepressant mianserin-HCL which inhibits TOO also apparently does not affect the uptake 
of biogenic amine 5-HT and NA (palazidou et ai., 1992). These abovementioned observations. t:aise 
questions that are difficult to reconcile with the classical biogenic amine hypothesis. However, the 
information does not eliminate associations at the level of the receptor with the various neuronal systems 
(Sulser et ai., 1978) or involvement of other factors. With respect to the noradrenergic system, there is no 
relief of the core symptoms of depression when treated with antidepressants that prevent re-uptake ofNA, 
such as desipramine (DMI) and maprotilene (Sylvalahti, 1994; Blier and de Montigny, 1994). 
Chronic DMI increases NA release at the pineal gland which acts on post-synaptic pcadrenergicreceptors 
(Sack and Lewy, 1985) and indirectly on ~-adrenoreceptors (Petterborg et aI., 1991) by causing re-uptake 
inhibition in depressed individuals. In animals, DMI and related antidepressants cause retardation of aMT 
secretion, ie a phase delay, while substances with known adrenergic activity, such as ~cblockers, potently 
affect aMT synthesis (Sack and Lewy, 1985). Fluvoxamine increases aMT levels in plasma, possibly via 
inhibition of aMT catabolism since there is a lack of correlation between urinary 6-sulphatoxy-aMT and aMT 
concentrations in blood (Skene et ai., 1994). Acute DMI and fluvoxamine both increase the time period of 
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aMT secretion, though in different ways: fluvoxamine retarding offset time and DMI causing a phase advance 
in peak aMT release (Skene et al., 1994). 
-< 
A controversial issue with respect to the effects ofTADs (specifically DMI) in humans on aMT secretion, 
is whether TADs actually cause down- or upregulation of post-synaptic p-adrenoreceptors (Peet, 1994). 
Drug therapy causes a variety of adaptive changes in receptor status throughout the noradrenergic system. 
It has peen reported that chronic antidepressant treatment results in p-adrenoreceptor downregulation which 
manifests itself via a reduction in the number of p-receptors, the levels of cAMP and other associated 
intracellular second messenger concentrations in depressed individuals (Sulser et a!., 1978). However, acute 
DMI treatment in depressives resulted in upregulation after day one, an effect that was maintained 
throughout six weeks of therapy (Preskorn, 1994). This finding casts doubt on the hypothesis which claims 
that the key event in TAD mechanism of action is p-adrenoreceptor downregulation (Sulser, 1978). 
Nevertheless, the phenomenon of increases in receptor number does not preclude ~-receptor downregulation, 
but could imply that other adaptive modifications, such as tXcadrenoreceptor downregulation, counteract the 
~-adrenoreceptor downregulation, and thus p-receptor upregulation is sufficient to alter net noradrenergic 
neurotransmission. However, if downregulation does occur, it is not pronounced enough to counteract the 
primary effects of the re-uptake blockade imposed by DMI which increases aMT output in d~press~d patients 
(Carter and Goldman, 1983; Preskorn, 1994). 
1.3.3.0 Seasonal affective disorder and aMT 
Seasonal affective disorder (SAD) is another form of depression which is characterised by annually recurring 
episodes of depression coupled with symptoms such as hypersomnia, anergia, fatigue, carbohydrate craving 
and weight gain (Wurtman and Wurtman, 1988; Waldhauser et al., 1993). This type of depression is of the 
bipolar variety with winter depression and summer mania (Waldhauser et a!., 1993). Seasonal alterations 
in aMT secretory patterns are related to changes in the photoperiod and SAD appears to be intricately 
associated with dysregulation of aMT circadian rhythms. In SAD there is a phase delay of the aMT peak, and 
morning phototherapy of a few hours is effective in alleviating the symptoms by synchronising the circadian 
oscillator (petterborg et al., 1991; Waldhauser et a!., 1993). Phototherapy is highly effective in treating 
SAD, but is apparently unrelated to the quantity and secretory pattern of aMT (Waldhauser et al., 1993). 
Phototherapy regimes attempt to re-synchronise the aMT rhythm with the normal day/night bio-rhythm 
(Daya, 1994). It is not known whether modification of the endogenous aMT rhythm is responsible for the 
therapeutic effects of phototherapy in the treatment of SAD, but it is clear that it is not a necessary event for 
remission (Waldhauser et a!., 1993). However, it is accepted, based on experimental data, that bright light 
of sufficient intensity reduces nocturnal aMT secretions, as has been shown in rat pineals (fig. 16). 
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In hea1thy individua1s, brief exposure to bright light for approximately 15 minutes suppresses aMT synthesis 
transiently, but not cortisol production. This reduction in synthesis is apparently due to a decrease in the rate 
of NAT activity in the pinea1 gland. Serum aMT is an easy and reliable biologica1 index in eva1uating the 
influence and efficacy of phototherapy (WeIman and Daya, 1990). aMT can have a negative effect in patients 
with abnorma1, irregular aMT rhythms, such as those found in SAD. Here the neurohormone exaggerates 
the depressive symptoms when administered during the day in certain depressed patients (Van Praag, 1982). 
The fact that phototherapy is effective in suppressing aMT levels in humans can be clinically advantageous, 
as this would allow for accurate regulation through control ofthe degree and intensity of the light. 
1.3.3.1 Mania 
It is hypothesised that in mania there is noradrenergic hyperfunction characterised by increased levels ofNA 
in the synapse as a result of dysregulation of the endogenous circadian rhythm generator. aMT levels in this 
type of affective disorder appear to be abnorma1ly high and acutely sensitive to bright light (Wurtman and 
Wurtman, 1988). This feature could serve as a state marker for mania, given that the ultrasensitivity to 
suppression by light is maintained during depression. However, phototherapy does not a1ways reduce the 
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aMT levels in manic depressives (Daya, 1994). 
1.3.3.2 Abnormal sleep chemistry 
Abnonnal sleep is a characteristic feature of depression and is accompanied by a deficiency of aMT. Based 
on this association, it is possible that aMT is partly responsible for this condition (Maurizi, 1990). The 
lipophillic nature of aMT allows the molecule to effecti vely traverse the blood brain barfier. -In the brain the 
neurohonnone is involved in numerous physiological manifestations (Birkeland, 1982). One of the roles of 
the indolealkylearnine is in REM sleep where release of the neurohormone is synchronised with the REM 
sleep biorhythm (Y ogman and Zeisel, 1983). The brain centre believed to be involved in regulating REM 
sleep, the SCN of the hypothalamus, is rich in aMT receptors, and in depression REM sleep is accompanied 
by an abnormal aMT circadian rhythm. Experimental findings indicate that REM sleep can be prolonged if 
dietary TRP concentrations are increased, while a LNAA rich meal reduces the amount of REM sleep 
(Weaver et ai., 1988). 
The manner in which aMT could influence REM sleep is by inducing the release of the nonapeptide vasotocin 
(pavel and Goldstein, 1979), which is present in the CSF of humans during REM sleep but absent during 
non-REM sleep (Rupfer et ai., 1994). Therapeutic action of the TADs is accompanied by improved sleep, 
and this could possibly be due to aMT, either directly or indirectly (Haimov et ai., 1994), given the fact that 
T ADs potentially elevate aMT synthesis in depressives (Skene et ai., 1994). In insomniac elderly people 
there is a good correlation between low aMT and low sulphatoxy-aMT concentrations. Disruptions in the 
circadian rhythm characterised by retarded aMT peaks are prevalent (Adey et ai., 1968). 
1.3.3.3 aMT and stress 
There is believed to be a correlation between the blood aMT levels and stress, with below basal levels linked 
to stress. However, conclusive evidence in this regard is lacking. It has been shown in a few cases that aMT 
has an ameliorating effect on stress via vasotocin induced by elevated corticosteroid levels on the 
hippocampus. The manner in which the neurohormone brings this about is by reducing the affinity of 
corticosterone for its receptor and thus preventing neuronal damage (Thompson et ai., 1985), as well as 
stimulating vasotocin release which in turn inhibits cortisol secretion by the adrenals (Zimmermann et ai., 
1993). 
1.3.3.4 Proposed regime for treatment of depression 
A rational treatment therapy based on the relationship between precursor TRP and its derivative aMT for 
depression would have to include both substances. The reason for this is that conventional antidepressant 
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treatment with a TAD such as DMI enhances aMT synthesis but does not provide the precursor TRP. By 
supplying the nutritional substrate it is thus possible to counteract the vicious cycle imposed upon the body 
by stress and its associated high levels of cortisol. This rt!gime would thus allow for raised TRP .... elevated 
5-HT .... increased aMT .... reduced cortisol .... lowered IDO activity - increased TRP (Maurizi, 1994). The 
treatment scheme, if instituted, could eliminate the three week lag period associated with the therapeutic 
response of efficacious antidepressants, and remission could be induced within 3 to 4- days, as with 
photot!terapy for SAD. This proposed therapy is dose and time dependent given the fact that both TRP and 
aMT promote sleep and could be potentially toxic in very high doses (Maurizi, 1990). 
Given the finding that acute TRP depletion in humans causes a marked reduction in nocturnal aMT secretion 
(Young and Silman, 1982), the opposite approach - increasing the levels ofTRP - should theoretically be 
effective in elevating the levels of aMT. In this regard, however, there has been limited success (Naamboodiri 
et a!., -1983). It has nevertheless been possible to increase daytime serum aMT to the levels achieved 
nocturnally, with exogenous 5-HTP administration. 5-HTP given to sheep during the day caused a sevenfold 
increase in aMT levels two hours later (Naamboodiri et al.,. 1983). This effect of 5-HTP on aMT is possible 
because 5-HTP promotes the synthesis ofNA and DA in addition to enhancing the production of 5-H'I (Van 
Praag, 1983). Thus there could be an increase in noradrenergic neurotransmission due to elevations in 
synaptic NA concentrations that would stimulate NAT synthesis and ultimately raise aMT levels. 
1.3.4 aMT as free radical scavenger and neuroprotectant 
As stated earlier, aMT can be found in extra-pineal tissue such as the retina, (Yu et al., 1981) Harderian 
gland (Rofinan et aI., 1989), gut (Bubenik, 1980) and leucocytes (Finochario et a/., 1988). Secretion in these 
tissues does not necessarily follow a circadian rhythm as is the case with the pineal. Thus it appears that the 
role of aMT does not purely reside in its ability to convey information about the photoperiod but possibly 
covers a wide spectrum of alternative activities (Hardeland et a/., 1993c). Other functions include its role as 
a neuroprotectant (ie a free radical scavenger) (Hardeland et aI., 1993a) (fig. 17) and the activities of its 
active metabolites, such as the methoxyindoles, J}-carbolines (Fenerty and Lindup, 1991) and kynurenamines 
(Kelly et al., 1984). The non-polar nature of aMT confers the ability to penetrate most tissues -hence its 
ubiquitous distribution both inside a number of tissues and in various body fluids including neuronal and 
non-neuronal tissue. This physicochemical property of aMT makes quantification of the number of aMT 
binding sites in any particular tissue difficult. (Hardeland et a/., 1993c). 
The molecular nature of aMT imparts a number ofunique biochemical features such as enhanced free radical 
trapping by the 5-methoxy group Uemura et a/., 1984, eliminating dimerisation of phenol radicals (Huether, 
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1990) and also fonnation of quinone imine structures at physiological pH (perez-Reyes and Mason, 1981) . 
. aMT, .!!evertheless, can interact with membrane r.eceptors· such as the 5-HT receptor in an agonistic or 
antagonistic manner. The N-acetyl group has an atten~ating effect on the binding of aMT to the 5-HT 
receptor, in addition to its role in preventing degradation by MAO. That the N-acetyl group inhibits MAO 
catabolism of aMT is borne out by the fact that an analogue, 5-methoxytryptamine, is broken down by MAO 
(Galzin et at., 1988). The primary function of the N-acetyl group concerns free radical scavenging (cited in 
Hardeland et a!., 1993c). 
It should be emphasised, however, that the most important and reactive part of the molecule is the pyrrole 
ring, given that ring opening results in the fonnation of a series of potent biogenic amines (Hayaishi and 
Yoshida, 1979). Ring cleavage could be due to one of two mechanisms, either non-enzymatic (fig. 17), via 
free radicals (Hardeland et a!., 1993c), or enzymatic by the enzyme indoleamine-2,3-dioxygenase (Hayaishi 
and Yoshida, 1979). 
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When considering the physiological properties of aMT and its derivatives it is important to take cognisance 
of the biological rhythm of the molecule. Circadian rhythmicity in most instances is a prominent feature of 
aMT and is quite pronounced in certain tissues such as the pineal (Reiter, 1988), but is virtually non-existent 
in others such as the Harderian gland (pevet et aI., 1980). In all species studied to date, the neurohormone 
peaks at subjective night with a much lower basal level during the subjective day. The intensity and duration 
of the pineal peak ultimately determines the quantity of aMT present in each particular tissue, and also the 
circadian pattern (Reiter, 1980). 
Research pertaining to the relative potencies of aMT and its metabolites indicates that for a particular effect 
at a connnon binding site, the parent molecule has a superior efficacy. However there are exceptions to the 
rule, as in the unicellular microorganism Gonyaulax polyedra where 5-methoxytryptamine shows a greater 
potency than aMT with respect to stimulating bioilluminescence (Balzer and Hardeland, 1991). Nonetheless 
this group of biogenic amines can be separated on the basis of the reactions in which they are involved, and 
the derivatives of aMT mainly differ from one another by virtue of modifications to their side groupings. A 
more pronounced change that involves the aliphatic side chain is cyclisation through the formation... of an 
additional5-atom ring structure coupled with hydroxylation and saturation ofthe 2,3-C double bond with 
the subsequent synthesis of a 2-hydroxymelatonin (Vakuri et ai., 1987) (fig. 18). This hydroxylated aMT, 
which possesses psychomimetic properties, is structurally similar to p-carboline and has been shown to have 
skin-blanching qualities (Frohm et a/., 1980). The molecule has been observed in human and rat urine from 
where it has been isolated. ~Carbolines are normally present in a variety of unrelated tissues that synthesise 
copious amounts of aMT (Vakuri et al., 1987; Kari, 1981) 
A possible alternative route of p-carboline production is via the addition of a carbon atom to aMT which 
allows cyclisation (fig. 18). The mechanism of synthesis is still a mystery, but it is possible that p-carboline 
is an artifact of purification. However the compound could be formed via peroxidation of 5-HT by the 
superoxide anion. The structure of aMT (specifically, its N-acetyl group) precludes p-carboline formation 
along this route, but is possible with aMT derivatives such as 5-methoxytryptamine. In rats, diets rich in 
TRP stimulate synthesis of a p-carboline derivative called 1 ,2,3,4-tetrahydro-p-carboline-3-carboxylic acid 
(Adachi et al., 1993). 
p-Carboline derivatives have a number of physiological effects within the cell which include, inter alia, 
binding to both benzodiazepine and 5-HT receptors. The molecule shares similar structure-activity 
relationships with TRP, benzodiazepines and 5-HT. It also binds to albumin (Adachi et a/., 1993) and thus 
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has the potential to displace TRP from SA and elevate plasma TRP levels. Given the fact that the molecule 
has psychomimetic properties, it can be inferred that it could have significant effects on these two 
neurobiological systems. The substance is known to affect an endocrine marker of serotonergic function, 
namely, prolactin, whose secretion is enhanced (Rovescalli et aI., 1986). In addition to its effects on the 
neuroendocrine system, p-carboline also inhibits MAO-B activity in 5-RT releasing neurons. A derivative 
ofp-carboline, pinoline (5-methoxytIyptoline) (fig. 18), a much more potent molecule, is known to be present 
in certain tissues and is effective at nanomolar concentrations. Pinoline can be synthesised indirectly from 
aMT via 5-methoxytryptamine (Airaksinen et a!., 1993). 
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Binding sites for pinoline have been found on the pineal gland and in certain brain regions such as the 
adrenal cortex and medulla. The unicellular microorganism Gonyaulax polyedra harbours pinoline, aMT and 
5-methoxytIyptamine, and is sensitive to IMI in a dose-dependent manner. This sensitivity manifests itself 
either through an increase or decrease in bioluminescence (poggeler, 1992). 
As stated earlier, aMI and some of its derivatives share a similar structure-activity relationship pertaining 
to the trapping of superoxide anions and hydroxyl radicals. In fact aMI has been proven to be the most 
efficient hydroxyl radical scavenger ever discovered (poggeler, 1992). In this process aMI is non-
enzymatically degraded, which effectively terminates the radical chain reaction. The mechanism of action 
ascribes a crucial role to cofactors such as hemin or other porphyrins, and is thought to involve the 
abstraction of an electron, forming an indolyl cation radical that can eventually trap a superoxide anion. The 
fact that aMT, besides its high affinity for the hydroxy radical, gives rise to an indolyl cation that reacts 
directly with another superoxide anion in the absence of a catalyst, imparts the unusually pronounced free 
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radical trapping ability (fig. 17). Another feature that makes aMT such a unique radical scavenger is that it 
does ~ot require regeneration as do other free radical trappers, such as ascorbate, a-D-tocopherol and 
-~ p 
glutathione (P6ggeler, 1992). 
aMT's role as the mediator of the photoperiod is in all likelihood secondaty to its function as a free radical 
scavenger (Hardeland et aI., 1993c; P6ggeler, 1992). This inference stems from the fact tJiat in the Harderian 
gland t):le circadian oscillation in aMT levels is negligible, and high concentrations of the neurohormone are 
related to increased levels of porphyrins in females. This state of affairs exists possibly to counteract the large 
amounts of hydroxyl radicals and superoxide anion transformers. 
An example that illustrates the protective function of aMT in the cell involves the carcinogen safrole which 
generates hydroxyl radicals in DNA Concentrations of aMT at physiological levels 1000 times less than the 
carcinogen practically abolish the negative effects of safrole, which include DNA adduct formation. The 
mechanism by which aMT achieves this is facilitated by the fact that aMT binding sites exist on chromatin. 
Binding sites for aMT have been shown to be present on both neuronal and non-neuronal tissue. The 
association ofaMTwith such binding sites affords DNA direct on site protection (Tan et al., 1994). A recent 
study involving aMT and homologues revealed that these compounds can offer protection against radiation. 
The homologues were prepared by acylation of 5-methoxytryptamine, and tested in mice. It was found that 
homologues with increased side chain lengths were more effective in preventing radiation damage than aMT 
(Blickenstaff et al., 1994). However the mechanisms and factors involved in the radioprotection still require 
clarification. 
Given these observations, it is clear that the indole amine aMT is unusually efficacious as a free radical 
scavenger that has the potential to offer protection against a range of highly reactive, potentially mutagenic, 
carcinogenic and cytotoxic hydroxyl radicals. Thus the therapeutic application of aMT could have significant 
implications for the physical well-being of individuals, particularly with respect to age-related neuro-
degenerative processes (such as Alzheimer's disease) which are linked, for example, to MAO-B (Tan et aI., 
1993). Ageing human beings have lower levels of aMT (Sack et ai., 1986; Maurizi, 1987), increased MAO 
activity, and show signs of mental depression (Maurizi, 1987). The activity of MAO serves as a prime 
generator offree radicals, and aMT could counteract this effect (Hardeland et al., 1993c). Oral aMT has been 
shown to reduce spontaneous mammary tumour proliferation in susceptible mice in a dose-dependent manner 
(Subramanian and Kothari, 1991). 
The biological significance of aMT covers a broad spectrum, particularly with respect to the synthesis of 
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biologically active metabolites that could potentially playa role in the regulation of GAB A-dependent 
chloride channels and serotonergic receptor function. The·neurohormone has an inhibitory effect on the 
hepatic mixed function oxidase cytochrome p-450 which i's also involved in heme metabolism (Tan et aI., 
1994). Potential advantages ofaMT, ifused as a natural pharmacological tool, include (amongst others) non-
toxicity, free radical scavenging, neural system protection, and action as a natural antidepressant and 
photoperiod mediator (Hardeland et aI., 1993c). 
1.4 
1.4.0 
DETERMINANTS OF TRP AND ITS METABOLITES' LEVELS IN BLOOD AND 
BRAIN 
TRP-hydroxylase 
TRP-hydroxylase is the rate limiting step in 5-HT synthesis in the brain (Carlson et aI., 1972). This points 
to a possible area of control (Boadle-Biber, 1982) (fig.6). 
Normally, in vivo, the saturation ofTRP-hydroxylase displays regional differences (Meek and Lofstrandh, 
1976), the rat brain enzyme is not fully saturated with substrate because of its poor affinity for TRP and thus 
is very sensitive to minor alterations in TRP concentrations which could have significant effects on·5-HT 
synthesis (Bengtson et al., 1991; Wallen and Rissanen, 1994). The TRP-hydroxylase enzyme of the pineal 
gland, on the other hand, is saturable (Sitarem and Lees, 1978 cited in Skene 1979). Both these enzymes are 
subject to a diurnal rhythm, with maximal activity occurring during the subjective day (Hardeland and 
Rensing, 1968). 
The hydroxylation ofTRP is an inducible phenomenon, and it is possible that the synthesis of 5-HTP does 
not only depend on the levels of TRP acquired via the diet but is intricately linked to pineal levels of the 
indole. This inference is based on the fact that TRP-hydroxylase activity and 5-HIAA levels are markedly 
reduced in the amygdala of male rats after pinealectomy. Thus by implication the serotonergic system of the 
amygdala could be crucial in the expression of pineal function within this endocrine system (Miguez et aI., 
1991). 
It is hypothesised that the supply and redox state of the essential cofactor tetrahydrobiopterin (BH4) could 
be the mechanism whereby the activity ofTRP-hydroxylase and consequently circulating TRP levels and 5-
HT synthesis is controlled with super sensitivity. It is therefore conceivable that regulation ofBH4 supply 
and redox state could be one of the ways whereby 5-HT synthesis in neurons is controlled (Bengtson et al., 
1991; Gal and Patterson, 1973) (fig. 19). 
FIG. 19: 
1.4.1 
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Schematic illustration of the mqjor step in the biosynthesis of 5-HTP (note shuttle between 
reduced (1) (active) and oxidised (2) (inactive) pterin cofactor [Rattray, 1992]. 
Catalyst: TDO 
In depression there is increased pituitary-adrenal gland activity with a consequent rise in plasma cortisone 
concentrations, coupled with an induction of TOO synthesis (Curzon, 1969). Given the fact that only a small 
proportion of total serum TRP is utilised in 5-HT production, enhanced TDO activity would result in 
diversion of most of the available TRP towards the TRP-kynurenine pathway (fig. 1). This results in 
increased urinary levels of kynurenine, an event which is consistent with TRP loading in depressives (Curzon 
and Bridges, 1970). In depression there is: 
i) early morning depression, associated with high plasma corticosteroid levels which are subject to a 
circadian rhythm (Bridges and Jones, 1966), 
ii) pituitary-adrenal hyperactivity in a large number of depressives (Rubin, 1967), and 
iii) lack offeedback inhibition of ACTH on the pituitary gland, and therefore no regulatory mechanism 
to control the output of glucocorticoids by the adrenal cortex (Gibbons, 1964). 
Hydrocortisone causes a marked reduction (±30%) in 5-HT levels due to increased synthesis of TDO (Curzon 
and Green, 1969). This effect is abolished in the presence of inhibitors such as allopurinol (Becking and 
Johnson, 1967) and yohimbine (Sourkes et aI., 1969). An analogue ofTRP, "-methyItryptophan, a dose-
dependent activator ofTDO (Schutz et aI., 1972), also causes a reduction in brain 5-HT (Curzon, 1969). 
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Empirical studies seem to indicate that the peak of enzyme activity induced by hydrocortisone coincides with 
the rapid transient fall in plasma TRP (Curzon, 1969). These observations imply that it is possible that the 
reduction in brain 5-HT levels is related to increased actiVity ofIDO and that adrenocorticoid hyperactivity 
could be an important factor in depression (Curzon, 1969). 
It is also known that immobilisation stress induces cortisone release with a consequent elevation in IDO. 
Howeyer, chronic administration of hydrocortisone or prolonged periods of stress do not cause the expected 
5-HT decrease (Curzon and Green, 1969). This initial enhanced IDO rate of catalysis with consequent 
reduction in 5-HT levels could be explained in terms of the time required to mobilise the presently unknown 
cellular components involved in opposing the rise in enzyme activity effectively (Curzon, 1969). Increased 
TDO activity is not always associated with depression, but is also implicated in a number of other illnesses 
linked to stress (Altman and Greengard, 1966) of which schizophrenia (F aurebye and Pind, 1964) is but one. 
However this does not preclude a crucial role for IDO in the depressed state and could be explained in a 
number of possible ways: 
i) In depression the availability and turnover ofTRP could be more critical than the actual activity of 
the enzyme itself 
ii) It is possible that, in depression, the reduction in 5-HT levels is not the sole contributory factor. An 
accompanying factor is possibly the inability to mount the appropriate countermeasures that would 
prevent the decline in 5-HT. These supplementary adaptations could involve elevated cofactor levels, 
and/or an increased rate ofTRP hydroxylase activity. In rats, depletion of5-HT levels by the NA 
depleter, reserpine, results in an increase in TRP-hydroxylase activity that increases 5-HT levels. 
iii) 5-HT regulation of hydrocortisone secretion by the pituitary-adrenal glands is affected by lowered 
5-HT concentrations, and this precipitates an increase in cortisone release which would stimulate 
TDO (Curzon, 1969). Pituitary-adrenal activation takes place in subjects treated with the drugs p-
chlorphenylalinine (Rosecrans, 1968) and reserpine (Westermann et al., 1962) that cause a lowering 
of brain 5-HT. 
It is therefore possible for there to be an inverse relationship between 5-HT levels and IDO activity. Thus 
low brain 5-HT concentrations and a high level of enzyme activity coupled with disturbances in the pituitary-
adrenal system are associated with depression in certain subtypes of depressives (Curzon, 1969). 
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1.4.1.0 TDO: Properties 
_ TDOLa heme dependent cytosolic enzyme, cataly~es the irreversible oxidative ring cleavage ofL-TRP to 
yield, as a reaction product, N-formylkynurenine (Schutz~ial., 1972; Mehler and Knox, 1954; Schutz and 
Feigelson, 1972). The enzyme (molecular weight 167000) is a tetramer consisting of two sets of identical 
subunits, ~P2' held together non-covalently (Schutz and Feigelson, 1972; Tanaka and Knox, 1959). 
Enzymes from both rat liver and pseudomonas have been purified to homogeneity (Kndx et al., 1970; 
Uchidaet al., 1985). These were found to contain 2 mole heme + 2 mole Fe (Schutz and Feigelson, 1972; 
Makino and Ishimura, 1976; Feigelson et aI., 1965), and IDO is the only oxygenase with organically bound 
Fe. Two forms of the enzyme are present within the cell, an inactive apoenzyme (no heme) (Feigel son et aI., 
1965; Greengard and Feigelson, 1962; Mehler et al., 1958) and an active metalloenzyme (apoenzyme + 
heme) (Feigel son et aI., 1965; Greengard and Feigelson, 1962; Knox and Ogata, 1965) (fig. 20) which is 
specific for TRP and the most stable form at optimum pH 7.2 (Uchida et aI., '1985). 
APOENZYME + L-TRP + HEMIN .... HOLOENZYME [reduced + active] 
(inactive) 
O2 + L-TRP l t + L-TRP - O2 
HOLOENZYME [inactive + oxidised] 
FIG. 20: Mechanism of activation and inactivation of IDO by substrate TRP and cofactor hemin 
[Knox and Tokuyama, 1964]. 
There is a loose association between the apo-enzyme and heme (Greengard and F eigelson, 1962). In the rat, 
activity of the enzyme IDO increases with age (Curzon, 1969). Hepatic cellular levels ofTRP ultimately 
determine the rate of apo- to holoenzyme and the distribution of hemin between the two forms and other 
heme binding proteins such as albumin, while two thirds of the total enzyme in the cell exists as apoenzyme 
(Knox and Piras, 1965). 
Catalyst IDO is a sigmoidal enzyme with interacting catalytic and regulatory sites (Makino and Ishimura, 
1976; Maeno and Feigelson, 1968), the catalytic site(s) being highly specific for substrate TRP, while the 
non-specific allosteric site(s) binds a range of different ligands including TRP. Intermediates such as 3-
hydroxyanthranilate (Wagner, 1964), as well as end product NAD(P)H (Cho-Chung and Pitot, 1967), are 
also examples. The extent ofinhibitionlactivation by effectors in general is tempered by substrate TRP and, 
to a lesser degree, by the concentration of the regulator. The mtYOf peripheral determinant of circulating blood 
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TRP levels in the body is believed to be hepatic IDO (Williams and Elvehjem, 1950; Salter and Pogson, 
1985L TRP serves as the only substrate of the enzy~e and thus determines its activity. IDO determines the 
fate of TRP with respect to uptake by the brain (Luc~~ et aI, 1994; Green et aI., 1962; Fernstrom and 
Wurtman, 1974; Hillier et al., 1975) and tissues, and for conversion to the nicotinyl moiety of the pyridine 
nucleotides (Williams et al., 1950; Cho-Chung and Pitot, 1967; Schutz and Feigelson, 1972) (fig. 1). 
1.4.1.1 TDO: Regulation 
As stated earlier, TDO is subject to hormonal and substrate induction as well as a number of other effectors 
(Knox and Auerbach, 1955). The substrate TRP increases activity, synthesis and stabilisation of the enzyme. 
Adrenal glucocorticoids also increase synthesis in rat liver (Civen and Knox, 1959) but via direct interaction 
with the genome which results in raised levels of mRNA leading to increased apoenzyme synthesis 
(Feigelson et aI., 1961; Greengard et aI., 1963; Greengard et aI., 1966) (fig. 21). 
FIG. 21: 
20~--------------------~------------------~ 
o apoenzyme III holoenzyme 
o 
hours afte-r cortIsonE' 4----- ----.... hours after TRP 
Change in the degree of saturation ofIDO with its cofactor during induction by TRP, but 
not by cortisone [Knox, 1963]. 
Rat TDO de novo activity reflects a circadian rhythm with an increase in synthesis from 09:00h to 18:00h 
and decreasing from 24:00h to 09:00h. There appears to be a relationship between the diurnal rhythms of 
glucocorticoids and enzyme activity. However there is no correlation between the maximum peaks ofTRP, 
glucocorticoids and enzyme peak activity (Hardeland and Rensing, 1968). The importance of glucocorticoids 
in maintaining basal plasma TRP levels is aptly demonstrated by the fact that adrenalectomised rats have a 
reduced ability to cope adequately with increased TRP levels. Adrenal aphasia abolishes the hormonal 
induced elevation in enzyme levels, but not that induced by substrate TRP (Civen and Knox, 1959; Schimke 
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et aI., 1965; Knox et aI., 1966). TDO levels could thus be increased in two ways: firstly, elevated synthesis 
initiated by glucocorticoids (Civen and Knox, 19.59) and -secondly, a reduced rate of degradation due to 
- . 
stabilisation by substrate (Schimke et aI., 1965) (fig. 2ir 
FIG. 22: 
Glucocorticoid Subslrote- fype 
induction. ~ ~ - ~ 
ocfinom cin ::;rom I . J' _ \ 
~ ~ RNA, .... __ E+Co ", __ "ECo+S ", __ "ECoS P 
II II II II 
II II II 
n 
Model of the two known mechanisms of enzymatic adaptation in animal tissues: substrate-
type induction, which accumulates more total enzyme by combining with the free enzyme 
in effective equilibrium with its precursors, and hormone type induction, which provides 
more of the limiting RNA species for the specific enzyme synthesis [Knox, 1963]. 
Substrate TRP stimulates enzyme synthesis via a mechanism that disrupts the reversible equilibrium between 
apo- and holoenzyme. The induction manifests itself through promotion of conjugation between heme -and 
apoenzyme, effectively depleting the levels of naked apoenzyme, and thus drawing protein synthesis through 
extant template RNA species (Feigelson and Greengard 1961a). This induced phenomenon then results in 
increased template RNA biosynthesis to restore the disturbed equilibrium. An additional effect emanating 
from substrate induction of enzyme synthesis is a reduction in the rate ofTDO catabolism due to substrate 
stabilisation of the enzyme which enhances resistance to breakdown by the intracellular proteolytic enzymes 
(Knox, 1963). Glucocorticoids on the other hand 'push' enzyme protein synthesis by stimulating increased 
template RNA production (Knox, 1958). These two modes of enzyme induction can be aptly demonstrated 
in the presence of inhibitors such as puromycin, an inhibitor of protein synthesis, and actinomycin D, which 
prevents RNA formation (Greengard et aI., 1963)(fig. 22). 
In experimentally induced diabetes, TDO activity is altered positively (Schor and Frieden, 1958). This effect 
could be due to a blockade in the synthesis of nicotinic acid which would precipitate an accumulation ofTRP 
that would stimulate the enzyme. This inferred mechanism is based on results obtained from studies 
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petfonned using alloxan-induced diabetic rats. The pancreatic hormones glucagon and insulin also alter IDO 
activity, but glucagon c~ only induce enzyme synthesis in the presence ofTRP. It is possible that the 
-c . 
honnone exerts its effect at the level of translation (Schor and Frieden, 1958). Insulin inhibits the effects of 
glucagon, and stimulation of the enzyme by insulin is potentiated by TRP. This enhancement is not always 
dependent on the adrenals (Nakamura et al., 1980). Other compounds such as histidine, adrenaline and 
histamine also stimulate IDO either through direct or indirect action on the adrenal gla1i:ds. AAdrenaline and 
histamine act on the pituitary that releases ACTH which in tum stimulates the adrenal glands to release 
hydrocortisone. Histidine, on the other hand, acts directly on the adrenal glands (Knox and Auerbach, 1955). 
A large intake ofTRP results in an increased production of hepatic pyridine nuc1eotides giving rise to an 
increased rate of enzyme protein synthesis. However, this induction occurs in a dose dependent manner. 
Smaller doses are more effective than larger doses (Jago et a!., 1964). TRP (both D and L forms) could also 
inhibi(e"uzyme degradation in vivo which could raise tissue enzYme levels (Feigelson et al., 1961). The 
amino acid is known to have a stabilizing effect because in its absence there is rapid degradation ofIDO 
while in its presence there is an increase in enzyme levels. Another way in which enzyme activity and levels 
can be raised is through increasing conjugation of extant apoenzyme with heme in the cell, thus nott#\rating 
total enzyme levels but merely active enzyme concentration via conversion of apoenzyme to holoenzyme 
(Knox and Auerbach, 1955). A relationship is believed to exist between heme saturation and increase in total 
enzyme concentration in the cell, and also between saturation and total enzyme activity. Saturation of enzyme 
with activator results in a concomitant increase in active holo-enzyme and a decrease in inactive apoenzyme 
levels. In the absence of substrate inducer TRP there is a consequent reduction in the heme s aturati on-that 
eventually leads to the basal level of activity. Experimental findings indicate that the extent of the heme 
saturation ofIDO is an important determinant of active holoenzyme concentrations in the cell (Feigelson 
et a!., 1961). Cortisone increases apoenzyme levels only, and thus, in the absence of added TRP and activator 
hemin, there will not be a marked increase in enzyme activity but a rise in total enzyme concentration only 
manifested as an increase in apoenzyme levels. The question now arises as to how TRP actually causes an 
increase in enzyme levels via a substrate and hormonal mechanism. It is proposed that the manner in which 
it is executed is based on the presupposition that there exist on the genome enzyme forming sites that are 
normally occupied by inhibitory apoenzyme molecules. These apoenzyme molecules are in a dynamic 
equilibrium with the free apoenzyme molecules within the cell. Raising the levels ofTRP induces conjugation 
between hemin and apoenzyme to allow for production of more active holoenzyme, with the resultant effect 
being the disruption of this dynamic equilibrium. To restore the balance, genome bound apoenzyme is 
released, thus lifting the blockade and allowing synthesis of additional apoenzyme via raised mRNA levels. 
Reducing the levels of circulating plasma TRP precipitates a dissociation between hemin and apoenzyme, 
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effectively raising the levels of apoenzyme that would now bind at the enzyme synthesising sites on the 
- DNA,thereby preventing_additional apoenzyme synthesis (Feigelson et al., 1961). Cortisone increases 
-;:, r 
enzyme synthesis by binding to the enzyme template on the DNA and controlling enzyme protein synthesis 
via mRNA It forms a steroid-receptor complex with steroid binding proteins that allows it to penetrate into 
the nucleus and associate with the chromatin from where it then directs the genetic machinery to transcribe 
RNA. Cortisone also delays mineralocorticoid activity independent of TRP. HydrOCortisone and TRP 
potentiate one another (Civen and Knox, 1959) while TRP alone induces the conversion of apo- to 
holoenzyme (F eigelson et al., 1961). These compounds also enhance IDO activity independently (Civen and 
Knox, 1959). It can thus be stated that hormones appear to mediate the rate of enzyme synthesis (Civen and 
Knox, 1959) while the rate of catalyst degradation and activation is modulated by TRP (Civen and Knox, 
1959; Schimke et al., 1965; Dubnoffand Dimick, 1959). 
1.4.1.i TDO: Effects of5-ALA 
A large number of hepatic porphyrias are characterised by increases in both porphyrins and IDO. It is 
possible that the elevated activity of the enzyme is due to -stimulation by certain porphyrins and this could 
contribute to the symptomatology of certain porphyrias (F eigelson and Greengard, 1961 b). Satur~tiQlr of rat 
liver IDO is promoted by the administration of the heme and porphyrin precursor, 5-ALA, and this is 
coupled with enhanced enzyme activity (fig. 23). 
FIG. 23: 
5-ALA.... HEMIN -+ TDO 
f IFBI tactivate ~ 
5-ALA synthetase +- exogenous heme TRP -+ kynurenine 
inhibit 
Relationship between heme and IDO activation. 
It has been reported, however, that saturation of the rat hepatic enzyme with exogenous hemin did not cause 
any m.yOf changes in activity (Jago et aI., 1964). Nevertheless it is possible, based on experimental findings, 
that there could be a relationship between TRP metabolism and porphyria, and factors that affect heme 
metabolism could have an effect on TDO activity (Badaway and Evans, 1973 a; Badaway and Evans, 1975). 
The rate limiting enzyme of heme biosynthesis, 5-ALA synthetase, is, under normal conditions, inhibited 
by excess heme and saturation ofIDO. In porphyria there is also enhanced excretion of the intermediates 
in the pathway between TRP and kynurenine. Inhibition of the enzyme could be brought about by salicylate 
which displaces TRP from SA and also binds heme, thereby effectively decreasing the concentrations of the 
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of porphyrin (Badaway and Smith, 1971). An inverse relationship exists between 5-ALA synthetase activity 
and the levels of holoenzyme. The degree of saturation of TDO apparently determines the catalytic rate of 
5-ALA (Welch and Badaway, 1980), and TRP potentiates this effect (Badaway et al., 1981). 
1.4.1.3 TOO: Allosteric effectors 
Feedback inhibition (FBI) ofTDO by the allosteric inhibitor, NAD(P)H, is thought to be due to dissociation 
of the r~ve subunits to a monomeric fonn, or alternatively induction of a confonnational change which 
gives rise to an inactive catalyst. These effects are mediated through a specific inhibitory binding site on the 
enzyme (Cho-Chung and Pitot, 1967). Rat TDO is inhibited by chronic drug treatment with nicotine (Cho-
Chung and Pitot, 1967) and pentobarbitone (Badaway and Evans, 1973a), and this inhibition is thought to 
be as a result of FBI by NAD(P)H (Badaway and Evans, 1975). Some nicotinic acid derivatives are acute 
inhibitors of TDO, as are the phenolic intennediates such as 3-hydroxy-anthranilate and 3-hydroxy-
kynurenine. In these instances the inhibitory site on the enzyme is either the same as the substrate binding 
site or is very close to it, due to the competitive nature of the inhibition. 
The inhibition of TDO by intermediates in the pathway between nicotinic acid and NADINADP could 
indicate how nicotinic acid supplementation allows for conservation of plasma TRP (Wagner, 1964). Other 
potent phenolic inlnbitors are the neurotransmitters 5-HT and adrenaline, which are believed to bind at the 
heme association site of both the bacterial and mammalian enzyme, thereby effectively preventing 
conjugation (Frieden et al., 1% 1). TADs such as DMI inhibit TOO by preventing conjugation between the 
apoenzyme and its cofactor heme. Thus it appears that the ability of the administered antidepressant to 
inhibit the enzyme could depend on the extent of the heme saturation of the enzyme in vivo. On the other 
hand, antidepressants could block substrate activation by TRP completely. However, studies with TOO have 
been performed with animal models, using very high concentrations of the antidepressant drug. It is not clear 
whether a similar mechanism of action is operative in humans, although MAOls weakly inlubit TDO 
(Badaway and Evans, 1981). 
1.4.1.4 . TOO: Mechanism of action (mammalian and rat) 
The mode of action of TOO is based on three experimentally determined observations: 
i) TRP alone can activate the enzyme, 
ii) hemin is essential for activity and binds to the enzyme in a reversible manner, and 
iii) the heme iron is indispensable for activity (the valence state of Fe changes during the reaction due 
to the method of activation of TRP and oxygen (Feigelson et aI., 1964a). 
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TOO is inducible. The inactive fonn of the enzyme can be converted to the fully active form by the substrate 
. TRP EGreengard and Eeigelson, 1961), and the prosthetic group hemin (ferroprotoporphyrin (ix)) can 
-c ~ -
activate the enzyme in the presence ofTRP irrespective ofthe valence state of the iron in the hemin. TRP 
binds directly to the enzyme and not to the prosthetic heme. During the catalytic process, the heme iron is 
subject to a cyclical chain of events brought about by TRP and oxygen. The binding ofL-TRP to the enzyme 
induces a fundamental change in the ligand binding affinity of the catalyst in addition to increasing the 
reactivity of the heme iron towards the substrate (Makino et a!., 1980). Two clearly defined sequential events 
are implicit in enhanced enzymatic catalysis due to substrate induction (Frieden et a!., 1961). These are: 
i) enzyme saturation by activator heme, and 
ii) increases in the levels of total enzyme concentrations. 
Empirical evidence obtained from a number of investigations suggests the following model to explain the 
mode of action ofTDO. This mechanistic model requires that TRP reduces the Fe of heme to its divalent 
state, Fe* ..... F?, because the ferrous state is necessary forthe initiation of catalysis (Hayaishi et al., 1957, 
Ishimura et a!., 1970). The exact mechanism of action is not absolutely clear and the overall reacti0Il involves 
no electron transfer, but it is highly likely that the individual reactions could involve redox reactions which 
function so as to activate the substrates for interactions (Knox and Ogata, 1965). 
It is generally accepted that a cationic TRP free radical (nucleophile) and a superoxide anionic free radical 
(electrophile) are generated during enzymatic catalysis. Furthermore, a ternary complex consisting oftRP---
HEMIN--02 is apparently also created. The lrTRP catalytic binding site is close to the iron of heme to allow 
interaction between O2 and TRP, thereby facilitating the cooperative movement of electrons from TRP via 
hemin to oxygen. This hypothesis requires that the transitory, intermediate free radicals generated remain 
enzyme bound throughout catalysis (Uchida et al., 1985; Ishimura et al., 1970). This postulated scenario 
could allow for the regeneration of the original catalytically active ferric site of the enzyme (fig. 24). 
i) 
ii) 
iii) 
FIG. 24: 
TRP + BEMIN---Fe3+ -+ BEMIN---Fe2+ + TRP+(ox) 
O2 + BEMIN---Fe2+ .... BEMIN---Fe3+ + 02-(red) 
TRP(ox) + 02(red) ..... N'-FORMYLKYNURENINE 
TRP + O2 -+ N'-FORMYLKYNURENINE 
Proposed sequence of events in the cyclical reduction ofTDO [Feigelson et ai., 1 964b]. 
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Thus the mode of action involves a cyclical reduction and re-oxidation of the metallic-organic factor from 
- protoporphyrin (ix) cofactor, encompassing a two step process: 
"~ ~ 
i) reduction ofFe3+ -+ Fe2+ by TRP, and 
ii) oxidation ofFe2+ -+ Fe3+ by oxygen, 
which allows free radical formation that would facilitate interaction at the surface of the enzyme (Feigelson 
et aI., 1964b; Feigelson, 1964). The reaction is characterised by direct oxygenation of substrate with 
molecular O2 by the ferrous enzyme (Hayaishi et a!., 1957; Feigelson, 1964), with the oxygenated form being 
the obligatory intermediate of catalysis (Ishimura et ai., 1970) (fig. 25). An alternative catalytic mechanism 
involves the donation of a hydride ion from TRP to the enzyme to create a carbonium ion instead of a cationic 
free radical (Feigelson, 1964). 
~R ~.) 
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dihydroxydihydrotryptophan 
FIG. 25: Hypothesised reaction mechanisms ofTRP oxidation [Hayaishi et al., 1957]. 
1.5 CONCLUSION 
In the context of the literature survey just completed, which covers experimental and clinical data 
accumulated over the past few decades, and links IDO, aMT and 5-HT to the pathophysiology of affective 
disorders, such as depression, it is clear that IDO occupies a central role in regulating tryptophan levels in 
the body, and ultimately synthesis of tryptophan derivatives in the brain. Thus, further study of the 
interactions between IDO, tryptophan derivatives, aMT and 5-HT, the pineal, albumin and popular 
antidepressants such as DMI and fluoxetine would appear to be useful. 
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CHAPTER 2 
TDO AND ITS EFF.ECTORS 
EXPERIMENT 1 
2.0 THE NATURE AND EXTENT OF SUBSTRATE INHIBITIONrOF.TDO 
2.0.0 Introduction 
The antagonistic interplay that exists between TRP and its various metabolites regarding the enzyme TDO 
ultimately determines the direction of flow of the amino acid (Schutz et al., 1972). Plasma levels of the 
indole and, in particular, the total TRP concentration in the body, could thus be crucial for the fmely 
balanced control of protein synthesis, and possibly brain indoleamine concentrations (Green et al., 1962). 
In view of these roles, specifically the branch point TDO occupies in TRP metabolism, it is highly likely 
that the enzyme could be a site for metabolic control. Persistent negative alterations in the required levels 
of this essential amino acid have been shown to lead to a reduction in the rate of hepatic protein synthesis 
in mice (Sidransky et al.,1968). However the inactivation of the enzyme in the absence of sUbsu,:ate is 
readily reversible (Knox and Piras, 1965). Regulation of the enzyme takes numerous forms, . mcluding 
hormonal (glucocorticoids) (Feigelson et al., 1961), feedback inhibition (N AD (P)H) (Wagner, 1964), 3-
hydroxyanthranilate (Schutz et al., 1972), and 3-hydroxykynurenine (Wagner, 1964), substrate TRP 
(Williams and Elvehjem, 1950; Feigelson et ai., 1961) and cofactor heme (Feigel son and Greengard, 
1961 a; Feigelson and Greengard, 1962b) activation and stabilization. The enzyme is also inhibi~e9 by 
chronic glucose, sucrose, high fat diets (Smith andPogson, 1980) and by chronic ethanol administration 
in rats, with a consequent increase in plasma free TRP and brain 5-HT (Badaway et al., 1979). 
A common deviation from the predictions of the Michaelis-Menton theory is substrate inhibition. This 
phenomenon occurs at relatively high substrate concentrations and has been observed with various types 
of enzymes including hydrolases, transferases and oxidoreductases (De Arragia et al., 1984). Previous 
work in this laboratory, with IDO revealed that the enzyme is inhibited by substrate TRP. The objective 
of the study was to investigate the nature of this inhibition, whether it could possibly have any physiological 
relevance, and also to characterise the kinetic properties of the enzyme at pH 7. 
2.0.1 Materials and methods 
Female rats of the Wistar strain weighing 200-250 g were purchased from the South African Institute for 
Medical Research, Johannesburg. The animals were housed four per cage under a diurnal lighting cycle 
12L: 12D with food and water ad libitum. Twenty-five animals were injected three times intraperitoneally 
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with 100 mg/kg TRP and 5 mg/kg of hydrocortisone to induce TDO. The animals were injected at the 
- following times: ll:OOh, 14;OOh and 17:00h. Ten hours after-the first injection at 21 :OOh, the animals were 
killed by neck fracture and the livers were removed and stored at -70°C until further use. The livers were 
thawed in 3 volumes of 0.14 M potassium chloride containing 0.01 M TRP (PH 7), homogenized briefly 
in a blender, sonicated and centrifuged (l37,500 x g, 1 hr). Since the enzyme is exclusively present in the 
soluble part of the cell, the supernatant was used for further purification. The purific~tion procedure 
followed was that described by Schutz and Feigelson (1972), with slight modifications. This particular 
method gives a thousand fold increase in purification as opposed to the cell sap, and the total yield 
routinely varies between 10 to 20 percent. The addition of O.OIM TRP to all solutions in this purification 
procedure was to stabilise and hence protect TDO. The stability of the enzyme is markedly affected by 
ionic strength and protein concentration, with low levels of either resulting in a reduction of the catalytic 
rate. 
2.0.1.0 Heat treatment (for the removal of unwanted protein) 
Hemin was added to the supernatant to give a fmal concentration of 46.5pM. The resultant solution was 
manually stirred in a warm water (H20) bath that was kept at 55· C for 3 minutes, rapidly _ coole~ hf'an ice 
bath and centrifuged at 10K x 40 minutes in a Beckman JA-lO centrifuge to precipitate denatured protein. 
2.0.1.1 pH 5 precipitation (to precipitate the enzyme) 
The supernatant was titrated to pH 5 with acetic acid, kept at 4 DC for 10 minutes, and subsequently spun 
at 13200 rpm x 30 minutes (70Ti rotor). Potasium phosphate buffer (O.IM) containing O.OIM -TRP 
(40mls) was used to dissolve the resulting precipitate, which was then clarified at 6000 rpm x 10 minutes 
(JA-21) by centrifugation. 
2.0.1.2 Diethylaminoethyl-sephadex (DEAE) chromatography (absorption of enzyme by anion 
exchange) 
A DEAE-sephadex A-50 column (3 x 30cm) equilibrated with O.OIM KH2P04/pH 7 containing O.OIM 
TRP was used for the application of the sample (45m1s). This anion exchanger was set up with a UV 
FRAC-300 collector. All solutions used in this particular step were equilibrated with 100 % N2 prior to use 
to create an anaerobic environment and prevent oxidative damage of enzyme. Subsequent to passage of 
all the sample through the column, the exchanger was washed with 3 to 4 volumes of 0.3M 
KH2P04/pH7/0.01M TRP and then subjected to a salt gradient ranging from 0.3M to 1.0M KH2P04 • The 
enzyme was displaced at approximately 6M KHZP04 and the fractions containing the coloured product 
were pooled. Removal of the enzyme from solution at pH 7 involved an equal volume of amonium 
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sulphate. This solution was centrifuged at 12500 rpm x 20 minutes (70 Ti rotor) and the resultant 
- precipitate re-dissolved in_3 to 4mls of KH2P04/pH 7/9.?lM TRP. This fraction was then u~ed for the 
activity assays. 
2.0.1.3 Activity assays 
The activity of TDO was determined spectrophometrically by continuous measurement at 321nm of the 
rate of appearance of N' -formylkynurenine, using a Shimadzu spectrophotometer. The specific activity 
of the enzyme was expressed in terms of /A-M N' -formyl/minute/mg protein at 30°C. Hemin was added 
to give a final concentration of 2/A-M, and buffer instead of water was added to the reaction mixture. The 
assay mixture consisted of Iml of 0.2M NaH2P04/pH 7, 0.3ml of 0.03M TRP, 0.2ml of 4.6/A-M hemin 
(fresh), enzyme solution and O.IM KH2P04 to give a final volume of 3ml. For all activity assays, the value 
present at the start of each experiment was taken to be zero and therefore subtracted from all subsequent 
photometric measurements for each particular assay. Protein concentrations were determined by the 
method of Lowry et al (1951), using whole BSA as standard. 
2.0.2 Results 
Maximum activity was obtained with a pH of 7 at a substrate concentration of 5mM (Sopt), and the activity 
decreased with increasing levels of substrate. Graphical representation of the data acquired for the 
uninhibited region by means of a Hanes-Woolf plot (Hanes, 1932) (fig. 26), for estimates of K. (K. = 
substrate concentration that gives 0.5V max = SO.5) and V max' in the presence of variable TRP concentrations 
ranging from 0.0625 to 5mM, resulted in a Km of 100/A-M and V""", of 15.8 JLM N'-
formylkynurenine/minlmg protein respectively. The Hill plot (Cornish-Bowden, 1979) (fig. 27) is biphasic 
(n= 1.1 and n=2.0) with a transition region where n = 0.5 (inset fig. 27). Given the fmding that TRP 
behaves both as a substrate and as an inhibitor, a theoretical activity curve (fig. 28) was constructed 
incorporating the approximations of V max and K, obtained from the Hanes-Woolf plot (in fig. 26), using 
the Hill equation to approximate the velocity. 
v = V max • [S]"/I{. + [S]" 
Assuming that the values associated with the theoretical activity are those that would be present if no 
inhibition occurred, calculation of the percentage inhibition due to the increase in TRP levels beyond Sopt 
is possible (De Arragia et at., 1984; Bernstein et al., 1978). A plot of percentage inhibition against S was 
sigmoidal (fig. 29). The Hill plot (fig. 30) graphed from the data for the inhibited region using the 
relationship (De Arragia et al., 1984): 
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log (V N lllal'V} = log!{. - n log I 
gave an I.c. so = 18.80mM and napp. = 1.9. 
r- -
2.0.3 Effects of pH on substrate inhibition 
Assays were performed at four different pH values 5, 6, 7 and 9. As stated previously, maximum enzyme 
activity occurs at pH 7. Raising the pH to 9 results in a drop in V max to 13.3JLM N'-
formylkynurenine/min/mg protein (fig.31). This is coupled with a shift in the Sopt from 5mM to 2mM, and 
an unchanged K", value of 100JLM. The profIle of this graph over the total concentration range, however, 
remains the same as the graphs obtained at pH 7 and pH 6 (fig. 31). The Hill plot (inset fig. 32) reveals 
napp. of 0.8. In the region where there is substrate inhibitiOlfP~l changes from 0.8 to 0.4. (fig. 32) 
indicating negative homotropic cooperativity at pH 9. The graph of percentage inhibition against [S] (inset 
fig. 29), is also sigmoidal in shape. 
At pH 6 there is a change in K. to 144 JLM TRPmaxV remains unaltered ar 15:8'ILM N'-
formylkynurenine/min/mg protein and Sopt shifts to 4mM. The data obtained at pH 5 depicts a 47 per cent 
reduction in Vrnax , a fivefold increase in ~.5' and ~Pt shifts to lOmM (fig. 31). The activity at 20mM is 
only 3.53 JLM N'-formylkynurenine/minlmg protein (22.32%Vmax (PH?)' and maximum velocity is 
approximately twice as high at pH 9 than at pH 5 for the enzyme. The response of the enzyme at pH 6 and 
9 (fig. 31) is very similar to that at pH 7, exhibiting positive cooperativity (albeit to a lesser degree) which 
extends over the whole concentration range, and is subject to substrate inhibition. Enzyme activity at pH 
5, 6, 7, 8 and 9 (fig. 34), at the inhibiting TRP level of 16mM, shows that the least inhibition occurs at 
pH 7, the maximum at pH 5, while the inhibition at pH 6 is less than at pH 8 and pH 9. 
2.0.4 Discussion 
With reference to the Hill plot (PH 7, fig. 27), it is apparent that initially, at low concentrations of 
substrate, there is very little or no cooperativity (naPP = 1.1). The enzyme is displaying hyperboloidal 
kinetics with only the catalytic site binding TRP (Cho-Chung and Pitot, 1967). As the substrate 
concentration increases the slope becomes less than unity (see inset), which is indicative of the involvement 
of two classes of binding sites (Van Holde, 1985). Increasing the levels of substrate results in all the 
binding sites on the enzyme being fIlled. The slope approximates two, and clearly demonstrates positive 
homotropic cooperativity. It is apparent that the enzyme is subject to differential kinetics of a complex 
nature (Cho-Chung and Pitot, 1967; Schutz et al., 1972), Michaelis - Menten kinetics at levels of TRP in 
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the vicinity of the K. and sigmoidal kinetics at higher concentrations (Schutz et al., 1972). 
TDO is inhibited at all concentrations of substrate ~e·diately beyond Sopt. The TRP concentration at 
which substrate inhibition is discernible not only depends on the pH of the environment (fig. 31) but also 
on the enzyme concentration (fig. 35). Here it should be noted that an increase in enzyme concentration 
results in a concomitant reduction in Sopt>even at TRP levels as low as between 800-900j..tM, while, on the 
other-hand, decreasing the enzyme concentration gives rise to an increase in Sopt. Thus, given the 
observation that substrate inhibition occurs immediately beyond V max at both high and low enzyme levels, 
as tested in this laboratory, it can be inferred that this type of inhibition could be an additional mechanism 
whereby the flux through the TRP-N' -formylkynurenine pathway is regulated in the rat. 
Plots of percentage inhibition against [S] (fig. 29) illustrate the sigmoidal mode of inhibition at pH 7 and 
pH 9 (inSet), which is also a characteristic feature at all other pH values. However, at pH 7 there is gross 
positive homotropic cooperativity, while at pH 6 and 5, this response is marginal. At pH 9, on the other 
hand, negative homotropic cooperativity occurs. This apparent pH dependence of cooperativity (Schutz 
et al., 1972) could imply that the allosteric behaviour of the enzyme is mediated through changes"in the 
ratios of protonated to deprotonated side chain amino acids. In this instance it is obvious that the transition 
from positive to negative cooperativity is due to the removal of hydrogen ions from the catalyst, TDO. It 
is, however, clear (fig. 34) that the activity of the enzyme is strongly dependent on the hydrogen ion 
concentration of the environment (Schutz et al., 1972). 
Substrate inhibition could be caused by the additional binding of substrate to either the regulatory or 
catalytic TRP binding sites. The latter site is the most likely candidate, for if any interference occurred 
at the regulatory site, it is very likely that there would be loss of cooperativity between the individual 
subunits, and the graphical response would take the form of a rectangular hyperbola. Graphs of velocity 
against [S] (fig. 31) initially depict sharp reductions in activity of 12% at pH 7, 21.35% at pH 9 and 
19.31 % at pH 6, which subsequently become more gradual. At both pH 7 and pH 6, the positive 
cooperative effect remains relatively constant in the transition to the substrate inhibited region, while at 
pH 9, there is a pronounced enhancement of the negative modulation. This behaviour of the enzyme -
namely, retention of the ability to respond cooperatively at all the indicated pH values in the presence of 
substrate inhibition - not only implicates the catalytic site as the affected area which causes the significant 
reduction in the catalytic rate, but also effectively excludes the regulatory site from any possible 
involvement. 
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The mechanism whereby substrate inhibition is brought about is unclear, but it could occur in one of the 
- following ways: firstly, there could be formation of a dead end complex between enzyme, sUQstrate and 
-~ . 
product, preventing release of the product. Alternatively, two molecules of substrate could each get 
partially lodged in the active site, giving rise to an inactive enzyme-S2 complex (Cleland, 1979). It could 
be argued that substrate inhibition in this instance is of no consequence, given that a particular phenomenon 
r - N 
is of physiological relevance only if it can be shown to take place under physiological conditions. It can 
also be claimed that the apparent inhibition observed is due to interactions between the hydrophobic side 
chain of TRP and non polar regions of the enzyme that would affect its integrity as a biological catalyst. 
All work done with purified TDO in this laboratory repeatedly demonstrated inhibition beyond Sopt at 
values ofTRP between 800fLM and 5mM (fig. 35). Clearly then, if an increase in enzyme concentration 
coupled with a reduction in Sop! also results in substrate inhibition at TRP levels approximately sixfold less 
than 5mM, it is unlikely that substrate inhibition could be due to non-specific interactions between enzyme 
and substrate. On the other hand, the Hill plot of the inhibited region (fig. 30) points to the presence of 
only two binding sites for substrate TRP, namely a catalytic site and a regulatory site. 
2.0.5 Conclusion 
In the major part of this study, TRP did not inhibit the reaction until an approximate concentration of 5mM 
was reached. However it must be emphasized that the substrate concentration at which inhibition occurs 
appears to be related to the maximum velocity of the reaction, ie the rate of product formation, which 
ultimately depends on the enzyme concentration at saturating levels of substrate. The higher the enzyme 
level, the greater the specific activity and vice versa. Thus the crucial marker seems to be V max , for once 
V max is reached any further increases in TRP gives rise to partial inhibition of TDO. 
In the light of these observations, it appears that the phenomenon of substrate inhibition in this instance 
might have a significant role to play in the regulation of TDO activity at a physiological level. 
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EXPERIMENT 2 
- 2.1 -- THE INHIBITION OF CRUDE RAT LIVER TDO BY MELATONIN in vitro. 
-:; ~ -
2.1.0 Introduction 
Metabolism in living tissue is controlled by enzymes, which are regulated by other factors, mainly 
r- -
hormones and substrates. The rat liver enzyme TDO is an example where such control is exercised. This 
enzyme is also characterised by circadian rhythms in the rat, the highest activity being observable during 
the late hours of the light period and the lowest activity towards the end of the dark period (Hardeland and 
Rensing, 1968). 
TDO is responsible for the catabolism of TRP, which possibly makes it one of the most important 
peripheral determinants of brain and plasma free TRP concentration (Badaway et al., 1980). Therefore 
the availability of TRP to the brain for the synthesis of 5-HT ultimately appears to be dependent on the 
level of activity of TDO. It can be assumed that an inverse relationship exists between TDO activity and 
5-HT synthesis (Badaway and Evans, 1981). This relationship has been demonstrated previously (Green 
etal., 1962). 
Stress causes rat TDO activity to rise and brain 5-HT levels to fall. Normally, rat TDO activity rises 
throughout the day while brain 5-HT levels are at a minimum during early darkness (Hardeland and 
Rensing, 1968). It is generally accepted that three peripheral mechanisms are involved in controlling the 
elevation of brain TRP concentrations. These are: lower TRP catabolism, resulting from a decrease in the 
activity of hepatic IDO; elevation of free plasma TRP concentrations; and a decreased level of circulating 
LN AAs, which compete with TRP for uptake into the brain (Green et al., 1962). 
Rat brain TRP concentrations have been reported to be elevated after acute administration of T ADs such 
as IMI and DMI (Hardeland and Rensing, 1968). Secretion of the pineal hormone aMT is enhanced by 
TADs and MAOIs. During stress, normal aMT levels are disturbed and treatment with TAD and MAOIs 
restores normal aMT levels after ± 3 weeks. This period is comparable to the time required for 
antidepressants to exert their clinical effect. Thus aMT could be responsible for relieving the symptoms 
of depression (Arendt et al., 1986). 
Present therapy to alleviate depression appears to involve inhibition of TDO, either directly or by factors 
which enhance the ability of TRP to increase brain 5-HT levels (Curzon, 1969). 
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This study was undertaken on the basis of a number of observations. These included fmdings that both 
aMT and TDO display diurnal variations although inverseiy under normal conditions in the rat, and that 
-;: . 
the activity of IDO is at its diurnal minimum at 12 o'clock (Hardeland and Rensing, 1968). aMT and TRP 
have a number of apparent structural similarities, and the natural rise in pineal aMT coincides with the 
normal increase in blood aMT. 
2.1.1- Materials and methods 
aMT and hemin were purchased from the Sigma Chemical Co. St. Louis, MO, USA. Twenty male rats 
of the Wistar strain weighing 200-292 g were purchased from the South African Institute for Medical 
Research, Johannesburg, and maintained in a light:dark cycle of 12:12 (lights on from 07:00h-19:00h). 
Food and water were provided ad libitum. The animals were killed by cervical dislocation at 09:00h and 
the livers were removed immediately and frozen at -70°C using liquid nitrogen until assayed. 
TDO activity was determined in triplicate according to the method described by Badaway and Evans, 
(1975). The livers were homogenised in 0.14M KCLl2.5n1M NaOH for 2 minutes with an electric driven 
homogeniser at ODC. 15mls of this homogenate were added to a beaker kept at ODC containing 5 mls of 
0.03M TRP/4mM NaOH at pH 7.2, 25mls ofO.2M NaH2P04 (PH 7.2). These solutions were thoroughly 
mixed and 3mls immediately added to boiling tubes which were kept on ice. After rapidly adding 
95%OzlC02 the tubes were stoppered and incubated in a shaking incubator oscillating (120/min) at 3rC 
for the desired time. To determine the appropriate time to measure IDO activity, a graph showing the time 
course of TRP catabolism was constructed both in the absence and the presence of hemin (fig. 36). A time 
point (60 minutes) on the linear portion of the graph was then chosen for all subsequent determinations. 
Each reaction was stopped through the addition of2mls ofO.9M tricarboxylic acid and shaken for a further 
2 minutes. The resultant suspension was flltered using Whatman No 1 filter paper in a Buchner funnel. 
To 2.5mls of the flltrate 1.5mls of 0.6M NaOH were added and the absorbance read at 365nm. The 
enzyme activity was determined in the absence and presence of hemin in order to evaluate the activity of 
the holo- and apoenzymes of IDO. In addition, IDO activity was measured in the presence of 50 p,M, 100 
J-LM and 200 J-LM aMT, in the presence of hemin. The antidepressant DMI was also tested in the same 
concentration range. 
Protein concentration was determined according to the method described by Lowry et al., (1951). The data 
were analysed by one-way analysis of variance, and the statistical significance among specific means was 
determined using the Newman-Keuls multiple range test. A p value of < 0.05 between groups was 
accepted as being statistically significant. 
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2.1.2 Results 
_ As shown in figure 37, TI?O activity was enhanced significantly (p < 0.05) in the presence of hemin. 
-9; • 
aMT caused a dose-dependent inhibition of the hemin-induced rise in TDO activity (p < 0.05) to levels 
approximating TDO activity in the absence of added hemin. DMI caused a similar effect, although to a 
lesser extent (fig. 38), while tluoxetine had no observable impact (fig. 39). The mean counts obtained for 
the tested concentrations 1.5 x 10-3 M, 1.5 X 10-5 M and 1.5 x 10-6 M showed no significant difference (p 
>0.03), and thus only the group mean was plotted against the control (fig. 39). 
2.1.3 Discussion 
Liver IDO is one of the most important peripheral determinants of brain and plasma TRP levels (Badaway 
et ai., 1980). Increased catabolism of TRP results when liver TDO activity is high (Badaway et al., 1981). 
Thus, when TDO is activated, less TRP becomes available for uptake by the brain, resulting in reduced 
cerebral concentrations of this indole and its metabolite 5-HT. fDO is a heme-dependent enzyme, the 
apoenzyme being dependent on hemin as a cofactor (Feigelson and Greengard, 1962b). 
The addition of hemin produced an expected rise in TDO activity in this study. aMT, a hormone seCreted 
by the pineal gland and implicated in the pathology of depression (Arendt et al., 1986), caused a dose-
dependent inhibition of hemin-activated TDO, with the highest concentration reversing the hemin-induced 
activation of TDO. Whether aMT interferes with the binding of hemin to the apoenzyme remains to be 
investigated. 
A number of T ADS have been shown to inhibit TDO activity in a similar fashion, thus causing enhanced 
levels of TRP and 5-HT in the brain (Badaway and Evans, 1981). aMT appears to have a similar action 
to these agents in that it causes inhibition of liver IDO activity. However it has been shown previously that 
acute administration of aMT to rats in a dose of 25 p,g reduces forebrain TRP concentrations but does not 
alter forebrain 5-HT concentrations (Daya et al., 1989). 
2.1.4 Conclusion 
aMT inhibits crude TDO competitively at micromolar concentrations in vitro. Whether chronic aMT 
administration results in increased brain TRP and 5-HT levels due to inhibition of TDO and whether aMT 
is responsible for the diurnal variation in TDO activity has yet to be determined. 
The SSRI fluoxetine in vitro, unlike the tricyclic DMI, does not inhibit TDO. It can be concluded that 
fluoxetine has no direct effect on the hepatic enzyme. 
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tluoxetine (F) on the hemin induced rise in rat liver tryptophan-2,3-dioxygenase activity 
(means ±SD; n = 4 for C and n = 12 for F). p > 0.05 for all tested concentrations 
within a and when compared to control (C). 
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EXPERIMENT 3 
2.2 THE MODE OF INHIBITION OF . RAT HEPATIC TDO BY EFFECTOR 
MELATONIN. 
2.2.0 Introduction 
Changes in the activity of TDO could affect the synthesis of related biogenic amines ill me brain such as 
the ne!lfotransmitter (5-HT) and possibly the neurohormone aMT. A reduction of circulating TRP in the 
blood could thus indirectly affect the synthesis of brain indoleamines (Mehler and Knox, 1954; Hayaishi 
et ai., 1957; Daya et ai., 1990). It is possible that the enzyme TDO could be a site for metabolic control 
since it initiates the catabolism of TRP to the pyridine moiety of NAD+ and related nucleotides (Fernstrom 
etai., 1971; Frieden etai., 1961). 
An inverse relationship exists between the levels of aMT and TDO activity. In the previous in vitro 
experiment performed in our laboratory, using a crude extract of TDO, it was demonstrated (fig. 23) that 
the pineal hormone aMT causes a dose-dependent inhibition of the enzyme at concentrations of 50 ftM, 
100 ftM and 200 ftM (Walsh et aI., 1991b). The purpose of the present study was to investigate the nature 
and degree of this inhibition using purified TDO. 
2.2.1 Materials and methods 
Male rats of the Wistar strain weighing 200-250 g purchased from the South African Institute for Medical 
Research, Johannesburg, were used in the experiment. The animals were housed four per cage under a 
diurnal lighting cycle 12L: 12D with food and water ad libitum. The method used for obtaining the enzyme 
was identical to that outlined in Experiment 1. The enzyme activity was determined both in the absence 
and in the presence of hemin in order to evaluate the activity of holo- and apoenzymes. 
2.2.2 Results 
Graphical analysis of the plotted data is as follows: V max = 1.50 ftM kyn/minlmg protein, K; = 100 ftM 
and ~ = 2.70 jLM. As shown in figure 40, a plot of V against [S] yields lines that are sigmoidal at all 
concentrations of substrate (S). Replotting this data SN against I (Eisenthal and Cornish-Bowden, 1974) 
results in parallel lines indicative of competitive inhibition (fig. 41). Figure 42 shows the same data plotted 
on a Hanes Woolf plot (SN against [S]) depicting parallel lines with a positive slope. The effect of 
substrate inhibition can be seen at concentration 3 mM. A secondary plot of Y- intercept against I gives 
a straight line (fig. 43) with a Ki of 2.70 jLM. Figure 44 shows the effects of high inhibitor concentration 
(60 jLM) on low (1 mM) substrate concentration. The specific activity of the enzyme varies with the 
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concentration of TRP and the highest specific activity was observed at 2.5 mM. 
2.2.3 Discussion 
aMT, a structural analog of TRP, appears to be a competitive inhibitor of liver TDO (fig. 41). The kinetic 
behaviour of the enzyme has been ascribed to the presence of two binding sites for the substrate L-TRP , 
namely a catalytic and a regulatory site (Schutz and Feigelson, 1972; Uchida et al., 1~85~Makino et al., 
1980; Ishimura et al., 1970). It is known that the binding of TRP to the enzyme induces a change in the 
heme ligand binding affinity of the enzyme. At low concentrations of substrate, binding only occurs at the 
catalytic site. With an increase in the concentration of TRP, additional binding takes place at the regulatory 
site. 
It is postulated that the binding of the second molecule of substrate influences the affinity at, and interaction 
between, the two binding sites. This behaviour of the enzyme is explained in terms of negative and positive 
homocooperativity. TRP appears to give rise to positive homotropic cooperativity (Schutz and Feigelson, 
1972). The binding of aMT, on the other hand, apparently negatively modifies the catalytic efficiency of 
the enzyme, with the degree and nature of the inhibition depending on the concentration of TRP (~~s. 41 
and 44). From figure 41 it can be seen that the sigmoidal mode of inhibition is very pronounced at high 
substrate concentration (> 1 mM). This effect is almost absent at 1 mM. Figure 44, on the other hand, 
depicts aMT (60 JLM) affecting basal enzyme (holoenzyme) activity at low concentrations of TRP (l mM). 
Thus, the homotropic cooperative interaction of the negative effector aMT is expressed when the e~me 
becomes progressively saturated with substrate. Schutz and Feigelson (1972) observed a similar effect on 
the enzyme in the presence of 3-hydroxyanthranilate. Maximum velocity is reached at a substrate 
concentration of 2.5 mM. However, as the concentration increases above this value, substrate inhibition 
becomes a factor, as indicated graphically in figure 42. This is particularly apparent at a concentration of 
4 mM. The effect is characterised by a sharp increase in the positive slope of the curve at a concentration 
of 3 mM. The manner in which substrate inhibition is brought about is not known, and remains to be 
examined (see Experiment 2). At the micromolar concentrations used, aMT appears to be highly specific 
when compared to other indoleamines. These TRP derivatives (eg tryptamine, 5-HT and 5-HTP) were 
marginally effective only at millimolar levels in vitro (Uchida et al., 1992). Whether the methoxyindoles 
such as 5-MTOH and 5-methoxytryptamine have a similar potency remains to be determined. 
The question now arises as to why a global regulatory mechanism, such as that resulting from the aMT 
rhythm, leads to a decrease in enzyme activity when the level of enzyme protein is relatively high. TDO 
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occupies a branchpoint in the pathway of TRP metabolism. A fraction of the free circulating amino acid 
is required for indoleamine synthesis, while a large propo,rtion of the remainder is catabolized by TDO 
to ultimately yield nicotinate and related compoUnds ~uch as picolinate and quinolinate. The onset of 
darkness necessitates an increase in the levels of free serum TRP, primarily for two reasons. On one hand, 
the requirements of the enzyme with respect to the TRP-nicotinate pathway have to be met, and secondly, 
TRP is needed for increased indole amine synthesis by both the brain and pineal. a1!T CDuid bring this 
relatively high serum TRP concentration about by displacing TRP from serum albumin. Concomitant 
modulation of TDO by aMT would then allow sufficient TRP to escape catabolism for uptake across the 
blood-brain barrier. 
The mode of aMT inhibition could be exerted in one of three possible ways. Firstly, the molecule may not 
be able to take a configuration appropriate for the catalytic reaction because of a lack of functional 
group(s) (RCHNH2COOH) for proper interactions with the prote,in part at the catalytic site. Secondly, it 
might have the correct functional groups and adopt a pertinent configuration to allow catalysis in addition 
to being potentially reactive, but may not be able to serve as a substrate because other functional group(s) 
(5-methoxy) make additional interactions with a protein side chain which greatly reduces the catalytic 
ability of the heme pocket (Uchida et ai., 1985). Alternatively, aMT could act as a free radical scavenger 
(Poegeler et ai., 1993) of the superoxide anion (02') that would be generated during the enzymatic reaction 
(Feigelson et ai., 1964a, 1964b) effectively preventing the formation of N'-formylkynurenine. 
The finding that a binding site for aMT exists on an enzyme found exclusively in the cytopla_sl)1 of 
hepatocytes supports the notion that the neurohormone does freely penetrate the liver cell in the absence 
of cell surface aMT receptors. That aMT does enter the cell is further borne out by the presence of nuclear 
protein binding sites in purified rat hepatic nuclei (Acufia-Castroviejo et ai., 1993). The mechanism 
involved with movement into the nucleus is at present still a mystery. However the lipophilic nature of the 
molecule could also allow for crossing of the nuclear envelope. Alternatively, a transport protein could 
facilitate traversal into the nucleus. 
2.2.4 Conclusion 
The results of the present study indicate that inhibition of liver TDO activity by aMT in supraphysiological 
concentrations could inhibit circulating TRP catabolism, resulting in greater availability of the amino acid 
for uptake into the brain (Daya etal., 1990). However, as stated earlier, the effect of aMT on the enzyme 
is ultimately dependent on TRP concentration, and further work in this regard is required to clarify the 
biological relevance of this fmding. 
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EXPERIMENT 4 
REVERSIBILITY OF TDO INHIBITION BY MELATONIN, THE NATURE OF 
5-HT AND NAD+ INHIBITION AND A COMPARISON OF THE RELATIVE 
POTENCIES OF MELATONIN AND SEROTONIN ON TDO (in vitro). 
2.3.0 Introduction 
Inhibition ofTDO by 5-HT is both non-competitive and reversible (app. 4.1) (Frieden et al., 1961). The 
initial studies on the relationship between TDO and 5-HT were performed with a crude extract; however, 
subsequent investigations using a purified form of TDO revealed that 5-HT is a weak inhibitor in the 
millimolar range (Uchida et al., 1992). aMT, on the other hand, has been shown to be quite a potent 
competitive inhibitor of TDO (Walsh et al., 1994), and this inhibition should therefore theoretically also 
be reversible in the presence of excess substrate. 
It was on the basis of these observations that it was decided to investigate whether the inhibitory effects 
of the neurohormone on TDO are reversible and to what extent the neurotransmitter 5-HT inhibits the 
enzyme. 
aMT is hailed as a possible therapeutic agent in the treatment of certain affective disorders such as SAD 
and depression. The two indoleamines also have opposing circadian rhythms, and it was therefore of 
interest to note the combined effect of these biogenic amines on TDO. 
NAD+ is one of the end products of TRP catabolism (fig. 1) and a key metabolic intermediate with respect 
to nucleotide synthesis and adenosine triphosphate (ATP) production. It was thus also decided to examine 
the possibility of interactions between TDO and NAD+. 
2.3.1 Materials and methods 
Purification of the enzyme and the experimental procedure were performed as outlined in Experiment 1. 
To determine whether the inhibition of TDO by aMT is reversible, both TRP and negative effector aMT 
concentrations were kept constant while TDO levels were increased. The results were plotted as specific 
activity of TDO against volume of enzyme (fig. 45). 
2.3.2 Results 
Reversibility of the aMT inhibition is depicted in the graph of figure 45 (compare with app. 4.1). The non-
competitive nature of the inhibition by 5-HT and the dose dependence are clear, in the light of the graph 
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obtained in figure 46. However, this phenomenon of non-competitive inhibition only manifests itself at 
. _ relativ~ly low 5-HT concentrations. At higher levels, the inhibition becomes mixed, also being competitive, 
as can be seen from the Ltneweaver-Burk plot (Linewe<aver and Burk, 1934) of the same da~ (fig. 47). 
It is apparent from figure 48 that aMT is a more potent inhibitor compared to 5-HT at equivalent 
concentrations (6J.lM). The combined treatment, however, reveals that 5-HT neutraliseS-the"effects of aMT 
(fig. 48). NAD+, on the other hand, appears to be an allosteric effector of TDO, inhibiting the enzyme 
at relatively high concentrations (6mM) and stimulating it at low levels (3mM) (fig. 49). 
2.3.3 Discussion 
5-HT seemingly has a greater affinity for the non-competitive binding site. It is apparent from the 
Lineweaver-Burk plot that, at relatively low 5-HT concentrations, there is non-competitive binding. This 
is evidenced by the fact that V max changes with no change in ~ (100pM). At higher levels of 5-HT, a 
mixed type of binding takes place, given that both the y- and the x-intercepts shift. This implies competitive 
and non-competitive inhibition. Thus at 6- and 12/LM, 5-HT first binds to the non-competitive high affinity 
site. With subsequent elevations in inhibitor levels (24/LM), binding also occurs at an additional site,-which 
is in all likelihood the catalytic TRP binding site. 
The combination of 5-HT and aMT (fig. 48) clearly shows that 5-HT eliminates the effects of aMT on 
the enzyme, apparently by inducing a conformational change which probably precludes the binding of aMT 
at the active site. The fact that the degree of inhibition is significantly greater for the individual 
neurohormone at the same concentration (6/LM) could indicate that the influence of 5-HT involves a 
downregulation of TDO activity, as opposed to a total inhibition. This reduction in the catalytic rate, in 
contrast to an inhibition of catalysis via displacement of substrate TRP from and subsequent occupation 
of the active site (as is the case with aMT), appears to be a form of ultramodulation of enzyme activity. 
The type of inhibition brought about by aMT, on the other hand, effectively reduces the concentration of 
active enzyme at anyone time, and appears to be more decisive. 
It is apparent that, at high levels of NAD+ (6mM) in vitro, the nucleotide acts as an inhibitor via the 
mechanism of feedback inhibition, but at relatively low (3mM) concentrations, the compound acts as an 
allosteric activator of the enzyme. This phenomenon could be related to the link between energy 
requirements within the cell and oxidative enzyme activity. Whether this event manifests itself in vivo in 
the rat still remains to be explored. 
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According to Frieden et al., (1961), 5-HT apparently prevents conjugation between cofactor hemin and 
the apoenzyme. However t1!e results obtained in this study seem to indicate that the neurotrans~itter binds 
at the allosteric site initially, at low concentrations, where it induces dissociation of the respective subunits, 
as is the case with the known allosteric effector NAD(P)H. 
2.3.4 Conclusion 
The inhibition of TDO by aMT, as is the case with 5-HT, is reversible in the micromolar range. 5-HT 
behaves as an allosteric inhibitor of the enzyme in vitro in the same manner as NAD(P)H. At low 
concentration the inhibition by 5-HT is non competitive, becoming mixed at higher levels. In combination 
with aMT, the inhibitory effect of the neurohormone on TDO is nullified. Individually, however, aMT has 
a much higher potency at equimolar levels. The coenzyme NAD+ is also an allosteric inhibitor of TDO, 
but in the millimolar range. 
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EXPERIMENT 5 
EFFECTS OF ACUTE 5-ALA ADMINISTRATION ON RAT TDO ACTIVITY 
AND FOREBRAIN 5-HT METABOLISM 
2.4.0 Introduction 
The heme precursor 5-ALA and hemin induce saturation of hepatic TDO (Daya et al~,-1989). Activation 
of this enzyme results in the enhanced catabolic conversion of TRP to N' -formylkynurenine during the fIrst 
and rate limiting step of the kynurenine-nicotinic acid pathway of TRP degradation (Badaway, 1979) (fIg. 
1). 
To investigate the relationship between TDO and forebrain 5-HT requires a direct determination of brain 
5-HT levels. Recently it has been shown that the acute administration of 5-ALA to rats reduces the 
cerebral concentrations of both 5-HT and TRP due to reduced availability of circulating TRP for uptake 
by the brain brought about by activation of liver TDO (Badaway et al., 1987). These fmdings were 
confirmed (Daya et al., 1989,) but it was also shown that if the 5-ALA treated animals were killed at 
night, in the presence or absence of light, they had signifIcantly higher forebrain levels of TRP anct5-HT 
(Daya etal., 1989; Daya etal., 1990). 
In an attempt to explain this rise in forebrain indoles, it was decided to study the effect of longer-term 
administration of 5-ALA to rats. Firstly, it was investigated whether the rise in forebrain indoles would 
persist in animals treated repeatedly with 5-ALA. Secondly, the state of activity of liver TDO was_also 
determined in the same animals by measuring both the activity of the apoenzyme as well as the holoenzyme 
(Badaway and Evans, 1975). 
2.4.1 Materials and methods 
Ten male Wistar rats weighing 200-250g obtained from the South African Institute for Medical Research 
were maintained in a light:dark cycle of 12:12 (lights on from 07:00-19:00 h). Food and water were 
provided ad libitum. The animals were divided into two groups of fIve animals each. The frrst group 
served as the controls and were injected subcutaneously with saline (1 m1 kg-I) at lO:00h and 20:00h for 
two consecutive days, followed by a further injection at 10:00h on the third day. The second group 
received 5-ALA (15 mg kg-I) in the same order. 
Two hours after the last injection, the animals were killed by cervical dislocation and forebrain tissue and 
livers were collected and frozen immediately on solid CO2 and stored at -70°C until assayed. The 
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forebrain consisted of a piece of tissue taken from the frontal pole of one cortical hemisphere and 
extending 5-10 mm caudally. 
-c: 
Forebrain 5-HT was measured according to the flourimetric method described by Maickel (1981) (fig. 50). 
TDO activity was determined according to the method described by Badaway and Evans (1975), as 
explained in Experiment 2 and the activities of both the holoenzyme and apoenzym~ were determined. 
Protein concentration was determined by the method of Lowry et al (1951). 
2.4.1.0 Fluorometry 
This method was developed by Maickel (1981). Both 5-ALA treated and untreated forebrains weighing 
between 200 - 300mg were homogenised using a dounce homogeniser in 4ml of cold acidified n-butanol. 
The resultant suspension was then centrifuged at 2000 rpm x 5 minutes to sediment protein. To 2.5ml of 
the butanol phase were added 5ml n-heptane plus OAml of a O.INHCL in a boiling tube. The tubes were 
stoppered and shaken on a mechanical shaker for 5 minutes, and then centrifuged at 2000 rpm x 5minutes. 
The two phases obtained, upper organic and lower aqueous, then separated. Fractions of 0.2ml of the 
aqueous phase containing the 5-HT were used for the o-phthaldehyde (OPT) reaction. 
2.4.1.0.1 OPT reaction 
This quantitative method of 5-HT determination is non-specific and thus requires isolation of the substance 
of interest from tissues such as the forebrain. Four different separation techniques are reported in the 
literature: both column and paper chromatography, acidified acetone, and liquid - liquid extractio~._ The 
use of column chromatography for the separation·of 5-HT was not practical, as excessive dilution with 
consequent loss of sensitivity occurs. In the case of paper chromatography the procedure is too lengthy and 
tedious, while the end results of the acidified acetone extraction have proven to be inconsistent and 
unsatisfactory. The method of liquid - liquid extraction was selected because of the high degree of 
reproducibility (small standard deviation; less than 10 percent of the mean values for twenty animals) 
(Maickel et al., 1975). 
Preparation of the OPT solution required taking between 4 - lOmg of the substance and dissolving it in 
100mls of ION HCL (OPT has a very poor solubility in H20). Volumes of 0.6ml were added to the 
fractions containing 5-HT, and thoroughly mixed (for the blank, O.lml distilled H20 replaced the 5-HT) 
in a boiling H20 bath for 15 minutes, and subsequently cooled with tap H20 for 10 minutes. The mixture 
was then tranferred to a cuvette, and the fluorescence measured at an excitation wavelength of 360mp, and 
with an emission fllter of 470mp,. 
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Here the high energy is associated with the shorter wavelength. When a molecule absorbs energy in the 
form of radiation, its energy level is increased. Some of this absorbed energy is converted to vibrational 
energy while the remainder is emitted as light of a lowel: energy (longer wavelength) than that which is 
absorbed. In the system employed, linearity was achieved for concentrations of 5-HT between 0.01 -
2.5p.,g. Recoveries were prepared by adding 0.1m1 of a lOp.,g/ml solution of 5-HT to 3m1s of acidified 
butanol, and the procedure already described followed. The percentage recovery fo~ 5-tIT was 97, and 
the blank consisted of 0.1m1 OPT + 1O.lml distilled H20. 
FIG. 50: 
OPT + 
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o-benzylene-2,1-benzamidazole 
(polycyclic flourescent product) 
An example of the proposed OPT reaction involving an ionizable amino group (Amos and 
Gillis, 1964). 
Results are expressed as means ±SEM. A student t-test was used to determine statistical significance. A 
p value of < 0.05 was regarded as being statistically significant. 
2.4.2 Results 
As shown in figure 51, the administration of 5-ALA induced a rise in forebrain 5-HT levels (p < 0.001). 
Figure 52 shows the saturation of TDO with heme, determined by measuring the ratio of 
holoenzyme:apoenzyme (Badaway et ai., 1987). 5-ALA administration induced a rise in saturation of the 
enzyme. As shown in figure 53, the holoenzyme activity was significantly elevated (p < 0.05) in livers 
of 5-ALA treated rats. 
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2.4.3 Discussion 
Acute administration of 5-ALA to rats increases liver TD9 activity (Badaway et al., 1987) and reduces 
- -
brain TRP and 5-HT (Daya etal., 1990; Uchida etal.,.1992). However, if the rats are killed several 
hours after acute treatment with 5-ALA, the levels of these indoles rise markedly (Daya et al., 1990). In 
the present study, chronic administration of 5-ALA induced a similar rise in forebrain 5-HT. This rise 
was, however, accompanied by a commensurate rise in saturation of the apoenzyn;le as well as in the 
activity of the holoenzyme of TDO. 
Ordinarily, an inverse correlation could have been expected between liver TDO activity and brain 
indoleamine levels (Daya et al., 1990). If TDO is the major peripheral determinant of the availability of 
TRP to the brain (Badaway et al., 1981), and consequently 5-HT synthesis in the brain, a high level of 
enzyme activity should theoretically be accompanied by low levels of brain 5-HT. The reasons for high 
levels of brain 5-HT accompanied by increased activity of TDOin the present study are not clear. One 
reason could be that the high affinity TRP uptake system in the brain could be activated, since this system 
can compensate to a certain extent for fluctuations in extracellular TRP concentrations (Loizou and 
Redfern, 1988). 
Alternatively, it is possible to speculate that a large percentage of this displaced TRP could escape its 
catabolic fate in the liver (Salter et al., 1989). A high level of free TRP resulting from this mechanism 
could account for greater uptake of this indole into the brain and its subsequent conversion to 5-HT 
(Wurtman and Fernstrom, 1975). Increases in the levels of TRP in the blood are known to re~qlt in 
increased synthesis of 5-HT in the brain (Badaway et al., 1987; Wurtman and Fernstrom, 1975). 
2.4.4 Conclusion 
The precursor of the iron-porphyrin cofactor hemin, 5-ALA, stimulates the activity of TDO in vivo, but 
paradoxically increases rat forebrain 5-HT levels. 
FIG. 51: 
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Effect of 5-ALA (5-amino levulinic acid) on forebrain serotonin (5-HT) levels (means ± 
SEM; n=5). As compared with control (C). * p < 0.01. 
FIG. 52: 
o 
0.. 
<: 
"-o 
o 
:c 
106 
30r-------------------------------~ 
20 
10 
c 5-ALA 
Effect of 5-ALA (5-amino levulinic acid) on the saturation of liver TDO (tryptophan-2,3-
dioxygenase) as determined by the ratio of holoenzyme: apoenzyme (means ±SEM; 
n=5). As compared with control (C) * p < 0.01. 
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Effect of 5-ALA (5-amino levulinic acid) on the activity of the holoenzyme of TDO 
(tryptophan-2,3-dioxygenase) (means ± SEM; n=5). As compared with control (C), * 
p < 0.05. 
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APPENDIX 5.1: serotonin (5-HT) fluorescence (F) standard curve (r = .998) 
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CHAPTER 3 
aMT, DMI, FLUOXETINE, TDO AND THE PINEAL 
EXPERIMENT 6 
THE EFFECTS OF CHRONIC ADMINISTRA TION OF DESIPRAMINE, 
FLUOXETINE AND MELATONIN ON TDO ACTIVIT¥- - A-ND PINEAL 
INDOLEAMINE METABOLISM 
3.0.0 Introduction 
aMT, given its implication in stress, affective disorders (such as depressed mood, loss of interest, 
hypersomnia, fatigue and weight gain or loss), as well as in ageing, has generated a lot of interest in 
psychiatric circles (Daya, 1994). One of the reasons for this is that there could be a link between aMT and 
mood, given that oral aMT results in a worsening of depression (Wurtman and Wurtman, 1988). 
Experimental evidence indicates that during major depression a reduction in the peak of the daily biological 
aMT rhythm occurs. The ratio of blood cortisol to aMT in depressives differs from those in healthy 
subjects and, in bipolar depression, mania is associated with elevated levels of aMT (Lewy et aZ., 1989). 
Major depression, on the other hand, is characterised by altered diurnal rhythms in body temperature and 
REM sleep (Wehr etaZ., 1979). However these fmdings are inconclusive, and thus far experimental data 
linking low aMT levels to depression are inconsistent, and the dysregulation hypothesis is not regarded as 
important in the etiology and treatment of depression (Waldhauser et aZ., 1993). This theory cannot, 
however, be discarded as it has relevance with respect to certain subtypes of depressives. 
The secretion of aMT is enhanced by TADs and MAOIs. In depression there is an apparent reduced aMT 
secretion, and the frequency of this affective disorder is more pronounced in spring and autumn when aMT 
levels are lowered. Rat pineal and plasma aMT are significantly elevated with antidepressants that have 
a different pre-synaptic effect such as maprotilene and CI (Nyback et aZ., 1975). The mode of action of 
clinically efficacious antidepressants, such as MAOIs and TADs, is characterised by a restoration of 
normal plasma aMT concentrations at approximately three weeks. This time frame coincideS with the 
period necessary for antidepressants to exert their therapeutic effects, and implicates aMT in the remission 
of the depressed state. 
Experimentally, aMT has been shown to behave as a MAOI (Urry and Ellis, 1975) and to increase brain 
levels of 5-HT (Anton et aZ., 1968) and NA (Wendel et aZ., 1974) in the rat. The aim of this experiment 
was to determine whether aMT potentiates the effects of chronic antidepressant (DMI and fluoxetine) 
no 
treatment on TDO and also on pineal indoleamine metabolism. 
3.0.1 Materials and methods 
25 Male Wistar rats, weighing between 200 and 250-g, were used in this study, and divided into-5 groups. 
These animals were subjected to an 8 day treatment in the following manner: 
i) control - 0.9% NaCl in absolute ethanol, 
ii) DMI (2.5mg/kg/day), 
iii) DMI (2.5mg/kg/day) + aMT (0.25mg/kg/day), 
iv) fluoxetine (2.5mg/kg/day), 
v) fluoxetine(2.5mg/kg/day) + aMT (0.25mg/kg/day). 
All treatments lasted 8 days except for the combination of group (v) which lasted 3 days only, due to the 
fact that these animals (group v) became acutely anaemic and started perishing. The excised livers were 
immediately stored in liquid N2 until assayed while the pineals from groups (I), (ii) and (iv) were organ 
cultured immediately after removal. On the eighth day the last dose was administered 2 hours before 
sacrifice. The time of the daily dosage was 10.30 am. 
3.0.1.0 Pineal organ culture 
Rat pineal glands, obtained from the animals, were immediately placed into sterile Kimble glass tubes, one 
per tube, containing 52JLI of BGJ culture medium supplemented with 8JLI of radiolabelled [14C] 5-HT 
(OAJLCi), in an atmosphere of carbogen (95%/5%, 02/C02), sealed with parafIlm and incubatedjn the 
absence of light at 37°C for 24 hours. Subsequent tci incubation the pineals were removed and the culture 
medium assayed for pineal indoles using two dimensional thin layer chromatography (TLC). To prevent 
oxidation of the indoleamines, care was taken to limit exposure to O2' and light. The tubes containing the 
culture medium were then stored at -20°C until further use. This particular technique was developed by 
Klein and Notides (1969) and improved by Daya and Fata (1986). 
3.0.1.1 Thin layer chromatography (TLC) for analysis of radiolabelled indoleamines 
This method is essentially that engineered by Klein and Notides (1969) with minor adaptations, and 
encompasses the following steps to allow identification of the various metabolites of the radiolabelled 5-
HT: 
a) 10 x10 cm ofTLC plates (from Merck, West Germany) were spotted with lOJLI aliquots of the 
culture medium and evaporated with a gentle stream of nitrogen. 
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b) Spots of "cold" indoleamine standards (lOp'!) were superimposed on a) and subjected to the same 
treatment. 
c) -- The prepared TLC plates were subsequently d€v5:loped twice in the same direction in a solvent 
mixture containing chloroform, methanol and acetate in a ratio of 97:3: 1, until the solvent front 
reached a distance of 9cm up the TLC plate. The plates were then evaporated to dryness with N2 
after each run. 
d) The fmal development was prepared in a solvent of ethyl acetate at right angles to the direction 
of the first, and the solvent front allowed to migrate 6cm up the alumina plates. The plates were 
removed and the solvent was evaporated in the same manner as before. 
e) To facilitate visualisation of the compounds the spots were sprayed with Van Urcks reagent (1 % 
4-dimethylaminobenzaldehyde solution in 12.5% HCI and 50% ethanol). Development of the spots 
was achieved by placing the plates in an oven at 60°C for 5 minutes. 
t) . The spots were excised individually and placed into vials containing 3ml scintillation cocktail 
(from Beckman, USA) plus Iml absolute ethanol. The vials were then agitated for 20 minutes and 
counted in a Beckman LS 2500 scintillation counter with a counting efficiency of 96 % for the 14C_ 
window. 
The preparation of the standards involved dissolving 4p,g of each indole in a minimal amountof 100% 
ethanol containing a 1 % (w/v) vitamin C, to limit oxidation, and kept in the dark at 4°C. 
3.0.1.2 TDO activity 
Refer to Experiment 3 for the method. 
3.0.2 Results 
3.0.2.0 Organ cultures 
Three sets of pineals, controls, DMI and fluoxetine, were incubated to investigate the effects of both DMI 
and fluoxetine on pineal indoleamine biosynthesis. All results are given with respect to the values obtained 
for the controls. 
Table 1: 
DMI 
FLU 
Effects of antidepressants DMI and fluoxetine (FLU) on the metabolism of various pineal 
indoleamines by pineal organ culture. Values are expressed as percentage increase (l) or 
decrease (!) compared to control (saline treated animals). 
NAS aMT 5-THOH 5-HIAA 5-MlAA 5-MTOH 
1 (600) (0) ! (50) (0) ! (1000) ! (350) 
! (30) ! (70) ! (90) (0) 1 (1000) 1 (350) 
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3.0.2.1 TDO Activity 
TDO activity appears to be affected by the tricyclic DM~ and the SSRI fluoxetine to a similar extent, 
although in different wayS (figs. 64-71). DMI affects<the ratio of apo- to holoenzyme in the cell by 
reducing the extant holoenzyme concentrations and increasing the apoenzyme levels (figs. 64, 65). 
Fluoxetine, on the other hand, apparently reduces the extant apoenzyme levels that are available for 
conjugation with hemin in a manner which involves raising the levels of active holoenzymejn the cell (fig. 
66, 67). In the presence of aMT, these effects are abolished, as can be seen from figures 68-71. Both 
antidepressants, however, reduce the total concentration of TDO in the hepatocytes (fig. 72). 
3.0.3 Discussion 
The effects of DMI and fluoxetine on pineal indole metabolism appear to be dissimilar, particularly with 
respect to aMT metabolism. This points to widely differing modes of action.aMT synthesis is apparently 
unaffected by DMI, but is inhibited by fluoxetine (figs. 56,.57). That DMI has an influence on 
noradrenergic neurotransmission is clear given the manifested elevations in NAS levels which demonstrate 
that DMI potentiates NA effects in the synapse, given the fact that NAS synthesis is dependent on 
stimulation of the nor adrenergic system. The TAD also seems to channel5-HT towards aMT syn~esis, 
as indicated by the reduction in the concentrations of the methoxyindoles (fig. 58). The hydroxy indole 
pathway of 5-HT catabolism has a reduced turnover rate, indicated by the decrease in the levels of 5-HIAA 
(figs. 62, 63). This probably occurs due to the fact that most of the 5-HT is channelled towards aMT 
synthesis. 
The results obtained in this experiment regarding DMI's influences on pineal indole metabolism are thus 
consistent with what is known about the mode of DMI action on the noradrenergic system - specifically, 
p-adrenergic receptor stimulation coupled with NA reuptake inhibition. 
Fluoxetine, on the other hand, seems to have a negative effect on aMT synthesis, judging from the 
observation that aMT synthesis is apparently reduced by 70% (fig. 57) coupled with an enhanced 5-HT 
catabolic rate probably stemming from elevated 5-HT levels, and in the light of the observed increased 5-
methoxyindoles concentrations (3.5-fold) (fig. 59). In addition, there is a reduction of about 30% in NAS 
levels (fig. 55) in the presence of fluoxetine. However, fluoxetine is also known to downregulate p-
adrenergic receptors, and this could in part account for the results obtained. That fluoxetine has an effect 
on the enzymes involved in the conversion of 5-HT - aMT, and 5-HT - 5-methoxyindoles is clear, but 
the site of specific action of the antidepressant requires clarification. The low concentrations of 5-HTOH 
(fig. 61) further support the contention that fluoxetine affects 5-HT metabolism. 
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Given the experimentally determined ratio of apo- to holoenzyme within the cell for OMI treated rats, it 
can be observed that the relative apoenzyme levels are very high. There is thus an apparent increase of 
155 % -In the catalytic rate of the enzyme in the presence of. hemin. This observation is consistent with the 
proposed role of OM!, which asserts that it acts to prevent conjugation between apoenzyme and the iron-
porphyrin (ix). However, an important additional effect is the reduction in total enzyme levels of 
approximately 58 % (fig. 65). Fluoxetine, on the other hand, has no significant effect O!.Ltht; activity of the 
catalyst upon heme supplementation, which indicates a higher degree of heme saturation coupled with 
-
significantly lower apoenzyme levels (fig. 67). The SSRI apparently reduces total enzyme concentration 
by about 48 %. These results seem to indicate that the antidepressants interact with the genome, affecting 
enzyme protein synthesis, since there is a reduction in total enzyme levels (fig. 72). 
aMT counteracts the effects of both antidepressants when administered in combination (figs. 68 - 71), and 
this could be brought about via prevention of binding to the enzyme and/or binding to the genome by the 
antidepressants. It is possible that the phenomenon of chemical antagonism is manifesting itself between 
the individual substances aMT, the apoenzyme and either OMlor tluoxetine. 
3.0.4 Conclusion 
OMI and tluoxetine both significantly reduced total TOO concentrations. In addition, the two 
antidepressants also affected the available apoenzyme concentrations in the hepatocyte, OMI causing an 
increase and tluoxetine a reduction. In the pineal, OMI stimulated NAS synthesis, and tluoxetine inhibited 
aMT production coupled with enhancement of 5-HT turnover. 
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The effects of intraperitoneally administered desipramine (DMI) on N-acetylserotonin 
(NAS) biosynthesis in rat pineal organ culture (n=4, p < 0.05, ±SD). Control = C. 
FIG. 55: 
115 
20~------------------------------, 
15 
(\j 
(l) 
f: 
Q.. 
.......... 
:::::; I 0 
.......... 
(f) 1.0 « 
z 
M 
0 ,..., 
><: 
8 
0-
"tj 
05 
0.0 
c 
The effects of intraperitoneally administered fluoxetine (F) on N-acetylserotonin (NAS) 
biosynthesis in rat pineal organ culture (n=4, p < 0.05, ±SD). Control = C. 
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The effects of intraperitoneally administered desipramine (DMI) on melatonin (aMT) 
biosynthesis in rat pineal o.rgan culture (n=4, p > 0.05 ( ns) ±SD). Control = C. 
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The effects of intraperitoneally administered fluoxetine (F) on melatonin (aMT) 
biosynthesis in rat pineal organ culture (n=4, p < 0.05, ±SD). Control = C. 
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The effects of intraperitoneally administered desipramine (DMI) on 5-methoxytryptophol 
and 5-methoxyindole acetic acid (5-MTOH + 5-MlAA) biosynthesis in rat pineal organ 
culture (n=4, p < 0.05, ±SD). Control = C. 
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The effects of intraperitoneally administered tluoxetine (F) on 5-methoxytryptophol and 
5-methoxyindole acetic acid (5-MTOH + 5-MlAA) biosynthesis in rat pineal organ 
culture (n=4,p < 0.001, ±SD). Control = C. 
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The effects of intraperitoneally administered desipramine (DMI) on 5-hydroxytryptophol 
(5-HTOH) biosynthesis in rat pineal organ culture (n=4, p < 0.05, ±SD). Control = 
C. 
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The effects of intraperitoneally administered fluoxetine (F) on 5-hydroxytryptophol (5-
HTOH) biosynthesis in rat pineal organ culture (n=4, p < 0.001, ±SD). Control = C. 
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The effects of intraperitoneally administered desipramine (DMI) on 5-hydroxyindole 
acetic acid (5-HlAA) biosynthesis in rat pineal organ culture (n=4, p > 0.05 (ns), 
±SD). Control = C. 
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The effects of intraperitoneally administered fluoxetine (F) on 5-hydroxyindole acetic acid 
(5-IllAA) biosynthesis in rat pineal organ culture (n=4, p > 0.05 (ns), ±SD). Control 
= C. 
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The effects of intraperitoneally administered desipramine (DMI) on crude tryptophan-2,3-
dioxygenase extant holoenzyme activity in rat liver (n=4,p < 0.05, ±SD). Control = 
C. 
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The effects of intraperitoneally administered desipramine (DMI) on crude TDO 
(tryptophan-2,3-dioxygenase) total enzyme activity in rat liver (n=4, p < 0.05, ±SD). 
Control = C. Velocity in J-LM N'-formylkynurenine/minute/mg protein. 
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The effects of intraperitoneally administered fluoxetine (F) on crude tryptophan-2,3-
dioxygenase extant holoenzyme activity in rat liver (n = 4, P > 0.05 (ns), ± SD). Control 
= C. 
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The effects of intraperitoneally administered fluoxetine (F) on crude tryptophan-2,3-
dioxygenase total enzyme activity in rat liver (n=4, p < 0.05, ±SD). C = Control. 
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The effects of intraperitoneally administered desipramine (DMI) +melatonin (aMT) on 
crude tryptophan-2,3-dioxygenase extant holoenzyme activity in rat liver (n = 4, P > 
0.05 (ns), ±SD), C = Control. 
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aMT+.F 
The in vivo effects of intraperitoneally administered melatonin (aMT) + fluoxetine (F) 
on crude tryptophan-2,3-dioxygenase extant holoenzyme activity in rat liver (n=4, p > 
0.05 (ns), ±SD). C = Control. 
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The effects of intraperitoneally administered desipramine (DMI) + melatonin (aMT) on 
crude TDO (tryptophan-2,3-dioxygenase) total enzyme activity in rat liver (n = 4, P > 
0.05 (ns), ±SD). C = Control. 
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The in vivo effects of intraperitoneally administered fluoxetine (F) + melatonin (aMT) 
on crude TDO (tryptophan-2,3-dioxygenase) total enzyme activity in rat liver (n = 4, P 
> 0.05 (ns), ±SD), C = Control. 
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Effects of desipramine (DMI) (n = 4) and fluoxetine (F) (n = 3) on total crude 
tryptophan-2,3-dioxygenase activity (for control (C) n = 5). There is a statistically 
significant difference (p < 0.05) between DMI and C and also between F and C but no 
significant difference between the two antidepressants. Velocity = fLM kynurenine/mg 
protein/minute at 365nm. 
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KEY: NAS= N-acetylserotonin 
5-MT=5-Methoxytryptamine 
5-HTOH=5-Hydroxytryptophol 
5-MTOH=5-Methoxytryptophol 
chloroform methanol acetic aCId 
(9371) 
aMT=me1atonin 
5-HT=Serotonin 
5-HIAA=5-Hydroxyindole acetic acid 
5-MIAA=5-Methoxyindole acetic acid 
APPENDIX 6.1: A typical hi-directional pineal indole thin layer chromatogram (modification of 
Klein &Notides, 1969). 
4.0 
134 
CHAPTER 4 
INSULIN AND PINEAL INDOLE METABOLISM 
EXPERIMENT 7 
EFFECTS OF INSULIN ON PINEAL INDOLE METABOLISM IN PINEAL 
ORGANCVLTURE 
4.0.0 Introduction 
As mentioned in Chapter 1, a carbohydrate rich diet has the effect of elevating serum TRP, brain TRP and 
brain 5-HT levels (Sulser et al., 1978), but has no effect on pineal TRP and indoleamines. The effects of 
the carbohydrates are known to be related to the release of insulin (Wurtman, 1982). However, it is not 
clear what the direct effects of insulin on the pineal gland are, given the fact that the pineal gland is located 
outside the blood brain barrier. It was thus decided to examine the effects of insulin on pineal indole 
metabolism in organ culture, and to investigate whether insulin inhibited NAT and consequently aMT 
synthesis. Regulation of aMT biosynthesis is (as stated previously) believed to be at the rate limiting 
enzyme NAT. However, the manner in which this occurs is still controversial. One of the ways in.which 
inactivation of NAT could occur is proposed to be via a disulfide-containing compound. This idea is based 
on the following observation: in broken pineal cell preparations, the hormone insulin inhibited the activity 
of NAT via the oxidation of the hydrogen sulfide group on the enzyme (Naamboodiri et al., 1981): 
ENZyME----S--H + X----S---S----X .. ENZYME----S---S----X + X----S--H 
(active) (inactive) 
4.0.1 Materials and methods 
The organ culture protocol that was followed was outlined in Experiment 7. 1 IV of insulin, Actraphane 
HM (ge), supplied by Novo Nordisk (Pty) Ltd. South Africa, was added to the incubation mixture to give 
a constant total volume of 52,ul. 
4.0.2 Results 
As can be seen from table 2 and the constructed histograms, the hormone insulin only affected pineal aMT 
metabolism. There was a significant reduction in aMT levels (fig. 77) by approximately 42 %, while NAS 
levels (fig. 75) were unaffected, as was the concentration of 5-HIAA (fig. 73). The 5-MTOH (fig. 74) and 
5-MIAA (fig. 76) in addition to 5-HTOH (fig. 78) concentrations also revealed no significant changes 
when compared to the controls. 
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Table 2: Results of the effects of insulin on pineal gland indole metabolism in organ culture. 
" .. 
Indole aMT 5-HIAA 5-HTOH 5-MlAA 5-MTOH 
% reduction 42 (p<0.05) ns (p > 0.05) ns (p > 0.05) ns (p > 0.05) ns (p > 0.05) 
4.0.3- Discussion 
The results obtained (table 2) ( figs. 73-77) clearly show that insulin has a significant effect on pineal gland 
aMT metabolism, and that the overall effect is a significant reduction in aMT synthesis (fig. 77). It could 
therefore be inferred that insulin has a negative effect on the anabolism of aMT. Judging from these 
results, it is evident that insulin has affinity sites on the pineal gland which are linked to inhibitory 
intracellular factors that affect aMT synthesis. 
The manner in which insulin brings about this effect is not clear, given that entry of insulin into the 
pinealocytes poses a major problem considering the size of the polypeptide. For the proposed hypothesis 
to be applicable, travers ion of the cell membrane would be a prerequisite. However, it is speclllated that 
insulin could cause a redox shift through an alteration in the redox potential of the cell membrane which 
is normally required for noradrenergic manipulation of NAT activity (N aamboodiri et al., 1981). 
Alternatively, the hormone could have selective receptors on the pinealocyte that are perhaps linked to 
inhibitory G-proteins or voltage operated calcium (Ca2+) channels. At present these assumptions are all 
rather speculative and require further investigation. However, the rise in serum and brain TRi>- and 
ultimately brain 5-HT following increases in circulating plasma insulin levels (Goldstein and Betz, 1983) 
could not only be due to the tissue uptake of the competing LNAAs caused by insulin. It could also be a 
result of the insulin-induced raised aMT plasma titres, which would have the effect of displacing albumin 
bound TRP, thereby increasing plasma free TRP and hence brain TRP, with a consequent elevation of 
forebrain 5-HT levels. The results obtained in this study differ from those obtained by Champney et al 
(1985), where insulin-induced stress caused an increase in NAT activity and aMT biosynthesis in the rat. 
However, these authors also found that, under the same conditions, insulin caused a marked reduction in 
aMT levels in the hamster. 
4.0.4 Conclusion 
The known inhibitor of pineal NAT enzyme in vitro, insulin, had a significant effect on pineal aMT 
metabolism in organ culture. The pancreatic hormone was shown to inhibit aMT synthesis markedly, an 
effect which is possible in vivo. 
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Effects of insulin (I) (1 IU/52/.tl) on 5-hydroxyindole acetic acid (5-HIAA) synthesis in 
pineal organ cultures (n = 4, P > 0.05 (ns), ±SD). C = control, IU = international 
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Effects of insulin (I) (1 IU/52.u1) on 5-methoxytryptophol (5-MTOH) synthesis in pineal 
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Effects of insulin (I) (1 IU/52J .. tl) on N-acetyl serotonin (NAS) synthesis in pineal organ 
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Effects of insulin (1) (1 IU/52/t1) on 5-methoxyindole acetic acid (5-MIAA) 
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Effects of insulin (I) (1 IU/52j..ll) on melatonin (aMT) synthesis in pineal organ cultures 
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Effects of insulin (1) (1 IU/52J.lI) on 5-hydroxytryptophol (5-HTOH) synthesis in 
pineal organ cultures (n= 4, p > 0.05 (ns), ±SD). C = control, IV = 
international unit. 
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CHAPTERS 
_ PHYSIOLOGICAL EFFECTS OF MELATONIN INCLUDING DISPLACEMENT OF TRP FROM 
5.0 
BSA BY VARIOUS AGENTS 
EXPERIMENT 8 
THE EFFECTS OF CHRONIC MELATONIN ADMINISTRA-TioN ON RAT 
HEPA TIC FATTY ACID, NUCLEIC ACID AND PROTEIN METABOLISM, 
PINEAL INDOLE METABOLISM AND TDO ACTIVITY. 
5.0.0 Introduction 
A survey of the available literature on aMT reveals that this neurohormone has a number of other functions 
within the vertebrate body besides being a circadian rhythm generator (ReIter, 1980) or a modulator of 
endocrine secretions (Arendt and Broadway, 1987). The compound has been demonstrated to be an 
effective oncostatic agent both in vitro and in vivo in rats (Demoss et al., 1981) and humans (Hill and Blask 
1988). 
An example that illustrates the protective function of aMT in the cell involves the carcinogen safrole which 
generates hydroxyl radicals in DNA. Physiological concentrations of aMT 1000 times less than safrole 
practically abolished the negative effects of safrole, which include DNA adduct formation. It is believed 
that aMT inhibits the hepatic mixed function oxidase cytochrome p-450 (Kothari and Subramanian, 1992) 
that is activated by safrole (Lewandowski et al., 1990). This enzyme generates a highly reactive 
electrophillic molecular species of safrole which causes biotransformations within the DNA. The inhibitory 
effects of aMT on nucleic acid synthesis have also been found to occur in a protozoan Stentor Coerrulus 
(Bannerjee et al., 1980). 
The metabolism of fatty acids involves a heme-containing enzyme cytochrome bs that is involved in redox 
reactions similar to the holoenzyme of TDO and the function oxidase mentioned above. aMT has been 
shown to inhibit TDO in vitro (Walsh et al., 1994) probably by scavenging the free radical generated 
during enzymic catalysis. By implication, aMT theoretically should also have an effect on the activity of 
cytochrome bs, which could take the form of either increasing the levels of saturated fatty acids or 
decreasing the concentrations of unsaturated fatty acids in the hepatocytes. In this context, and given the 
ubiquitous presence of aMT in the rat body, it was decided to examine the in vivo effects of the 
neurohormone after chronic treatment on a number of different metabolic aspects such as hepatic fatty acid 
metabolism, nucleic acid and protein turnover, pineal indole amine metabolism and TDO activity. 
RNA 
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5.0.1 Materials and methods 
Twelve rats weighing between 200-250mg were given a d9se of 0.25 mg/kg aMT intraperitoneally once 
daily fur 6 days at 11 :OOh: On day 6 the animals ~ere ~acrificed 2 hours after treatment. Tissues (blood 
and liver) were rapidly removed and frozen rapidly in liquid N2 until further use. The pineal glands were 
subjected to culture immediately, and the effects of aMT observed after incubation. 
5.0.1.0 TDO activity 
This assay was performed according to the method of Badaway and Evans (1975) (as described earlier) 
using crude liver homogenates. Enzyme activity was determined at two different substrate concentrations, 
ImM and 2.5mM, in the presence and absence of cofactor hemin. The incubation period was 65 minutes. 
5.0.1.1 Extraction of nucleic acids 
The two classical quantitative colorimetric assays generally employed for nucleic acids are the orcinol 
(Biels) test for RNA and the diphenylamine (Dische) assay for DNA. Both tests are performed in an 
extreme acid environment that allows for quantitative depurination ·of the nucleic acid. In the case of RNA, 
the acid liberated D-ribose is dehydrated to furfural. Furfural then condenses with orcinol in the pr~sence 
of ferric ions to produce a solution consisting of a variety of compounds with an intense blue-green colour, 
which absorbs maximally at 665nm (see fig. 79 for the reaction). 
CSQ< CH20H 0 3HzO O-~-H 
H ~ H OH ./' + H '\ 0 Colored HJPO. ~ condensation Furfural products, 0 OH Amax = 660 nm 
H,O / ;5 ~ O=P -0· H+ / 0- + 
Purines HO::::""" OH 
+ 
Pyrimidine nucleotides Orcinol 
FIG. 79: The orcinol test for RNA (Clarke and Switzer, 1977). 
DNA on the other hand, yields upon concentrated acid hydrolysis, 2-deoxy-D-ribose, which dehydrates 
to w-hydroxylevulinylaldehyde that condenses with diphenylamine to produce a combination of coloured 
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products with a distinctive hue (blue) and a wavelength maximum of 600nm (see figure 80 for outline of 
reacti~)n). For both RNA and DNA the resultant ~olour pFOduced is proportional to the concentration of 
the nucleic acid. -:, r 
Both experimental and control livers were homogenised using a Waring blender and the resultant 
homogenate centrifuged at 2000g for 10 min. The supernatant was retained and the pel1erdiscarded. 5rnl 
of 5 % TCA solution was added to the supernatant to precipitate the crude nucleic acid. The resultant 
suspension was centrifuged at 2000g for 10 min. and the sediment treated with 8rnl of a 5 % TCA solution. 
This mixture was boiled in a H20 bath at 100°C for 15 min. To prevent evaporation, the test tubes were 
covered with marbles. The solution was allowed to cool, and then centrifuged at 2000g for 10 minutes. 
The supernatant containing the purified nucleic acids was kept for analysis (Plummer, 1978). 
DNA 
H',II,O 
~\--. 
H,PO. 
1 
Purines 
+ 
Pyrimidine nucleosides 
1-
Pyrimidine nucleotides 
o~ /H 
C I ' 
CH z I 
H-C-OH 
I 
H-C-OH 
I 
CHzOH 
n 
o H ~/ 
I 
H+ CH z 
--\10;;-->' I 
n CHz 
HzO I 
c=o 
I 
CHzOH ~ 
w-Hydroxylevulinyl 
aldehyde 
H 
o-~-o 
Diphenylamine 
FIG. 80: The diphenylamine assay for DNA (Clarke and Switzer, 1977). 
5.0.1.2 RNA determination 
Orcinol reaction 
Colored 
condensation 
products. 
>-max = 595 nm 
For the preparation of the standard curve (appendix 3), 2rnl fractions of the appropriate dilutions of the 
yeast extract RNA (0.2mg/ml) were added to 6ml of orcinol reagent, boiled for exactly 15 min, cooled, 
and the extinction read at 665nm against an orcinol blank. 3mls of the test samples were subjected to the 
same treatment after an initial purification step outlined above (Plummer, 1978), 
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5.0.1.3 DNA determination 
Diphenylamine reaction 
For the DNA standard curve (appendix 2), 10 mg of the nucleic acid was dissolved in 50mi of borate 
buffer at a pH of 8.5. To appropriate dilutions of 2mls, 4mls of diphenylamine reagent was added. This 
solution was then heated on a boiling H20 bath, cooled, and the extinction read at 600nm against a H20 
blank. 3mls of the experimental and control samples were treated similarly after an initial purification step 
outlin~d above (Plummer, 1978). 
5.0.1.4 Protein determination 
This was determined according to the Folin-Lowry (1951) protocol. 
5.0.1.5 Fatty acid determination 
The sal'Onification, esterification and extraction of fatty acids were performed according to a modification 
of the methods ofCatala etal., (1975), Carreau etat., (1980), Faas and Carter (1981; 1982), De Schriver 
and Privett (1982), and Alam et at., (1984). 
Hepatocytes were homogenised using, firstly, a Warring blender, followed by a dounce homogeruser. All 
tubes were rinsed with a minimal amount of a 10 % methanolic KOH solution. For the stromal fatty acid 
determination the cells were only homogenised 30 times with a tight plunger in order to rupture the cell 
and release the free fatty acids. 
The lipids were then saponified by heating with reflux and under nitrogen for 45min. at 85°C. These were 
then acidified to free fatty acids by the addition of Iml of 7M HCl. The fatty acids were extracted twice 
(shaking vigorously for 2min each time) with 3ml of petroleum ether (bp 40-60°C). The pooled aliquots 
for each sample were then 90% evaporated under nitrogen at 60°C. The residual fatty acids were then 
methylated by heating with BF3-methanol reagent (0.3ml) under nitrogen for five minutes at 100°C. The 
fatty acid esters were extracted twice, as outlined before, with Iml of petroleum ether. These were then 
90% evaporated at 60°C under nitrogen, reconstituted to the desired volume, and stored at -20°C under 
nitrogen and protected from light to prevent oxidation. 
The capillary-column gas chromatographic system was coupled to a flame ionisation detector. During 
analysis of the volatilised fatty acids, the samples were kept on ice to limit evaporation and oxidation. The 
carrier gas used was nitrogen and the program parameters are tabulated in table 3. 
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Table 3: Program parameters for the gas chromatography. 
", . 
column Quadrex 007-23 sample volume 0.51',,1 
program gradient oven temperature 190°C 
initial temperature 120°C initial time 15min 
=-
A 
final temperature 190°C fmal time 30min 
injector B 210° detector A 210° 
oven temperaturemax 190° equilibrium time 0.5min 
flow rate (mllmin) 14.5 rate (OC/min) 3.0 
The fatty acid standards were supplied by Sigma chemicals (USA) and the gas chromatograph can be found 
in appendix 8.4. Examples of chromatographs for both stromal and membrane fatty acids appear in 
appendix 8.5. To determine the ratio of one particular fatty acid relative to others, the following fatty acids 
were used: palmitoleate, stearate, oleate, linoleate, linolenate, arachidate, arachidonate, eruca.te and 
lignocerate. 
5.0.1.6 Organ culture 
8 Pineals (2 sets: 4 controls and 4 experimentals) were incubated for 24 hours according to the procedure 
outlined in Experiment 7. 
5.0.2 Results 
5.0.2.0 TDO activity 
At low substrate (hnM) levels (figs. 90, 91) there were no significant differences between the aMT treated 
and control livers, as was the case at the higher concentration of 2.5mM for both apo- and holoenzymes 
(figs. 92, 93). 
5.0.2.1 Nucleic acid determination 
The effect of aMT on both DNA and RNA levels (figs. 87, 88) for the aMT treated rats as compared to 
the controls was not significant. See appendices 8.1 (DNA) and 8.2 (RNA) for standard curves. 
5.0.2.2 Protein determination 
The neurohormone had a negligible effect on hepatic protein synthesis when the controls were compared 
to the experimentals (fig. 89). Note appendix 8.3 for protein standard curve. 
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5.0.2.3 Fatty acid metabolism 
There appeared to be a significant degree of modification ~ hepatic fatty acid composition of only some 
of the stromal fatty acids (figs. 94 - 102) and none in the· membranes (figs. 103 - 111) when'compared 
to the controls. Chronic aMT administration brought about changes in hepatic fatty acid synthesis in the 
cytoplasm. These alterations were manifested either by increases or decreases in the fatty acid ratios. In 
the stroma, there were increases in the level of arachidonate (fig. 101) and the saturated.stearate (fig. 95). 
5.0.2.4 Organ culture 
The experimental pineals revealed no significant difference in aMT (fig. 83) and NAS (fig. 84) levels after 
the incubated period. A similar result was obtained with respect to 5-HIAA (fig. 85) and 5-HTOH (fig. 
86), when compared to the controls. 5-MIAA (fig. 81) and 5-MTOH (fig. 82), on the other hand, 
manifested the most marked alterations, depicting statistically significant increases of 3.5- and 2.5- fold 
respectively. Table 4 below shows the tabulated results. 
Table 4: The results of the effects of aMT on pineal illdoleamine metabolism in pineal organ 
culture. Results are expressed as percentage increase (i) relative to the controlsjns = 
not significant at p > 0.05 ). 
aMT NAS 5-HIAA 5-HTOH 5-MTOH 5-MIAA 
aMT ns ns ns ns (i) 350 (i) 250 
5.0.3 Discussion 
5.0.3.0 Hepatic TDO activity 
There was no statistically significant difference in enzyme activity for both aMT treated and control 
animals (figs. 90 - 93). 
5.0.3.1 Hepatic nucleic acid synthesis 
aMT had no significant effect on hepatic nucleic acid synthesis, as can be seen from figures 87 and 88. 
5.0.3.2 Hepatic fatty acid metabolism 
There does seem to be a trend in the modifications caused by aMT on hepatocyte fatty acid metabolism. 
It can be observed that the neurohormone has an effect on certain pathways such as the one which involves 
the desaturation of unsaturated fatty acids from the results obtained. The ratio of the unsaturated fatty acid 
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stearate is significantly elevated in both the membrane and the cytoplasm, while that of oleate is not 
altered. Conversion of stearate to oleate involves an enzyme system that is potentially susceptible to the 
- -
antioxidant effects of the ~eurohormone. The mecharifsrn of action of this microsomal fatty- acyl-CoA 
desaturase and cytochrome b5 reductase involves redox reactions utilising an iron porphyrin factor, Oz, 
and the transfer of two electrons (Mathews and Van Holde, 1990). Thus, given the hypothesised mode of 
action of aMT in free radical scavenging (Hardeland et ai., 1993), it is possible that the- neurohormone 
could_negatively influence this reaction. 
Cytoplasmic ratios of arachidonate depict statistically significant increases while those of the membranes 
reveal none. The ratios of the potential arachidonate precursor linolenate is unaffected. However, there 
could be stimulation of this pathway which involves the delta-6 desaturase enzyme system. When taken 
in conjunction with the supposed effects on the oleate -+ stearate pathway there could, on the one hand, be 
inhibition of the cytochrome b5 reductase and, on the other hand, stimulation of t:..6 desaturase. These 
influences manifest themselves as an increase in ratios of stearate and arachidonate respectively. It may 
be speculated that these modifications in fatty acid concentrations are possibly due to direct effects of 
melatonin on some of the previously discussed enzyme systems involved in fatty acid biosynthesis,. or on 
- ----' 
another factor such as a hormone which is involved in regulating the synthesis of hepatic fatty acids. 
5.0.3.3 Pineal organ culture 
The results obtained with the organ culture experiment reveal no changes with respect to NAS and aMT 
synthesis, but marked elevations in the 5-HT catabolites such as the 5-MTOH and 5-MlAA, which is 
consistent with what would be expected if the levels of a particular metabolite (5-HT) are increased within 
the cell and/or there is a channelling of precursor away from one branch in a particular pathway. It is also 
possible that the pineal is saturated with aMT (due to the imposed treatment), which subsequently gives 
rise to a type of feedback inhibition by the indolealkyleamine on some of the enzymes (NAT and/or 
HIOMT) in the relevant biosynthetic pathway of 5-HT to aMT. 
5.0.4 Conclusion 
Chronic aMT treatment of rats had no significant effect on DNA, RNA, protein and membrane fatty acid 
metabolism. Similar treatment, however, brought about marked alterations in cytoplasmic fatty acid 
composition. Here levels of stearate and those of arachidonate were both significantly increased. The 
activity of TDO was also significantly curtailed, and this inhibition could be ameliorated by exogenous 
TRP. Thus aMT does seem to have an effect in vivo on both iron porphyrin utilising enzymes. 
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Effects of chronic intraperitoneally administered melatonin (aMT) (O.25mg/kg) on 5-
methoxyindole acetic acid (5-MIAA) biosynthesis by the pineal (n = 4, P < 0.05, ±SD). 
C = control. 
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Effects of chronic intraperitoneally administered melatonin (aMT) (O.25mg/kg) on 5-
methoxytryptophol (5-MTOH) biosynthesis by the pineal (n = 4,p > 0.05, ±SD). c = 
control. 
FIG. 83: 
151 
21 
ro I 
QJ 
c: 
5.. 
~ 
~ 
:::l 14 
0 
~ 
f--
::z 
ro 
'b 
~ 
E 
0-
"0 
07 
00 
c aMT 
Effects of chronic intraperitoneally administered melatonin (aMT)(O.25mg/kg) on 
endogenous pineal aMT synthesis (n = 4, P > 0.05, ±SD). C = control. 
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Effects of chronic intraperitoneally administered melatonin (aMT) (O.25mg/kg) on N-
acetylserotonin (NAS) metabolism in rat pineal organ culture (n=4, p > 0.05 (ns), ±SD). 
Control = C. 
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Effects of chronic intraperitoneally administered melatonin (aMT) (O.25mg/kg) on 5-
hydroxyindole acetic acid (5-HlAA) metabolism in the pineal (n = 4, P > 0.05 (ns), 
±SD). C = control. 
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Effects of chronic intraperitoneally administered melatonin (aMT) (O.25mg/kg) on pineal 
5- hydroxytryptophol (5-HTOH) metabolism. (n = 4, P > 0.05 (ns), ±SD). C = 
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Effects of chronic intraperitoneally administered melatonin (aMT) (O.25mg/kg) on 
hepatic deoxyribonucleic acid (DNA) synthesis (n = 4, P > 0.05 (ns), ±SEM). C = 
control. 
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APPENDIX 8.1: Deoxyribonucleic acid (DNA) standard curve (r = .997). Absorbance = Abs. 
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Effects of chronic intraperitoneally administered melatonin (aMT) (O.25mg/kg) on hepatic 
ribonucleic acid (RNA) synthesis (n = 4, P > 0.05 (ns), ±SEM). C = control. 
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APPENDIX S.2: Ribonucleic acid (RNA) standard curve (r = .995). Absorbance = Abs. 
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Effects of chronic intraperitoneally administered melatonin (aMT) (O.25mg/kg) on 
hepatic tryptophan-2,3-dioxygenase extant holoenzyme activity (n = 4, P > 0.05 (ns), 
±SD) at ImM tryptophan (TRP). C = control. 
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Effects of chronic intraperitoneally administered melatonin (aMT) (O.25mg/kg) on hepatic 
tryptophan-2,3-dioxygenase total enzyme activity (n = 4, P > 0.05 (ns), ±SD) at ImM 
tryptophan (TRP) + hemin (H). C = control. 
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Effects of chronic intraperitoneally administered melatonin (aMT) (O.25mg/kg) on hepatic 
tryptophan-2,3-dioxygenase extant holoenzyme activity (n = 4, P > 0.05 (ns), ±SD) at 
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Effects of chronic intraperitoneally administered melatonin (aMT) (O.25mg/kg) on hepatic 
tryptophan-2,3-dioxygenase total enzyme activity (n = 4, P > 0.05 (ns), ±SD) at 2.5 
mM tryptophan (TRP) + hemin (H). C = Control. 
FIG. 94: 
165 
4 
-,--
---,------
2 
o 
Ca Ma 
Effects of chronic intraperitoneally administered melatonin (aMT) (O.25mg/kg) on 
stromal fatty acid composition (n = 4, P > 0.05 (ns), ±SD): Ma = aMT + 
palmitoleate. Ca = control. 
FIG. 95: 
166 
2 
I 
I 
o 
Cb Mb 
Effects of chronic intraperitoneally administered melatonin (O.25mg/kg) on stromal fatty 
acid composition (n = 4, P < O'()OI , ±SD): Mb = aMT + stearate. Cb = control. 
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Effects of chronic intraperitoneally administered melatonin (aMT) (O.25mg/kg) on 
stromal fatty acid composition (n = 4, P > 0.05 (ns), ±SD): Mc = aMT + oleate. Cc 
= control. 
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Effects of chronic intraperitoneally administered melatonin (aMT) (O.25mg/kg) on 
stromal fatty acid composition (n = 4, P > 0.05 (ns), ±SD): Md = aMT + linoleate. 
Cd = control. 
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Effects of chronic intraperitoneally administered melatonin (aMT) (O.25mg/kg) on 
stromal fatty acid composition (n = 4, P > 0.05 (ns), ±SD): Me = aMT + linolenate. 
Ce = control. 
FIG. 99: 
170 
15 
.10 --
T 
--
05 
o 
Cf Nf 
Effects of chronic intraperitoneaIly administered melatonin (aMT) (0.25mg/kg) on 
stromal fatty acid composition (n = 4, P > 0.05 (ns), ±SD): Mf = aMT + erucate. 
Cf = control. 
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Effects of chronic intraperitoneally administered melatonin (aMT) (O.25mg/kg) on 
stromal fatty acid composition (n = 4,p > 0.05 (ns), ±SD): Mg = aMT + arachidate. 
Cg = control. 
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Effects of chronic intraperitoneally administered melatonin (aMT) (O.25mg/kg) on 
stromal fatty acid composition (n = 4, P < 0.001 (ns), ±SD): Mh = aMT + 
arachidonate. Ch = control. 
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Effects of chronic intraperitoneally administered melatonin (aMT) (O.25mg/kg) on 
stromal fatty acid composition (n = 4, P > 0.05 (ns), ±SD): Mi = aMT + lignocerate. 
Ci = control. 
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Effects of chronic intraperitoneally administered melatonin (aMT) (O.25mg/kg) on 
membrane fatty acid composition (n = 4, P > 0.05 (ns), ±SD): Ma = aMT + 
palmitoleate. Ca = control. 
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Effects of chronic intraperitoneally administered melatonin (aMT) (O.25mg/kg) on 
membrane fatty acid composition (n = 4, P > 0.05 (ns), ±SD): Mb = aMT + stearate. 
Cb = control. 
FIG. 105: 
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Effects of chronic intraperitoneally administered melatonin (aMT) (O.25mg/kg) on 
membrane fatty acid composition (n = 4, P > 0.05 (ns), ±SD): Mc = aMT + oleate. 
Cc = control. 
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Effects of chronic intraperitoneally administered melatonin (aMT) (O.25mg/kg) on 
membrane fatty acid composition (n = 4, P > 0.05 (ns), ±SD): Md = aMT + 
linoleate. Cd = control. 
FIG. 107: 
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Effects of chronic intraperitoneally administered melatonin (aMT) (O.25mg/kg) on 
membrane fatty acid composition (n = 4, P > 0.05 (ns), ±SD): Me = aMT + 
linolenate. Ce = control. 
FIG. 108: 
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Effects of chronic intraperitoneally administered melatonin (aMT) (O.25mg/kg) on 
membrane fatty acid composition (n = 4, P > 0.05 (ns), ±SD): Mf = aMT + erucate. 
Cf = control. 
FIG. 109: 
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Effects of chronic intraperitoneally administered melatonin (aMT) (0.25mg/kg) on 
membrane fatty acid composition (n = 4, P > 0.05 (ns), ±SD): Mg = aMT + 
arachidate. Cg = control. 
FIG. 110: 
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Effects of chronic intraperitoneally administered melatonin (aMT) (O.25mg/kg) on 
membrane fatty acid composition (n = 4, P > 0.05 (ns), ±SD): Mh = aMT + 
arachidonate. Ch = control. 
FIG. 111: 
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Effects of chronic intraperitoneally administered melatonin (aMT) (O.25mg/kg) on 
membrane fatty acid composition (n = 4, P > 0.05 (ns), ±SD): Mi = aMT + 
lignocerate. Ci = control. 
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I 
C:dble (CH,-)Fatty acid RT 
bond 
12:0 Laureate (I) 11.76 
14:0 Myristate (2) 14.13 
16:0 Palmitate (3) 20.90 
18:0 Palmitoleate (4) 22.48 
18:1 Stearate (5) 27.71 
3 18:2 Oleate (6) 28.80 
4 18:3 Linoleate (7) 30.47 
20:0 Linolenate (8) 32 . .53 
20:1 Arachidate (9) 33.01 
20:2 Eicosanoate (10) 33.76 
5 20:3 Dihomo-y-linoleate.(II) 35.28 
6 20:4 Arachidonate (12) 36.27 
7 20:5 Unidentified (13) 37.03 
22:0 Behenate (14) 37.43 
22:1 Erucate (15) 38.01 
22:4 Docatetranoate (16) 41.73 
8 
9 10 
11 24:0 Lignocerate (17) 42.50 
12 
24:1 Nervonate (18) 44.52 
14 13 
15 
18 
Fatty acid standard (STD) gas chromatogram (RT = retention time; C:dble = 
number of carbons (C) and double bonds (dble». 
APPENDIX 8.5: 
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Chromatograms of control (C) and experimental (M) traces of membrane fatty 
acid samples (to identify the individual fatty acids refer to appendix 6). 
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EXPERIMENT 9 
5.1 DISPLACEMENT OF TRP FROM BSA BY MELATONIN AND VARIOUS 
DRUGS IN VITRO 
5.1.0 Introduction 
A number of studies have shown that depression is associated with depressed day-time- and night-time 
levels_of aMT (Vaughan, 1984). 
It has been demonstrated that TRP can be displaced from SA by a number of agents which are known to 
bind to SA, such as salicylates (Tagliamonte et al., 1973) and non-esterified fatty acids (Curzon et al., 
1973; Badawy et al., 1984). The purpose of the present study was to investigate whether aMT, a 
compound structurally related to TRP and known to bind non-covalently to SA (Reiter, 1981), could 
possib1y'displace TRP from SA. The effect of certain antidepressants such as DMI, AMI and tluoxetine 
was also examined. The drug sulphanilamide, a known displacer of TRP from SA, was used as a reference 
standard. 
5.1.1 Materials and methods 
Defatted BSA and aMT were purchased from the Sigma Chemical Company, S1. Louis, Mo, USA. The 
radiolabel, L-[methylene-14C]TRP, specific activity 54 mCi mmol-1 , was purchased from Amersham 
International, Amersham, UK. 
Displacement studies were performed according to a modification of the method described by Smith and 
Pogson (cited in Fernstrom et al., 1971) using equilibrium dialysis. Brietly, 950 JLI aliquots of Krebs-
Henseleit bicarbonate buffer was supplemented with BSA to a fmal concentration of 0.003 % (w/v) and 
pre-equilibrated with 0.1 JLCi of radio labelled e4C) TRP for 30 minutes. This was followed by the addition 
of aMT to this compartment in fmal concentrations of 5 x 10-8 M, 5 X 10-7 M and 5 x 10-5 M. 
Following this, each compartment was dialysed against Krebs-Henseleit bicarbonate buffer while shaking 
in a H20 bath at a rate of 120 oscillations min-! for 3.5 h at 37° C. After the 3.5 h incubation, 100 JLI 
aliquots of the dialysate was assayed for the presence of radioactivity using radiospectrometry. 
The experiment was performed in triplicate for each concentration of aMT and the experiments were 
repeated four times. The results are expressed as the means ± SEM. The data were analysed by one-way 
analysis of variance and the significance among specific means was determined using the Newman-Keuls 
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multiple range test. A p value of less than 0.05 between groups was accepted as statistically significant. 
This particular method was' chosen after initial attempts "With affinity chromatography involving Affi Gel 
Cibracon blue. The TRP failed to bind SA in this system, probably because the binding of SA to the Affi 
Gel altered the TRP binding site. More importantly, equilibrium dialysis yielded consistent results. 
5.1.2 Results 
As shown in figure 112, the addition of aMT at a concentration of 5 x 1O.8M caused a significant 
displacement of radiolabelled (l4C) TRP (p < 0.05) and an even more significant displacement (p < 
0.001) at concentrations of 5 x 1O-7M and 5 x 1O-5M. 
None of the tested antidepressants had any effect on TRP displacement at the concentration range applied 
(j.tM to-mM) (figs. 113, 114 and 115). For the drugs AMI, DMI and fluoxetine, there were no significant 
differences between the individual assays within a group or between the various groups with reference to 
the control (p > 0.05) level. Thus the mean values for each group were plotted against the control. 
The drug sulphanilamide on the other hand (fig. 113), at a concentration of 5 x 10-7, gave a statistically 
significant displacement (p < 0.001) of TRP from BSA. 
5.1.3 Discussion 
aMT, a hormone of the pineal gland secreted in a circadian rhythm (Reiter, 1981), is derived from. TRP. 
TRP is the only amino acid which is non-covalently bound to SA (Curzon et al., 1975). The concentration 
of circulating TRP is an important factor regulating the uptake of TRP in the brain (Fernstrom et al. , 
1971; Curzon et al., 1975), and consequently the synthesis of 5-HT in the brain (Smith, 1991). High 
concentrations of 5-HT in the brain, in turn, are known to result in the elevation of mood (Lucca et al., 
1994). Thus, agents which displace bound TRP in vivo would have the potential to raise 5-HT levels in 
the brain, thereby eliciting antidepressant effects. 
The SSRI fluoxetine is known to be transported in blood bound to SA, and 94% of orally administered 
fluoxetine is associated with the protein in plasma. However, the antidepressant had no observable effect 
on TRP binding to BSA at the concentrations tested. This fmding, raises the possibility that the 
antidepressant could bind to a distinct site which is clearly separate from the TRP affmity site. 
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5.1.4 Conclusion 
The results of the present study show that the pineal hor~one, aMT, is able to displace TRP from BSA 
in vitro at the micromolar ievel, suggesting the possibility· that aMT has the potential for displacing TRP 
in vivo. However, this possibility requires further investigation. The antidepressants DMI, AMI and 
fluoxetine had no statistically significant effect at the range of concentrations tested and it can be concluded 
that their mode of action does not involve displacement of TRP from SA. 
FIG. 112: 
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Effect of different concentrations of melatonin on radiolabelled tryptophan (TRP) bound 
to bovine serum albumin (means ±SEM; n = 4). b as compared with a, p < 0.005; c 
as compared with a, p < 0.00]; d as compared with a, p < 0.00]. 
FIG. 113: 
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Effect of reference standard sulphanilamide (Sl = 5 x 10-8 M and S2 = 5 x 10-7) on the 
binding of tryptophan (TRP) C4C) to bovine serum albumin in vitro_ (means ±SEM; n 
= 4)_ Sl as compared with control (C), p > 0_05; S2 as compared with C, p < OJJOl_ 
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Effect of different concentrations ( 1 x to-6M, 1 x to-SM, 1 x to-3M) of fluoxetine (F) on 
radiolabelled tryptophan (TRP) e4C) bound to bovine serum albumin (means ±SEM; n 
= 4). P > 0.05 for all tested concentrations within the group and also with respect to 
control (C). 
FIG. 115: 
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Effect of different concentrations ( 1.5 x 1O-6M, 1.5 x 10-5 M, 1.5 X 10-3 M) of 
amitriptyline (AMI) on radiolabelled tryptophan (TRP) C4C) bound to bovine serum 
albumin (means ±SEM; n = 4)_ P > 0.05 for all tested concentrations within the group 
and also with respect to control (C). 
FIG. 116: 
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Effect of different concentrations ( 1.5 x lO-6M, 1.5 x 1O-5M, 1.5 x 1O-3M) of desipramine 
(DMI) on radiolabelled tryptophan (TRP) e4C) bound to bovine serum albumin (means 
±SEM; n = 4). P > 0.05 for all tested concentrations within the group and also with 
respect to C. C = control. 
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CHAPTER 6 
FINAL SUMMARY AND CONCLUSIONS 
-~ , 
6.0 FINAL SUMMARY 
Figure 117 provides a diagrammatic summary of the research findings of this study. 
6.0.0 - Chapter 1: Literature review 
This chapter reviews the physiological role of the amino acid TRP with respect to its fate in the body in 
relation to uptake into the brain, transport in blood and catabolism by hepatic TDO. TRP shares a common 
transport system for uptake into the brain with other LNAAs, and it is the ratio of TRPILNAA which 
ultimately determines the amount ofTRP that will be taken up by the brain. The potential roles ofTRP and 
its derivatives in depression are reviewed, as are the peripheral determinants of brain TRP, specifically IDO. 
A brief overview of the literature on TRP-hydroxylase is given, but the focus is mainly on the regulation and 
mechanism of action ofTDO. In addition, the different depression theories are outlined, although the biogenic 
amine deficiency hypothesis is covered in greater detail, with specific reference to the role of 5-HT, the TAD 
DMI, the SSRI fluoxetine and aMT. The physiological aspects of the function of aMT in h\!mans and 
animals, particularly the neurohormone's role in depression and its neuroprotective role, are also dealt with. 
6.0.1 Chapter 2: TDO and its effectors 
At pH 7, the biocatalyst, rat hepatic TDO, show a constant Ksof ±100J.lM, and is subject to inhibition by 
substrate TRP at high TRP concentrations. aMT inhibits both the crude and purified enzyme competitively 
in vitro in a reversible fashion. 5-HT, at low concentrations, inhibits the enzyme non-competitively, 
becoming competitive at high levels. The inhibition ofIDO by aMT is more potent than that of 5-HT at 
equimolar concentrations, however in the presence of 5-HT the effects of aMT are abolished. 
The coenzyme NAIr affected IDO in an opposing manner in vitro. On the one hand, relatively low 
concentrations of the coenzyme (3mM) stimulate the enzyme, while relatively high levels (6rnM) inhibit the 
enzyme. This molecule thus also appears to be an allosteric effector of IDO, similar to its phosphate 
derivative NAD(P)H. The precursor of the iron-porphyrin cofactor hemin, 5-ALA, stimulates the activity of 
IDO in vivo, but paradoxically increases rat forebrain 5-HT levels. 
6.0.2 Chapter 3: aMT, DMI, F1uoxetine, TDO and the pineal 
Both antidepressants inhibit TDO but in combination with aMT this effect is abolished. DMI increases NAS 
levels in the pineal while fluoxetine inhibits aMT synthesis. 
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6.0.3 Chapter 4: Insulin and pineal indole amine metabolism 
The pancreatic hormone insulin is shown to inhibit aMT synthesis and also to stimulate 5-HT breakdown 
- -
to a significant degree. .~ . 
6.0.4 Chapter 5: Physiological effects of aMT including displacement of TRP from BSA by various 
agents 
ChroQic aMT treatment had no significant effect on DNA and RNA levels, and no observable effect on 
protein metabolism and the fatty acid composition of hepatocyte membranes in vivo. However, significant 
alterations in the composition of liver cell cytoplasm fatty acids occurs. IDO activity in vivo is curtailed 
significantly, but this inhibition can be ameliorated by supplementation of exogenous substrate TRP. 
aMT is shown to displace TRP from BSA in vitro at micromolar concentrations. The antidepressants AMI, 
DMI and fluoxetine had no effect on the binding ofTRP to BSA in vitro at the concentrations tested. 
6.1 CONCLUSIONS 
An increasing body of experimental evidence acquired from studies on animals indicates that, in depression, 
aberrations in indolearnine metabolism are metabolically related to IDO. The findings oftlus sU;dy further 
support this assertion, particularly the results obtained with the antidepressant drugs used and aMT. A 
common denominator in the mode of action of these therapeutically efficacious antidepressants, DMI and 
fluoxetine, is their ability to influence IDO behaviour negatively. Inhibition of IDO resulted in 
accompanying changes in events in the pineal, specifically 5-HT metabolism. Stimulation ofIDO by 5-ALA 
was also followed by alterations in forebrain 5-HT levels. 
Another implication of the results of this research is the potential role of aMT as the natural antidepressant 
given the neurohormone's potential role in displacing bound TRP from IDO and inhibiting IDO. The net 
effect of these phenomena result in sufficiently elevated blood free TRP levels with a concomitant increase 
brain 5-HT and aMT synthesis. Additional experimental support for a possible therapeutic role by aMT in 
depression is the observation that the disruptive effects ofDMI and fluoxetine on IDO activity are abolished 
in the presence of the neurohormone. 
The potential role of aMT as a free radical scavenger is a distinct possibility given the proposed mechanism 
of action ofIDO. The study demonstrates that enzymic catalysis is inhibited by aMT. Whereas allosteric 
effectors such as 5-HT and NAD(P)H exert their inhibitory effects on IDO via induction of a conformational 
change, the mode of action of the neurohormone aMT involves the IDO active site. It is highly likely that 
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either one or both of the potential free radicals (superoxide anion or the electrophillic TRP) generated during 
the reaction is scavenged by aMT, thereby causing effective inhibition of the reaction. A similar motif could 
account for the neurohormone's effect on fatty acid compbsition in rat hepatocytes, which is mamfested by 
a reduction in the desaturated fatty acids. 
The fi!ldings ofthis study, namely: 
i) a restoration of normal IDO activity by aMT in the presence ofDMI and fluoxetine, 
ii) the inhibition ofIDO by aMT, 
iii) 'displacement ofTRP from BSA 
implicate aMT in both depression and as a possible neuroprotectant. These experimental observations, when 
viewed in combination, point to a function for aMT as a potential neuropsychiatric probe, in addition to 
having potential effects on a number of other physiological parameters. 
The findings of this study support the biogenic amine deficiency hypothesis, implicating some of the major 
biogenic amines such as NA, 5-HT and aMT in depression. The drug DMI could act firstly by inhibiting 
TOO and thus increasing plasma TRP levels, and secondly stimulate NA release and prevent NA uptake at 
the pinealocyte membrane. The overall effectwould be to enhance aMT synthesis with eventual remission. 
Fluoxetine appears to employ a different pharmacological mode of action in comparison to DMI. This SSRI 
appears to focus on the preservation of 5-HT. The fact that aMT counteracts the effects of both 
antidepressants, and restores the activity of IDO to that of the controls, is also consistent with the 
observation that the therapeutic action of drugs such as these coincides with the restoration of normal plasma 
levels of the neurohormone in depressives. 
6.2 POSSmLE FUTURE AREAS OF RESEARCH GENERATED BY THIS STUDY. 
i) Examine specifically the interaction between aMT and fluoxetine also aMT and DMI, the 
experimental animals, particularly the older rats, had a low survival rate when treated with this 
combination. The possibility of chemical antagonism appears to be a distinct possibility and studies 
in this regard should definitely be pursued. 
196 
ii) Determine if any binding sites on the rat genome exist for DMI and fiuoxetine, and if so, whether 
aMT has an affinity for the receptor site. This should be done in an attempt to explain the 
neutralising effect of aMT on IDO inhibition by both antidepressants. 
iii) Ascertain the effects of aMT on fatty acid synthesising enzymes, particularly those early in the 
biosynthetic pathway, to try and understand how the indoleamine causes alterations in hepatocyte 
_ fatty acid composition in both the membrane and cytoplasm. 
iv) Determine whether the experimental findings with NAlY have any physiological significance in 
vivo. 
v) Attempt to identify the mechanism of insulin action on aMT synthesis, whether insulin receptors 
'are present on the pinealocytes, and if inhibition of NAT and enhancement of 5-HT turnover is 
glucose-dependent. 
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